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Persons living with human immunodeficiency virus (HIV) are living longer and therefore 
are more likely to suffer significant morbidity due to potentially treatable liver diseases.  Liver 
diseases alone have been shown to have a significant negative effect on one’s health-related 
quality of life (HRQOL).  Clinical evidence suggests that persons living with HIV and liver 
disease, a growing number of individuals, may have a poorer HRQOL than persons living with 
HIV who do not have liver disease.  Thus, this study examined the multiple components of 
HRQOL by testing Wilson and Cleary’s model in persons with HIV and in persons living with 
HIV and liver disease using structural equation modeling. This secondary analysis used de-
identified baseline and medical record review data from a parent study testing interventions to 
improve medication adherence in persons living with HIV (R01 NR04749).  The Wilson and 
Cleary model components include: biological/physiological factors (HIV viral load, CD4 
counts), symptom status (Beck Depression Inventory II, Medical Outcomes Study HIV Health 
Survey [MOS-HIV] mental function), functional status (missed appointments, MOS-HIV 
physical function), general health perceptions (Perceived burden visual analogue scale, MOS-
HIV health transition), and overall QOL (Satisfaction with Life Scale, MOS-HIV overall QOL). 
Characteristics of the individual and environment were also explored. The Wilson and Cleary 
(1995) model was found to be useful in linking clinical indicators to patient-related outcomes. 
 iv 
The findings provide the foundation for development and future testing of a targeted bio-
behavioral nursing intervention to improve HRQOL in persons living with HIV and liver disease. 
 
 v 
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1.0  INTRODUCTION 
Since the introduction of highly active antiretroviral therapy, persons living with human 
immunodeficiency virus (HIV) are living 20 to 30 years beyond the time of diagnosis (Tedaldi et 
al., 2003). The result is that persons living with HIV are more likely to suffer significant 
morbidity and mortality from other disorders such as liver disease and its related complications 
(anemia, end stage liver disease, lipodystrophy, and hepatocellular carcinoma) than from HIV 
(Tedaldi et al., 2003).  Because of the toxic and metabolic effects of antiretroviral medications on 
the liver and co-infection with liver disease, the number of persons living with HIV and liver 
disease is increasing (W. R. Kim, 2002).   
Estimates suggest that more than 50% of persons living with HIV are co-infected with 
liver disease related to Hepatitis C Virus (HCV).  Quite possibly, the number of cases of HCV in 
the United States may be four to five times greater than the number of cases of HIV (Alter et al., 
1999). The number of persons with liver disease is significantly higher than that of HCV alone, 
as liver disease includes a number of liver conditions (infectious, chronic, steatosis, and 
cirrhosis). These potentially treatable liver conditions have been shown to have a significant 
negative effect on persons’ health-related quality of life (HRQOL) (Foster, Goldin, & Thomas, 
1998). As the first goal of Healthy People 2010 (US DHHS, 2000) is to increase life expectancy 
and improve HRQOL of individuals of all ages, the challenge for researchers and practitioners is 
to determine what aspects of individuals’ HRQOL are affected when they live with multiple co-
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morbid conditions. There are few theory-driven studies that explore HRQOL and liver disease in 
persons living with HIV (Fleming et al., 2004).  Thus, this study examined the Wilson and 
Cleary (1995) model of HRQOL in persons living with HIV and persons living with HIV and 
liver disease.  
1.1 SIGNIFICANCE OF THE PROBLEM OF HIV AND LIVER DISEASE 
The rate of liver-related complications is increasing in persons living with HIV and liver disease. 
This increase is due in large part to longer survival of persons with HIV, and toxic and metabolic 
effects related to long-term use of antiretrovirals (Soriano, Martin-Carbonero, Maida, Garcia-
Samaniego, & Nunez, 2005).  Moreover, HIV medication schedules and side effects are 
becoming less burdensome; however, larger doses of these medictions at less frequent intervals 
can be more liver-toxic.  Newer antiretroviral medications are being linked to lipodystropy and 
steatosis (fatty liver) and have an impact on liver function and HRQOL (Sax & Gathe, 2005). 
Therefore, liver toxicity in persons living with HIV becomes magnified when co-morbid liver 
disease is present. 
Chronic liver disease is one of the leading causes of morbidity and mortality in persons 
living with HIV.  Estimates are that over four million people in the United States have infectious 
liver disease (NIH, 2002). The prevalence of co-infection (HIV and liver disease) is estimated to 
be between 70-90% in urban populations (Soriano et al., 2005).   The co-infection epidemic 
emerged in the 1980s, and is expected to increase significantly in the next 15 years, in part due to 
the long duration from infection to negative health outcomes (Adler, Goubau, Nevens, & Van 
Vlierberghe, 2002; R. S. Brown & Gaglio, 2003) Approximately 30-90% of the one million 
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persons living with HIV in the United States are thought to be co-infected with HIV and liver 
disease; this number of persons with co-infection is increasing each year (Alter et al., 1999; NIH, 
2002; United States Census Bureau, State and County Quick Facts, 2000).  Approximately 85% 
of those with acute liver disease will develop chronic liver disease (Lawrence, 2000).  
Factors that predict a worse clinical prognosis when liver disease is present include co-
infection with HIV, obesity, nonalcoholic steatohepatitis syndrome, duration of illness, and viral 
genotype (Ortiz, Berenguer, Rayon, Carrasco, & Berenguer, 2002).  The long-term consequences 
of chronic liver disease include decreased HRQOL, chronic fatigue and anemia, chronic viral 
hepatitis, cirrhosis, and hepatocellular carcinoma (Cosby, Holzemer, Henry, & Portillo, 2000). 
These outcomes may be augmented when combined with the potential complications and side 
effects of HIV, including decreased HRQOL, neuropathy, malnutrition, and lipodystrophy (Arey 
& Beal, 2002). Factors that have been identified to predict a worse prognosis in persons living 
with HIV include infectious liver disease viral genotype, lack of sustained viral response to 
treatment, poor adherence, decreased HRQOL, obesity, substance abuse, and advanced age at 
infection (Monto, Alonzo, Watson, Grunfeld, & Wright, 2002; Ortiz et al., 2002). 
The prevalence of liver disease may be greatly underreported (Alter et al., 1999). Liver 
disease is more prevalent among ethnic minorities (3.2% African Americans, 2.1% Hispanic 
Americans) compared to the general United States population of Caucasians (1%) (Shiffman, 
1998). Among the homeless or the incarcerated the prevalence of liver disease may be as high as 
40% (W. R. Kim, 2002).  Approximately 85% of those with acute liver disease will develop 
chronic liver disease (Lawrence, 2000).  Chronic liver diseases of all types rate as one of the top 
10 causes of death in the United States, with infectious liver disease comprising 77% of these 
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deaths (W. R. Kim, 2002).  Approximately 25-30% of these cases are diagnosed due to long-
term mild symptoms of chronic fatigue, anemia, and joint pain.  
The impact of chronic liver disease accounts for significant absenteeism at work; 
estimates are that over one billion dollars were expended in US health care utilization for this 
disorder in 1998. Economists predict a four-fold increase in liver disease hospital expenditures 
from 1990 to 2015 and a continued rise in the future (W. R. Kim, 2002).  Indirect cost estimates 
including lost wages and lost fringe benefits equated to approximately 3.7 billion dollars in 1997 
(Leigh, Bowlus, Leistikow, & Schenker, 2001). 
Co-infection with both HIV and liver disease yields a significant increase in disease 
progression for both diseases. Persons living with HIV are living longer since the institution of 
highly active antiretroviral therapies, but they are dying from liver-related complications. The 
consequences of liver disease are often debilitating far beyond the individual’s current state of 
health while living with HIV as a chronic disease. 
The empirical support measuring HRQOL in the liver disease population has, more often 
than not, been reported as overall quality of life or as components of quality of life (See 
manuscript in Appendix A).  Many studies that have HRQOL as a primary outcome variable are 
not theory-driven (Fleming et al., 2004; Foster et al., 1998; Hauser, Holtmann, & Grandt, 2004; 
Hickman et al., 2004; Pojoga et al., 2004). While there have been studies on the effect of liver 
diseases on HRQOL, fatigue, and depression, specific recommendations for translating this 
research into clinical practice for persons living with HIV and liver disease have not been made.  
The goals of measuring the multidimensional nature of HRQOL within the population of 
persons living with HIV and liver disease are to identify those areas of HRQOL that are 
negatively and positively associated with the disease and then to tailor bio-behavioral 
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interventions aimed at improving overall HRQOL in persons with HIV and liver disease, thus 
meeting one of the goals of Health People 2010 (US DHHS, 2000). The knowledge gained from 
persons with HIV and liver disease in this study may provide patients, researchers, clinicians, 
and policy makers with opportunities to collaborate in addressing the complex illness 
management issues that they may face. Targeted interventions have the potential to delay 
mortality, and decrease morbidity, healthcare costs, and the spread of resistant strains of HIV and 
potential future infections. HRQOL offers a comprehensive and potentially clinically meaningful 
outcome measure that is patient-defined (Lorenz, Cunningham, Spritzer, & Hays, 2006).   
1.2 MODEL OVERVIEW 
The framework chosen for this study to investigate the concept of HRQOL within the context of 
persons living with HIV and persons living with HIV and liver disease was the model developed 
by Wilson and Cleary (1995). Wilson and Cleary have conceptualized HRQOL as a multi-
dimensional directional model encompassing five components including biological/physiological 
factors, symptom status, functional status, general health perceptions, and overall perceived 
quality of life.  Each component of the model influences the next, yielding complex relationships 
that build upon each other to comprise the ultimate outcome of a well-fitted HRQOL model.  
The components may thereby predict and have the potential to directly influence the individual’s 
overall quality of life (see Figure 1 and approval for use in Appendix B).   
As a theoretically-driven study of HRQOL of persons living with HIV and liver disease is 
not yet available, the components that influence a potentially curable liver disease population, 
compared to those that influence a population that has had to learn to live with HIV as a chronic 
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disease, is not well understood (H. S. Wilson, Hutchinson, & Holzemer, 1997). Examination of 
the components of QOL within the framework of the Wilson and Cleary (1995) model has the 
potential to bridge the gap between biological/physiological indicators and individual 
perceptions of their overall quality of life, thereby modeling HRQOL. This theoretical model has 
been shown to be useful in understanding HRQOL in persons with HIV (see Chapter 2); 
however, it has not been studied in persons living with HIV and known liver disease.  
Biological and 
Physiological 
Factors
Functional Status Overall Quality of Life
General Health 
Perceptions
Symptom 
Status
Characteristics of 
the Individual
Characteristics of 
the Environment
 
 
 
Figure 1. Wilson and Cleary Model of Health-related Quality of Life 
 
Permission to include from: Wilson I. B., & Cleary, P. D. (1995).  Linking clinical variables with 
health-related quality of life: A conceptual model of patient outcomes. JAMA, 273, 59-65. 
Copyright 1995, American Medical Association (see correspondence in Appendix B). 
 
 6 
1.3 
1.4 
PURPOSE 
The purpose of this secondary analysis was to test the fit of the Wilson and Cleary (1995) model 
of HRQOL in two groups of patients: persons living with HIV without liver disease and persons 
living with HIV and liver disease. Wilson and Cleary have theorized that HRQOL has five 
components: biological/physiological factors, symptom status, functional status, general health 
perceptions, and overall quality of life, and they have proposed a directional model. 
SPECIFIC AIMS AND RESEARCH HYPOTHESIS 
1.4.1 Primary Aim 
 The primary aim was to test the null hypothesis, wherein, the hypothesized model would hold 
true with the components (biological/physiological factors, symptom status, functional status, 
general health perceptions, and overall quality of life) in persons living with HIV without liver 
disease and in persons living with HIV and liver disease.  The null hypothesis was that there 
would be no difference in the model in persons living with HIV without liver disease and in 
persons living with HIV and liver disease. 
1.4.1.1 Primary Aim Research Questions 
(1.) Does the Wilson and Cleary (1995) model of HRQOL hold true in persons living with 
HIV without  liver disease?  
 7 
(2.) Does the Wilson and Cleary (1995) model of HRQOL hold true in persons living with 
HIV and liver disease (HIV+LD)?  
(3.) Is there a difference in the models between persons living with HIV with liver disease 
and in persons living with HIV+LD? 
1.4.2 Secondary Aim 
The secondary aim was to test the relationships proposed within Wilson and Cleary’s (1995) 
directional model of HRQOL between biological/physiological factors, symptom status, 
functional status, general health perceptions, and overall quality of life among persons living 
with HIV without liver disease and persons living with HIV and liver disease. The hypotheses 
for the secondary aim were as follows: 
1.4.2.1 Secondary Hypothesis 2.1 
 Biological/physiological factors have a direct effect on symptom status in persons living with 
HIV without liver disease and in persons living with HIV and liver disease. 
1.4.2.2 Secondary Hypothesis 2.2  
Symptom status has a direct effect on functional status in persons living with HIV without liver 
disease and in persons living with HIV and liver disease. 
1.4.2.3 Secondary Hypothesis 2.3  
Functional status has a direct effect on general health perceptions in persons living with HIV 
without liver disease and in persons living with HIV and liver disease. 
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1.4.2.4 Secondary Hypothesis 2.4  
General health perceptions has a direct effect on overall quality of life in persons living with HIV 
without liver disease and in persons living with HIV and liver disease. 
1.4.3 Exploratory Aim 
The exploratory aim was to identify whether there were different relationships with regard to the 
characteristics of the individual (age, sex, ethnicity/race, and number of years of education) and 
the environment (social support and household income) between and among persons living with 
HIV without liver disease and persons living with HIV and liver disease. 
1.5 DEFINITION OF TERMS  
1.5.1 HIV 
Human immunodeficiency virus (HIV) is an autoimmune disorder for which there is no cure.  
HIV is a retrovirus that attacks T lymphocytes, which are necessary to maintain immune function 
in humans. When a person living with HIV has suppressed immunity, he or she has less 
resistance to infections (McCance & Huether, 2006; Wahren et al., 1987).  A history of HIV 
diagnosis was ascertained by self-reported data from the Co-morbidity Questionnaire, Center for 
Research in Chronic Disorders (CRCD), University of Pittsburgh School of Nursing (1999).   
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1.5.2 Liver Disease 
For the purposes of this study, liver disease was defined broadly as any liver problem or 
pathology known to and identified by a person living with HIV, as self-reported on the Co-
morbidity Questionnaire, CRCD, University of Pittsburgh School of Nursing, (1999) or recorded 
in the Medical Record Review (J. A. Erlen, personal communication, February 1, 2006), or Co-
morbidity Conditions Problem list (CRCD, 2000). All persons living with HIV who self-reported 
a “liver problem” were included in the HIV and liver disease group regardless of whether 
objective medical record data were available. Furthermore, all persons living with HIV who had 
a liver disease noted in their baseline medical record were included in the liver disease group. 
Such noted liver diseases included but were not limited to infectious liver diseases, such as 
hepatitis A, B, or C; steatosis (fatty liver); alcoholic liver disease; cirrhosis; hepatocellular 
carcinoma; and liver toxicity (see questionnaires/tools in Appendix C). 
1.5.3 Biological/Physiological Factors 
Wilson and Cleary (1995) have conceptualized biological/physiological factors as any 
measurable function of the cells or organs of an individual.  This component includes other 
clinical indicators such as measures of change in the function of the cell, organ, or organ system.  
HIV viral load and CD4 counts were the biological and physiological factors that were assessed. 
HIV viral load is the amount of HIV virus that is measurable in the peripheral blood stream of an 
individual. HIV viral load was reported categorically as detectable or undetectable (below 
laboratory norms for analysis).  The retrovirus HIV suppresses the immunity of its host by 
attacking the CD4 T lymphocytes, which are necessary for immune response.  The HIV targets 
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the CD4 receptor located on lymphocytes. Lymphocytes are white blood cells that help to fight 
viral infections. Indirectly, CD4 counts indicate the level of HIV disease progression (Strathdee, 
O'Shaughnessy, Montaner, & Schechter, 1996).  Lower CD4 counts indicate a possible inability 
of the host to fight infections, thereby providing a proxy measure of immune status (Lauer & 
Walker, 2001; McCance & Huether, 2006).  HIV viral load and CD4 count were ascertained 
from self-reported and medical record review data. 
1.5.4 Symptom Status 
Symptom status was described theoretically as any psychophysical, emotional, or cognitive state 
that influences the individual (Wilson & Cleary, 1995).  Often depressive symptoms and mental 
health are included in this definition.  Symptom status was operationally assessed using each 
subject’s Beck Depression Inventory II (BDI-II) score and the Medical Outcomes Study HIV 
Health Survey (MOS-HIV) mental function summary score (Wu, Revicki, Jacobson, & Malitz, 
1997).  The  BDI-II (Beck, Steer, & Brown, 1996) measured the emotional component specific 
to depressive symptoms. The MOS-HIV (Wu, Revicki et al., 1997) mental function summary 
score measured self-reported mental well-being more broadly, as it includes mental health, health 
distress, and cognitive function subscales.   
1.5.5 Functional Status 
Functional status was defined as one’s ability to perform specific tasks such as going to work or 
making and keeping medical appointments (Wilson & Cleary, 1995).  Functional status was 
measured with the MOS-HIV physical function summary score (Wu, Revicki et al., 1997) and 
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missed clinic appointments during the prior 6 months.  The MOS-HIV physical function 
summary score (Wu, Revicki et al., 1997) was used to report self-perceived functionality. Missed 
clinic appointments were quantified using self-report or chart review data from the Medical 
Record Review (J. A. Erlen, personal communication, February 1, 2006) and were categorized as 
missed or not missed.   
1.5.6 General Health Perceptions 
General health perceptions were theoretically defined as how individuals perceive their own 
health, based on integration of biological/physiologic factors, symptom status, and functional 
status combined with the effect of the particular disease or organ state on the individual (Wilson 
& Cleary, 1995).  General health perceptions were measured by the Perception of Illness Visual 
Analog Scale (J. A. Erlen, personal communication, February 1, 2006) and the MOS-HIV health 
transition score, a single item score (Wu, Revicki et al., 1997).   
1.5.7 Overall Quality of Life 
Theoretically, overall quality of life was described as how satisfied individuals are with all 
aspects of his or her life (Wilson & Cleary, 1995).  Overall quality of life was measured with the 
Satisfaction with Life Scale (Diener, Emmons, Larsen, & Griffin, 1985) and a single MOS-HIV 
item assessing overall HRQOL   (Wu, Revicki et al., 1997).  
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1.5.8 Characteristics of the Individual 
Characteristics of the individual were specific descriptors of the person (Wilson & Cleary, 1995). 
For the purpose of this study, secondary measures assessing the characteristics of the individual 
included age (measured in years), sex (categorized as male or female), ethnicity/race 
(categorized as white and non-white and further categorized based on self-report), and number of 
years of education. All of these characteristics were ascertained from the CRCD Socio-
demographic Questionnaire, University of Pittsburgh, School of Nursing (1999) or the Medical 
Record Review (J. A. Erlen, personal communication, February 1, 2006).  
1.5.9 Characteristics of the Environment 
The characteristics of the environment theoretically included all of the individual’s surroundings, 
including tangible or intangible available resources (Wilson & Cleary, 1995).  An intangible 
resource that is often associated with health outcomes is social support. Social support was 
conceptually defined as a structural or functional resource provided by another individual (S. 
Cohen & Syme, 1985). For the purpose of this study, social support was limited to one measure 
of subjective and one measure of objective social support.  The subjective measure of the extent 
to which individuals feel that they have interpersonal resources available to them was ascertained 
from the total score of the Interpersonal Support Evaluation List (ISEL) (S. Cohen, Mermelstein, 
Kamarck, & Hoberman, 1985).  Income, as a potentially tangible supportive influence from an 
individual’s environment, was measured by annual gross household income. Self-reported annual 
gross income was ascertained from the CRCD Socio-demographic Questionnaire, University of 
Pittsburgh, School of Nursing (1999).  
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2.0  LITERATURE REVIEW 
This chapter provides an overview of the literature pertaining to quality of life (QOL) and health-
related quality of life (HRQOL) in persons with HIV and liver disease and in persons with HIV 
without liver disease.  After initial discussion of QOL and QOL models, this review explores the 
literature specific to the use of the Wilson and Cleary (1995) model of HRQOL in persons with 
HIV with or without liver disease. Further relevant literature pertaining to the latent constructs 
and factor relationships within the Wilson and Cleary model are described. Literature regarding 
physiological/biological factors and the latent constructs in the model (i.e., symptom status, 
functional status, general health perceptions, and overall quality of life) are reviewed.  Finally, 
the roles that characteristics of the individual (age, sex, ethnicity/race, and number of years of 
education) and characteristics of the environment (social support and income) have in regard to 
the theoretical underpinnings of the Wilson and Cleary (1995) model are described.  
2.1 FOUNDATION FOR QUALITY OF LIFE MODELS 
The World Health Organization (1996) defines health as not only a state of the absence of illness 
or disease, but also the positive sense of well-being.  The state of perceived health and its effect 
on the person is termed QOL.  Measures for QOL are person-centered with overall perceptions 
of QOL varying from person-to-person depending on what is important to the particular 
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individual’s existence (Cella, 1992; Murrell & Kenealy, 1999). As individuals with chronic 
diseases are living longer, the significant effects of illness and health on QOL have suggested to 
researchers that the term health-related quality of life (HRQOL) may be more appropriate 
(Corless, Nicholas, & Nokes, 2001). Many HRQOL models include measures that focus on the 
health status or disease condition of the person (Dalgard, Egeland, Skaug, Vilimas, & Steen, 
2004; Hyland & Kenyon, 1992; Sousa, Holzemer, Henry, & Slaughter, 1999; Taillefer, Dupuis, 
Roberge, & Le May, 2003; Vidrine, Amick, Gritz, & Arduino, 2005; Wettergren, Bjorkholm, 
Axdorph, & Langius-Eklof, 2004; Wilson & Cleary, 1995). 
The phenomenon of QOL is hypothesized to be multidimensional and therefore has 
several domains (Dew & Simmons, 1990; Hornquist, 1992), including physical, cognitive, 
psychosocial, and spiritual well-being (Cella, 1994; Clingerman, 2004; Croog, 1990; Cummins, 
2005; Dew & Simmons, 1990; Evans, 1994; Felce & Perry, 1995; Hornquist, 1992; Rapkin & 
Schwartz, 2004; Zhan, 1992).  Overall semantic clarity regarding the phenomenon of QOL is 
lacking.  Thus, there is debate over the exact definition of QOL and its domains (Cummins, 
2005; Dupuis, Taillefer, Hardy, Pellerin, & LeMay, 2000). 
A limitation to findings of studies focused on QOL is that researchers have not always 
approached QOL using a similar definition of the concept (Brod, Stewart, & Sands, 1999; 
Horstkotte, 1992; Larsson et al., 1994; Van Dijk, 2000; Viney et al., 1993).  Most theorists 
generally define global QOL as a phenomenon that cannot be directly observed. Rather, they 
contend that this phenomenon can be examined through the use of conceptual models, 
conceptual frameworks, or theoretical frameworks (Fawcett, 1999, pp. 91-94).  
Currently, there are multiple QOL and HRQOL theories and models; differences exist 
among disciplines such as the social sciences, nursing, medicine, and economics (Cummins, 
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2005; Milbrath, 1982; Shye, 1989; H. S. Wilson et al., 1997; Zhan, 1992). Global QOL includes, 
but is not limited to, satisfaction (general or life); performance; goal attainment; and functioning, 
well-being, and health (Taillefer et al., 2003).  An individual’s self-perceived “well-being” is 
often used as the definition of QOL within a theoretical model (Andrews & Withey, 1976; 
Becker, 1998; Brod et al., 1999; V. Brown, 1995; Bubolz, Eicher, Evers, & Sontag, 1980; 
Cantril, 1965; Cella, 1994; Cowan, Graham, & Cochrane, 1992; Evans, 1994; Felce & Perry, 
1996; Hornquist, 1992; Kaplan & Anderson, 1996; Nelson, Wiltshire, Hall, Peirson, & Walsh-
Bowers, 1995; Ormel, Lindenberg, Steverink, & Vonkorff, 1997; Sarvimaki & Stenbock-Hult, 
2000).   
There are three primary QOL models. The first, hereafter referred to as the Toronto 
Model, is socially rooted and defines QOL as the degree to which an individual enjoys and 
engages in the important possibilities in his or her life (University of Toronto, 2004). A second 
model, conceptualized by Cella (1994), hereafter referred to as Cella’s conceptualization of QOL 
(1994), is an example of a model that defines QOL in terms of domains of well-being.  The final 
model described by Wilson and Cleary (1995), and hereafter referred to as such, includes the 
addition of health-related and social factors and defines QOL in terms of the person’s perceived 
health.  
2.2 CONCEPTUAL ISSUES 
There are three different types of theoretical models used in describing QOL: conceptual models, 
conceptual frameworks, and theoretical frameworks. Conceptual models are considered to be the 
least sophisticated of the three aforementioned theoretical models.  Conceptual models specify 
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domains and subcomponents of the concept of QOL, such as functional, social, physical, and 
emotional (Fawcett, 1999, p. 130).  A weakness of conceptual models is the potential lack of 
clarity as to how the conceptual model actually operates (Cummins, 2005). Conversely, 
conceptual frameworks are organized in such a way that the nature and direction of the 
relationships within the model and among the domains are indicated. In contrast, theoretical 
frameworks offer not only the nature and direction of relationships, but also the structure of 
components within the hypothesized model (Akinsanya, Crouch, Fletcher, & Cox, 1994).  
Additional strengths of theoretical frameworks are the added specifications of potential causality.  
The causal variables measure the processes that ultimately generate the outcome, whereas, the 
constant or indicator variable is the measured outcome. 
2.3 TORONTO AND CELLA QUALITY OF LIFE MODELS 
This section examines the Toronto Model (2004) and the Cella (1994) conceptualization of QOL. 
The subsequent section describes the Wilson and Cleary (1995) model of HRQOL, which 
focuses primarily on health-related issues and QOL. 
The Toronto Model (2004) is socially rooted in personal goal attainment including social 
and role functions, similar to other  QOL models (Becker, 1998; Browne et al., 1994; Campbell, 
Converse, & Rodgers, 1976; Cella, 1994; Dupuis, Taillefer, Etienne et al., 2000; Felce & Perry, 
1995; Gerin, Dazord, Boissel, & Chifflet, 1992; Horstkotte, 1992; Maas, 1991; MacFarlane, 
Brown, & Bayer, 1989; Milbrath, 1982; Ormel et al., 1997; Shye, 1989; University of Toronto, 
2004; Wilson & Cleary, 1995).  The Toronto Model (2004) theorizes QOL in terms of three 
socially rooted domains: being, belonging, and becoming. Being is defined as one who is. The 
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subcategories of this domain include physical being (physical health, personal hygiene, nutrition, 
exercise, grooming and clothing, and general physical appearance), psychological being 
(psychological health and adjustment, cognitions, feelings, self-esteem, self-concept and self-
control), and spiritual being (personal values, personal standards of conduct, and spiritual 
beliefs).  The domain of belonging is defined as the connections one has with one's 
environments. The subcategories of the belonging domain are physical belonging (home, 
workplace/school, neighborhood, and community), social belonging (intimate others, family, 
friends, co-workers, neighborhood and community), and community belonging (adequate 
income, health and social services, employment, educational programs, recreational programs, 
community events and activities). The third domain is becoming, which is defined as achieving 
personal goals, hopes, and aspirations. The subcategories included in this domain are practical 
becoming (domestic activities, paid work, school or volunteer activities, and seeing to health or 
social needs), leisure becoming (activities that promote relaxation and stress reduction), and 
growth becoming (activities that promote the maintenance or improvement of knowledge and 
skills, and adapting to change).  
When examining the Toronto Model (2004),  an existence of self is necessary to be, 
belong, and become.  That self, or being, is influenced by and influences the other dimensions 
within a social, physical, and cultural context.   Instruments used to measure, the domains of this 
QOL model may not contain the core of the person’s perceived existence.  As being is defined as 
one who is, “being” may not be easily measured if the negative state of what someone is not is 
not also assessed.  It may be easier for the researcher to measure what someone is not; in terms 
of lack of functional, social, physical, and emotional well-being; but that may be measuring 
nothing at all if it is not specific to the individual’s existence. Although the components that 
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make up this QOL model are generally accepted within the social sciences, they do not provide 
clear direction for interventions as the person’s current health status is not included. The model 
does not consider the interaction of the social indicators with medical co-morbidities, such as 
HIV and liver disease. Furthermore, being, belonging, and becoming are considered to be on a 
continuum with relationships to each other that are not directional or summative in nature. In 
other words, one could perceive themselves as fully belonging in a physical, social and 
community context, but have no sense of their place or purpose in those environments.  
Therefore,  the Toronto Model (2004) lacks sufficient health-related domains to be instructive in 
research addressing health-related outcomes as a function of or related to QOL. 
Cella (1992) describes three basic purposes for assessing QOL in patients (i.e., cancer); 
“(1) to assess rehabilitation needs, (2) as an endpoint in evaluation of treatment outcome, and (3) 
as a predictor to future treatment”(Cella, 1992, p. 9).  Cella's  (1994) conceptualization of QOL 
focuses on well-being and includes four domains: functional well-being, social well-being, 
physical well-being, and emotional well-being. Cella (1994) notes that the functional well-being 
domain of QOL correlates with the physical well-being domain; however they are conceptually 
and empirically distinct from one another. Although Cella’s (1994) conceptualization does not 
have a causal process, the model does suggest that the domains impact one’s subjective QOL. 
There is no noted indication as to the level of significance or amount of each of the domains that 
comprise overall QOL. Likewise the linkages between the domains are not specified. An 
additional limitation to Cella’s conceptualization of QOL (1994) is the exclusion of symptom 
indices and symptom duration measures (see Preliminary Data section in Chapter 4 for results of 
a pilot study using Cella’s (1994) conceptualizatoin of QOL).  
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The Toronto Model (2004) and Cella’s conceptualization of QOL (1994) each have their 
own inherent strengths.  However, both models lack a distinct conceptual framework and the 
inclusion of health-related factors. 
2.4 WILSON AND CLEARY HEALTH-RELATED QUALITY OF LIFE 
HIV and liver diseases have been shown to significantly impact individuals’ HRQOL.  There are 
multiple interpretations and conceptual frameworks for HRQOL, most of which consider 
HRQOL to be a multidimensional phenomenon in which the components make up the whole. 
HRQOL is defined as the state of perceived health and its effect on the person (Chadwick, 1994; 
Horstkotte, 1992; Hyland & Kenyon, 1992; Kaplan & Anderson, 1996; Levy & Guttman, 1975; 
Testa & Simonson, 1996; Ware, 1984; Wilson & Cleary, 1995).  The Wilson and Cleary (1995) 
model of HRQOL includes health-related and social factors.  As a causal model Wilson and 
Cleary allows for identification of potential causal factors in the overall HRQOL paradigm.  The 
model links biomedical and social science paradigms; therefore it has the potential to bridge the 
gap between physiological indicators and patients’ perceptions of their overall QOL.  
 After pilot testing (see Chapter 3) Cella’s conceptualization of QOL (1994), the potential 
for measurement error due to the high correlation of the domains became evident to this 
researcher (Henderson, Caruthers, & Erlen, 2005).  Given the aforementioned limitations of the 
Toronto Model (2004) and Cella’s conceptualization of QOL (1994), this dissertation was 
shaped by Wilson and Cleary’s (1995) model of HRQOL, which focuses on dimensions that 
culminate in perceived HRQOL (See Figure 1, model overview, and definition of terms in 
Chapter 1). 
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 2.5 QUALITY OF LIFE MODELS IN HIV AND LIVER DISEASE 
Liver disease has been shown to have significant negative effects on an individual’s QOL (Foster 
et al., 1998).  The available empiric support measuring QOL in persons with liver disease reports 
overall QOL or has QOL domain subscale scores.  Recent research on QOL in liver disease 
defines QOL as an outcome (Fleming et al., 2004; Foster et al., 1998; Hickman et al., 2004; 
Nicholas, Kirksey, Corless, & Kemppainen, 2005; Pojoga et al., 2004); however, the studies are 
not theory-driven (Fleming et al., 2004; Foster et al., 1998; Hauser et al., 2004; Hickman et al., 
2004; Pojoga et al., 2004).  For example, Foster et al. (1998) showed that adults with chronic 
liver disease have impaired physical and social functioning compared to population norms. 
Although there is literature regarding the effect of liver disease on QOL, fatigue, and depression 
(Foster et al., 1998), specific recommendations to translate this research into clinical practice 
have not been made.  
The ultimate goal of methodically modeling HRQOL and its domains within the 
population of those co-infected with HIV and liver disease is to empirically identify those areas 
of HRQOL that are negatively affected and then to tailor interventions specifically to individuals 
to aid them toward an improved overall HRQOL. While there has been considerable research 
with the use of the Wilson and Cleary (1995) model of HRQOL in persons living with HIV, the 
model has not been used in a sample of persons living with HIV and liver disease.  This 
dissertation addresses this gap in the existing literature.   
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2.6 RESEARCH EXAMINING THE WILSON AND CLEARY MODEL IN HIV 
Wilson and Cleary’s (1995) model of HRQOL has been applied to multiple disease processes 
including HIV/AIDS (Clingerman, 2004; Phaladze et al., 2005; Sousa et al., 1999; Sousa & 
Kwok, 2006; Vidrine et al., 2005), heart failure (Heo, Moser, Riegel, Hall, & Christman, 2005), 
gastrointestinal bleeding (Sousa & Williamson, 2003), diabetes (Chia, 2007), and Hodgkin’s 
lymphoma (Wettergren et al., 2004). The use of Wilson and Cleary’s (1995) model of HRQOL 
specifically in persons living with HIV is presented in this section.  
One of the first studies to use the Wilson and Cleary (1995) HRQOL model in HIV was 
preformed by Sousa and colleagues (1999) who tested the model in a sample (N=142) of persons 
with a diagnosis of AIDS.  The authors performed a series of multiple regression analyses with 
single measures for each of the seven dimensions (biological/physiological factors, symptom 
status, functional status, general health perceptions, overall QOL, characteristics of the 
individual, and characteristics of the environment) of the HRQOL model as proposed by Wilson 
and Cleary (1995). AIDS-specific physiological variables were collected and combined to make 
a modified acute physiology and chronic health evaluation score that measured the 
biological/physiological factor. These variables included temperature, heart rate, respiration rate, 
mean blood pressure, blood urea nitrogen, creatinine, albumin, hematocrit, sodium, glucose, and 
white blood cell count. Symptom status in the model was measured with the HIV–Problem 
Checklist (Holzemer, Henry et al., 1999; Holzemer, Henry, Reilly, & Slaughter, 1994). 
Functional status was measured with the HIV Quality Audit Marker (Holzemer, Henry, Stewart, 
& Janson-Bjerklie, 1993). General health perceptions (In general your health is…?) and overall 
QOL (Your QOL during the past 4 weeks has been…?) were measured with separate single item 
scores from the MOS-30 (A. W. Wu et al., 1991). Characteristics of the individual included age, 
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sex, and ethnicity, while characteristics of the environment included living arrangements, health 
insurance status, and employment status.  The authors found that 32% of the variability in overall 
QOL was explained by the total Wilson and Cleary HRQOL model. Symptom status, functional 
status, and general health perceptions together explained 20% of the variability in the model. The 
authors noted that the dummy coding of categorical variables may have placed limitations on 
their analysis because an aggregated path coefficient was replaced with change in R2 as the 
categorical variables were entered into the model. Categorical variables are generally not 
normally distributed nor are the residual terms associated with them. Therefore, standard 
assumptions of linearity of multiple data points may be biased, making it less likely for 
researchers to find a significant influence of the dummy coded categorical variable in the 
analysis (J. Cohen, 2003). 
Clingerman (2004) conducted a descriptive study guided by the Wilson and Cleary model 
in a sample of 78 persons (90% male) living with HIV in a community setting. This cross-
sectional study examined three dimensions in the Wilson and Cleary model: functional status 
(physical activity), social support, and overall QOL.  Physical activity was measured with the 
Physical Activity Questionnaire (Ainsworth et al., 1999; Jones et al., 1999), while social support 
was measured with the Norbeck Social Support Survey (Norbeck, 1995). Overall QOL was 
measured with the Medical Outcomes Study HIV Health Survey (MOS-HIV) (Wu, 1996) with 
the single-item overall QOL score. Standard multiple regression analysis was performed to 
assess the ability of the independent variables (physical activity and social support) to predict the 
dependent/outcome variable (HRQOL). Together physical activity (weekly, 30-minute 
participation in moderate to vigorous activity) and social support (friend support) were 
significantly related to HRQOL, (p<.01), predicting 37% of the variability in HRQOL.  
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Sousa and Kwok (2006) further tested Wilson and Cleary’s (1995) model of HRQOL 
using patients living with AIDS (N=917) from the AIDS Time-Oriented Health Outcomes Study 
conducted in outpatient clinics in California. In this study, structural equation modeling was used 
to test the five main concepts (biological/physiological factors, symptom status, functional status, 
general health perceptions, and overall QOL) in the model.  The authors noted that 395 of the 
917 patients had available CD4 count data for inclusion of the biological/physiological factor in 
the data analysis.  Symptom status as the higher order general factor was measured with a 
revision of the Sign and Symptom Checklist for Persons with HIV disease (Holzemer, Henry et 
al., 1999). The second-order factor structure of symptom status included six HIV-specific 
symptoms: malaise/fatigue, confusion/distress, fever/chills, and gastrointestinal pain, shortness 
of breath, and nausea /vomiting.  Functional status as the higher order general factor was 
measured with the Health Assessment Questionnaire-Disability Index (Singh et al., 1991).  The 
second-order factor structure of functional status included eight functional components: 
activities, reach, grip, eating, dressing, hygiene, walking, and arising. General health perceptions 
were measured in two ways:  (1) the first using a 100 mm visual analog scale that was double-
anchored with “very poor health” and “very healthy”, and (2) an ordinal scale that reversed the 
scoring of the anchors, with 1 being “excellent” and 5 being “poor.” The two items were then 
standardized into the same scale.  Overall QOL as a higher order general factor was derived by 
combining two specific second-order factors including mental health and health worry (Sousa & 
Chen, 2003). The results of the study showed that Wilson and Cleary’s (1995) model of HRQOL 
fit the data, with each of the relationships between the higher order general factors being 
significant (p<0.05).  The authors were able to specify an alternative model that linked symptom 
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status directly to general health perceptions and overall QOL. Alternative models have been 
generated to identify better fitting models that are more parsimonious. 
Vidrine and colleagues (2005) tested a modified Wilson and Cleary (1995) model in a 
sample of 348 outpatients living with HIV in south central United States. In this cross-sectional 
descriptive study, four of the five factors in the model were operationalized as follows: 
biological/physiological factors by self-reported nadir CD4 count, symptom status by the New 
England Medical Center pain scale (Rogers, Wittink, Wagner, Cynn, & Carr, 2000), functional 
status by the Household and Leisure Time Activities Questionnaire (Vidrine, Amick, Gritz, & 
Arduino, 2004), and overall QOL by the MOS 12-item short form health survey (Ware, 
Kosinski, & Keller, 1996). The characteristics of the individual included socioeconomic status 
that was measured by two educational variables (years of education and educational attainment) 
and one occupational variable (a six-item ordinal hierarchy of occupational functionality as 
defined by the 1970 United States Census Bureau). The authors’ model modifications were 
theoretically influenced by Brenner, Curbow, and Legro (1995) to include the additional variable 
of individual risk behaviors to the Wilson and Cleary (1995) model of HRQOL.  These 
individual risk behaviors included smoking status (mean number of cigarettes/day), alcohol use 
(mean number of drinks/day), and illicit drug use (total number of uses in the past month).  
Using structural equation modeling (SEM), the authors simultaneously tested all of the causal 
relationships among the factors that comprise HRQOL. The analysis conducted with LISREL 
8.54 included descriptive statistics, correlations, SEM, direct and indirect effects, squared 
multiple correlation, root mean square error of approximation, and full information maximum 
likelihood estimations.  The researchers found that the conceptualized adapted model was 
 25 
supported and well fitted, χ2 (44) = 57.62, p=0.08, though the behavioral variables were highly 
correlated between .94 and .99 and may have yielded some measurement error.   
A descriptive, cross-sectional study conducted in 2002 in sub-Saharan Africa tested the 
Wilson and Cleary (1995) model in a sample of 743 persons (39% male) living with HIV 
(Phaladze et al., 2005). Data were collected via a self-report instrument that was administered in 
face-to-face interviews. Biological/physiological factors were measured by self-report of 
presence of any co-morbid conditions and a history of an AIDS diagnosis.  Symptom status was 
measured as the number of current daily symptoms and symptom intensity using the Revised 
Sign and Symptom Checklist for persons with HIV disease (Holzemer, Hudson, Kirksey, 
Hamilton, & Bakken, 2001). Functional status was measured in three ways: the HIV/AIDS-
Targeted QOL tool (Holmes & Shea, 1997, 1999), subjective reports of spending more than 80% 
of the day in bed, and history of receiving home health visits.  Separate subscales of the 
HIV/AIDS-Targeted QOL Tool (Holmes & Shea, 1997, 1999) were used to measure general 
health perceptions (health worries subscale) and overall QOL (life satisfaction subscale). The 
analysis included separate stepwise multiple regressions to identify significant predictors in the 
model when each measure was entered according to the proximal-distal or a left-to-right 
organized Wilson and Cleary (1995) model (see Figure 1 in Chapter 1). The model explained 
53% of the variance in overall QOL, with over 30% uniquely derived from reported functional 
status. An additional 10% of the variance was attributed to financial worries as a measured 
characteristic of the environment in the model.  An interesting finding in this study was that the 
average number of daily symptoms reported was over 17; however, when functional status was 
entered into the regression model (B=-.432, r2=.492), symptom status was no longer significant 
(B=-.028, r2=.186).  This finding may be due to a potential measurement issue in that the two 
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variables may have been a measuring similar phenomenon, thus over-saturating the regression 
model. This over-saturation of variables may imply that the symptom and functional status 
variables were measuring similar constructs, not that functional status overrode symptom status, 
but that there was no unique contribution of functional status when symptom status was already 
significant in the model.   
In summary, the Wilson and Cleary (1995) model of HRQOL has been shown to be 
useful in modeling the multiple domains of HRQOL in individuals living with HIV. The 
aforementioned studies used different measures and various samples across a variety of settings, 
but in each study the model was found to be well-fitted to the data (see Table 1).  
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 Table 1. Measures and Outcomes for Components of the Wilson and Cleary Model for 
Studies Involving the HIV Population 
Author 
(Year) 
Sample 
 
Biological/ 
Physiological 
Factors 
Symptom 
Status 
Functional 
Status 
General Health 
Perceptions 
Overall  
Quality of Life 
Clingerman 
(2004) 
N=78 
 
n/a n/a Physical 
Activity 
Questionnaire 
n/a MOS-HIV;  
R2 = 37% 
Phaladze et al. 
(2005) 
N=743 
Co-morbidity;  
AIDS 
diagnosis 
Symptom 
intensity; Total 
number of 
symptoms-
Revised Sign 
and Symptom 
Checklist for 
Persons with 
HIV Disease 
 
 HIV/AIDS-
Targeted  
Quality of Life –
overall function; 
Bed time; 
Received home 
visits 
HIV/AIDS- 
Targeted 
Quality of 
Life-Health 
worries 
HIV/ AIDS-
Targeted Quality 
of Life- Life 
satisfaction;  
R2 = 53% 
Sousa, Holzemer,  
Henry, & Slaughter 
 (1999) 
N=142 
 
Acute 
physiology & 
chronic health 
evaluation 
 
HIV Symptom 
Checklist 
HIV Quality 
Audit Marker 
MOS-SF-30  MOS-SF-30; 
R2 = 32% 
Sousa & Kwok 
(2006) 
N=917 
CD4 Sign and 
Symptom 
Checklist for 
Persons with 
HIV 
 
Amended Health 
Assessment 
Questionnaire 
Disability Index 
 
Visual Analog 
health 
perception 
scale 
Mental health 
question & health 
worry question; 
RMSEA=.075 
Vidrine, Amick, 
Gritz, & Arduino  
(2005) 
N=348 
CD4 New England 
Medical 
Center Pain 
Scale 
Household and 
Leisure Time 
Activities  
n/a MOS SF-12 
mental and 
physical summary 
scores; 
RMSEA=.03 
 
 
Note. n/a = not applicable, R2 = Percent in regression model, MOS-HIV= Medical Outcomes 
Study HIV Health Survey, MOS-SF-30= Medical Outcomes Study-Short Form 30 item,  
RMSEA = root mean-square error of approximation. 
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2.7 FACTORS INFLUENCING HRQOL  
Each of the components in the Wilson and Cleary model (biological/physiological factors, 
symptom status, functional status, general health perceptions, and overall QOL, see Figure 1 in 
Chapter 1) have been addressed separately in numerous studies. To the extent that these studies 
were relevant to HIV and liver disease and to the operationalized Wilson and Cleary (1995) 
model of HRQOL (Figure 2) that provided the basis for this dissertation, they were reviewed. 
 
Biological/
Physiological 
Factors
CD4 Count
HIV Viral Load
Functional Status
Missed Appts
MOS-HIV Physical
Overall Quality of Life
Satisfaction with Life Scale
MOS-HIV Overall QOL
General Health 
Perceptions
Perception of Illness
MOS-HIV Health 
Transition
Symptom Status
BDI-II
MOS-HIV Mental
Characteristics of 
the Individual
Age/Sex
Ethnicity/Race
Years of Education
Characteristics of 
the Environment
ISEL
Household Income
 
Figure 2. Operationalized Wilson and Cleary Model 
Modified from: Wilson, I. B. & Cleary, P. D. (1995). Linking clinical variables with health-
related quality of life: A conceptual model of patient outcomes. JAMA 273, 59-63. Copyright 
1995, American Medical Association. 
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2.7.1 Relationship between Biological/Physiological Factors and Symptom Status 
According to the Wilson and Cleary (1995) Model of HRQOL, biological/physiological factors 
are hypothesized to have a direct effect on symptom status.  Biological/physiological factors 
often include a measurable function of the cells or organs of an individual.  These components 
include other clinical indicators such as measures of change in function of the cell, organ, or 
organ system.  Symptom status is described theoretically as any psychophysical, emotional, or 
cognitive state that influences the individual.  Often depressive symptoms and mental health are 
included in this definition. The following is a review of the empirical support for the relationship 
between biological/physiological factors and symptom status. 
2.7.1.1 Results from HIV Studies 
In persons living with HIV, clinically meaningful biological/physiological factors that serve as 
indicators of disease status have been HIV viral load and CD4 count. Holzemer, Corless, and 
colleagues (1999) found continuous measures of CD4 counts to predict HRQOL in persons 
living with HIV using the Wilson and Cleary (1995) model. The sample (N=420) included 
persons living with HIV (80% male) from seven cities around the United States. The 
participants’ mean CD4 count was 321 mm3, and those with lower CD4 counts and higher viral 
loads were likely to have more depressive symptoms and miss more medical appointments than 
those with higher CD4 counts and lower viral loads. 
 Numerous investigators have found relationships between biological/physiological 
factors (CD4 count, HIV viral load) and HRQOL using different measures of HRQOL and 
different analytic approaches.  A prospective, Italian cohort study by Murri and colleagues 
(2003) included 809 persons (68% male) with HIV who were taking highly active antiretroviral 
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therapy. Data were collected at baseline and six months. HRQOL was measured with the MOS-
HIV Health Survey (A. W.  Wu, 1996) physical and mental health summary scores (Revicki, 
Sorenson, & Wu, 1998).  Fifteen possible symptoms were scored by an investigator-generated 
symptom tool that queried severity of symptoms in the preceding four weeks.  A backward 
sequential logistic regression model was used with an alpha of .05 set for inclusion in the 
analysis. The MOS-HIV physical and mental summary scales were initially scored with the 
standardized algorithm (Revicki et al., 1998), then further dichotomized into high and low 
groups, thus enabling the logistic regression analysis. Baseline variables included age, gender, 
stage of HIV disease, mode of HIV transmission, CD4 count and HIV viral load, type of HIV 
medication, physical and mental health summary scores, symptom score, hospitalization history 
within past 3 months, education, monthly income, and employment status. The authors found 
that CD4 counts and symptoms were independently related to the MOS-HIV physical function 
composite score.  Additionally, the symptom score was highly negatively related to the mental 
health summary score, such that the more symptoms a person reported the lower the mental 
health summary score. Thus, in this study there was a significant relationship between 
biological/physiological factors and symptom status as hypothesized in Wilson and Cleary 
(1995) model of HRQOL. 
2.7.1.2 Results from HIV and Liver Disease Studies 
The biologic/physiologic co-morbidity of liver disease, liver toxicity, and/or hepatitis has direct 
impact on the synthetic function of the liver.  When the liver’s basic function of signaling bone 
marrow to produce red blood cells is compromised, many systems of the human body are in turn 
also affected.  That is, when the liver is inflamed, it is unable to filter out toxins from the blood 
and keep the body in homeostatis (McCance & Huether, 2006).  Additionally, when the liver is 
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not functioning properly, HIV medications can have augmented toxic effects at a relatively low 
dose (Monto et al., 2002; Shiffman, 1998; Tedaldi et al., 2003). Hepatitis A, B, and C are viral 
infections that attack the liver, causing inflammation as the body attempts to fight the infection; 
proliferative changes ensue (Lauer & Walker, 2001; McCance & Huether, 2006). Individuals 
with liver disease can be asymptomatic or have mild symptoms.  Serum laboratory values may 
indicate altered liver transaminases. Synthetic function can be abnormal or normal, yielding 
altered blood coagulation, hemoglobin and hematocrit, and albumin and iron values. Clinically 
the liver may be palpable and tender; ascites may be present.  Jaundice with altered bilirubin 
values may occur with acute or severe chronic liver infections or liver toxicity. Many persons 
with liver disease have no symptoms.  They do not present for treatment until they are in 
fulminate liver failure or cirrhosis; at this point prognosis is poor (Lauer & Walker, 2001). 
Other biologic/physiologic influences on HIV and liver disease progression are obesity 
and visceral adiposity (Hickman et al., 2004; NIH, 2002; Ortiz et al., 2002).  Obesity can result 
in non-alcohol fatty liver disease, which can lead to liver fibrosis without the co-morbidities of 
HIV or liver disease being superimposed to potentially further damage the liver (Ortiz et al., 
2002).  Additionally, drug metabolism can be altered due to increased weight. Safe weight-based 
guidelines are not in place for individuals greater than certain weights (NIH, 2002).  Hickman 
and colleagues (2004) found that overweight patients with chronic liver disease who had 
engaged in physical activity and had a modest weight loss experienced sustained improvements 
in alanine aminotransferase, fasting insulin, and QOL.  In contrast, interferon treatment can 
impact the nutritional status of patients by making them have a decreased appetite, thereby 
contributing to weight loss, anemia, and fatigue (Hickman et al., 2004). 
 32 
A significant potential influence on negative liver-related outcomes is the amount of 
alcohol consumption. A daily intake of more than 50 grams of alcohol yields significant 
differences of liver fibrosis upon biopsy.  The risk for liver cirrhosis and altered synthetic liver 
function increases with consumption of greater than 60 grams of alcohol per day in men and 40 
grams per day in women (Herrine, 2002).  Alcohol intake and hepatitis C viral load are inversely 
related to responsiveness to interferon therapy.  
There are limited reports addressing individuals with HIV and liver disease that link 
biological/physiological factors with symptom status.  However, there is evidence that 
biologic/physiologic factors have little influence on symptom status among individuals with liver 
disease.  For example, Hauser et al. (2004) conducted a study in Germany using a sample of 
patients (N=204) with various stages of liver disease.  These researchers examined the effect of 
chronic liver diseases on HRQOL by using the socio-demographic questionnaire of the 
Competence Network Bowel Disease, morbidity list of the German Pain Questionnaire, the 
German version of the Hospital Anxiety and Depression Scale, and the Medical Outcomes Study 
36-Item Short Form Health Survey (SF-36) as generic HRQOL instruments; they used the 
German version of the Chronic Liver Disease Questionnaire (CLDQ) as a disorder-specific 
HRQOL-instrument. Their findings showed that active medical and psychiatric co-morbidities 
(including depression) and not the severity of biological/physiological factors of liver disease 
corresponded with decreased HRQOL (Hauser et al., 2004).  Therefore this study of patients 
with liver disease demonstrated that biological/physiological factors were not predictive of 
symptom status  as hypothesized by the Wilson and Cleary (1995) model of HRQOL.  However 
symptom status as measured by self-reported depressive symptoms did predict overall QOL.   
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2.7.2 Relationship between Symptom Status and Functional Status 
According to the Wilson and Cleary (1995) Model of HRQOL symptom status is hypothesized to 
have a direct effect on functional status.  Symptom status is described theoretically as any 
psychophysical, emotional, or cognitive state that influences the individual.  Often depressive 
symptoms and mental health are included in this definition. Functional status is defined as an 
individual’s functional capacity to carry out social roles like attending school or work and 
maintaining relationships. Functional status includes physical abilities to perform tasks such as 
activities of daily living and the ability to attend medical appointments.  The following studies 
provide empirical support for the relationship between symptom status and functional status. 
Depression is classified by the DSM IV criteria as a Major Depressive Disorder if one is 
down, sad, or blue everyday for two weeks (First, Frances, & Pincus, 2002).  Additionally, if an 
individual has four or more symptoms associated with depression including, but not limited to, 
change in appetite, sleep disturbances, decreased energy, altered concentration, altered self-
motivation, and motor affects, then a depression classification is warranted (First et al., 2002). 
The BDI-II (Beck et al., 1996) and the Center for Epidemiologic Studies-Depression Scale 
(Radloff, 1977) are the most commonly used instruments to assess for depressive symptoms in 
persons living with HIV.  Several researchers have reported between 30-50% of persons living 
with HIV to have significant depressive symptoms (see Table 2) as assessed with the BDI-II  
(Gibbie et al., 2006; Judd et al., 2005; S. C. Kalichman, Rompa, & Cage, 2000; Weiser et al., 
2006).   
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 Table 2. Use of the BDI-II to Assess Depressive Symptoms in Persons Living with HIV 
 
 
Author 
 
Year 
 
Sample size 
 
Sample Description 
 
Findings 
 
Gibbie et al. 
 
(2006) N=129 HIV + 95% male, 18 years 
and older, able to read and 
write, receiving HAART. 
34.8% scored ≥ 14 on the 
BDI, suggestive of depressive 
symptoms.   
 
Hinkin, van Gorp, Satz, 
Weisman, Thommes, & 
Buckingham  
(1992) N=54 HIV + mostly symptomatic 
homosexual/bisexual males 
aged 20-60 
Depression as determined by 
BDI does not necessarily lead 
to a decrease in 
neuropsychological function. 
 
Judd, Mijch,  
McCausland, &  
Cockram, 
(1997) N=192 HIV + outpatient treatment 
facility 
95 patients resulted in ≥ 14 on 
the BDI, and of these 33% 
were identified as having a 
depressive disorder.  
 
Kalichman, Graham, 
Luke, & Austin 
(2002) N=241 HIV + 163 men and 78 
women not receiving 
antiretroviral treatment. 
Individuals not receiving 
antiretroviral treatment were 
0.9 times more likely to have 
cognitive depression (a 
subscale of the  BDI-II)  than 
those who were treated after 
adjusting for ethnicity and 
education  
 
 
Kalichman, Rompa, & 
Cage  
 
(2000) 
 
N=357 
 
HIV +  
 
When assessing depression in 
patients with AIDS, removing 
the somatic symptoms from 
tools such as BDI makes the 
tool more sensitive. 
 
Weiser,  Riley, Ragland, 
Hammer, Clark, & 
Bangsberg 
(2006) N=239 HIV + homeless and 
marginally housed men 
134 respondents scored ≥ 14 
on the BDI, indicating 
depressive symptoms. 
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 2.7.2.1 Results from HIV Studies 
Symptom status has been linked to functional status in multiple studies involving persons living 
with HIV (Albert et al., 1995; Anandan, Braveman, Kielhofner, & Forsyth, 2006; Breitbart et al., 
1996; Crystal, Fleishman, Hays, Shapiro, & Bozzette, 2000; Henderson, Erlen, Sereika, & 
Schlenk, 2007; Hudson, Lee, & Portillo, 2003; Hughes, 2004; Murri et al., 2003; Phaladze et al., 
2005; Sousa et al., 1999; Sousa & Kwok, 2006; Vidrine et al., 2005; Voss, 2005; Wilson & 
Cleary, 1995; Wu, Revicki et al., 1997).  For example, Sousa and colleagues (1999) found that 
there was a negative correlation between symptoms and functional status (r=-.34, p<.05) in a 
sample (N=142) of persons living with an AIDS diagnosis.  The more symptoms with greater 
intensity that were reported as measured by the HIV-Problem Checklist (Holzemer et al., 1994),  
the lower the self-reported functional self-care ability as measured by the HIV Quality Audit 
Marker (Holzemer et al., 1993). 
There are other similar findings evident in the literature; however, researchers used 
different measures of symptom status and functional status. For example, Hudson and colleagues 
(2003) conducted a study of women living with HIV (n=104) that explored fatigue symptoms 
and functional ability to care for their home and/or family.  Symptoms were inversely related to 
functional status (r=-.24, p=.01), indicating that the more self-reported fatigue the lower the 
women’s perceived ability to care for their home and/or family.  Voss et al. (2005) had similar 
findings in that there was a significant relationship of symptoms of fatigue (p=.006) and 
depression (p<.0001) toward predicting MOS-HIV physical status. However, the MOS-HIV 
mental status scores were not significantly related to the fatigue status scores (p=.77) in the 
sample (N=372) of ethnically diverse persons living with HIV.  This could be due in part to 
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measurement error, as fatigue was measured as a symptom and as a component that cross-loads 
on both the mental and physical summary scores of the MOS-HIV (Revicki et al., 1998).   This 
lack of correlation is important when considering unique contributions of each variable.  
Two other studies (Murri et al., 2003; Powers et al., 2006) examined the relationship of 
HIV symptoms to physical and mental health summary scores (Revicki et al., 1998) from the 
MOS-HIV(Wu, 1996).  Powers and colleagues (2006) examined the effects of continuous versus 
long-cycle, structured, intermittent highly active antiretroviral therapy on HRQOL and symptom 
distress in 46 adults living with HIV who received care at an outpatient clinic associated with the 
National Institutes of Health. The sample was predominately male (93%); all subjects had 
undetectable HIV RNA levels in the plasma (less than 50 copies/ml). A repeated measures 
design was used; the study was not theory-driven.  HRQOL was measured with the MOS-HIV, 
with computation of the subscale scores into two summary scores (physical and mental function). 
Symptom distress was measured with the Symptom Distress Scale (McCorkle, Cooley, & Shea, 
1998; McCorkle & Young, 1978). The questionnaires were completed at baseline and 4, 12, and 
40 weeks. The authors used separate mixed ANOVAs for each of the three outcome variables 
(symptom distress and both physical and mental function summary scores) to assess differences 
between the two groups of patients over time.  The findings showed a significant decline in the 
mental function summary score for those persons with HIV in the structured, intermittent 
medication group.  There was a significant effect of the aforementioned intervention on the 
symptom distress score or the physical function summary score over time.  The authors 
attributed the change in mental function summary scores to the medication schedule change in 
the treatment group. They hypothesized that changing a medication regime to a structured 
intermittent routine from continuous daily routine may yield a decline in subjectively-reported 
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mental function.  The authors did not consider other potential rationales for the decrease in 
mental function.  For example, intermittent higher dosing of antiretrovirals has been found to be 
more liver toxic and alterations in liver function have been associated with altered cognitive 
function in persons living with HIV (Ena, Amador, Benito, Fenoll, & Pasquau, 2003). Although, 
as previously noted, Murri et al. (2003) used different measures of HIV symptoms than Powers 
et al. (2006). Murri and colleagues also reported significant (p<.05) relationships between high 
symptom scores and poor physical and mental health status [n =175, OR = 9.60, 95% CI = (6.24-
14.77); n =199, OR= 7.02, 95% CI = (4.88-10.09)].  
In a sample (N=420) of individuals living with HIV, Holzemer, Corless, and colleagues 
(1999) reported that higher depression scores are positively related to likelihood of missing HIV 
clinic appointments. This finding supports the relationship between measures of symptom status 
and functional status hypothesized in the Wilson and Cleary (1995) Model of HRQOL. 
Functional status measures by missed clinic appointments have also been linked to symptom 
status in multiple studies involving persons living with HIV. These studies are listed in Table 3 
and indicate the relationship with increased symptom status and decreased functional status.  For 
example, the higher the self-reported depression scores the more likely individuals with HIV 
were to miss medical appointments (Holzemer, Corless et al., 1999).  
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 Table 3. Relationship between Symptom Status and Functional Status (Missed Appointments) 
Author Year Sample Size Sample Description 
 
Findings 
Aloisi, Arici, Balzano, Noto, 
Piscopo, Filice et al.  
(2002) N = 366 HIV + on retroviral 
therapy in Italy 
Age and current drug use 
were significantly associated 
with nonadherence, including 
missed appointments.   
 
Beach, Keruly, & Moore  (2006) N = 1,743 HIV+ Better provider relationships 
were significantly related to 
fewer missed appointments 
(p<.001)and lower HIV viral 
loads (p<.001). 
 
Berg, Safren, Mimiaga, 
Grasso, Boswell, & Mayer  
(2005) N = 995 HIV+ in urban 
community 
healthcare 
Missed appointments were a 
significant predictor of lower 
CD4 counts. 
 
Giordano, White, Sajja, 
Graviss, Arduino, Adu-
Oppong et al.  
(2003) N = 354 HIV+ entering care 
in Texas  
Missed appointments 
(OOR=5.85, p < .001), CD4 
count ≥ 200cells/uL (OR = 
2.50, p =.001), female sex 
(OR = 2.53,  
p = .001) were independent 
predictors of not receiving 
HAART. 
 
 
Holzemer, Corless, Nokes, 
Turner, Brown, Powell-Cope 
et al.  
 
(1999) 
 
N = 420 
 
HIV+, mean age 
39, 20% women, 
51% white, mean 
CD4 count 321 
mm3. 
 
 
Higher depression scores were 
positively related to missed 
appointments. 
Nacher, El Guedj, Vaz, 
Nasser, Randrianjohany, 
Alvarez et al.  
(2006) N = 1,213 HIV+ in French 
Guiana 
Younger age groups and 
patients with CD4 counts 
more than 400/mm3 were 
more likely to miss 
appointments. 
 
Weiser, Riley, Ragland, 
Hammer, Clark, & 
Bangsberg  
(2006) N = 239 HIV + homeless 
and marginally 
housed men 
30.1% of patients missed 
medical appointments within 
90 days. 
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 2.7.2.2 Results from HIV and Liver Disease Studies 
There are many potential interrelationships between symptom and functional status and HIV and 
liver disease; however, there is limited evidence describing the relationship between symptom 
and functional status in this population. The chronic disease symptoms associated with 
depression (e.g., fatigue, lack of energy or vitality) in persons with HIV and liver disease may be 
related to liver diseases or altered physiologic function of the liver.  In the case of individuals 
with HIV and liver disease who have symptoms of depression, baseline psychological 
assessment prior to treatment for hepatitis is recommended (NIH, 2002).  Furthermore, the 
autoimmune features associated with the replication of the infectious liver disease viruses have 
been documented to include painful disorders like rheumatoid arthritis (RA), cryoglobulinemia, 
polyarteritis nodosa, anti-phospholipid syndrome, systemic lupus erythematosus, and Sjogren’s 
syndrome.  The manifestions in individuals with liver disease may include arthralgias, arthritis, 
muscular involvement, cutaneous involvement, and peripheral neuropathy (Ramos-Casals, Trejo, 
Garcia-Carrasco, & Font, 2003). The perceived pain features in persons with liver disease are 
divided between mental anguish symptoms associated with the depression and pain associated 
with the disease that alters physical functioning (Ramos-Casals et al., 2003).  
Fleming and colleagues (2004) studied the effect of co-infection with HIV and/or 
Hepatitis C Virus (HCV) on HRQOL.  The goal of their study was to evaluate HRQOL in an 
urban cohort (N=299) of individuals co-infected with HIV and HCV. The authors compared the 
HRQOL of those with both HIV and HCV (n=136) with the HRQOL of urban individuals with 
either HIV (n=53) or HCV alone (n=110). Then all three groups were compared to an adjusted 
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United States sample to compare the differences in HRQOL. The generic SF-36 physical and 
mental summary scales were used in order to compare with United States normative data for the 
general population without known HIV or HCV. All three groups had significantly lower 
physical and mental health summary scores when compared to the general population; however, 
there was no statistical difference between the co-infected and single virus-infected group scores. 
In this analysis, HCV, as a form of liver disease, did not have a significant impact on HIV.  
Mandatory clinical laboratory reporting of HCV did not begin until 2002 in the United 
States. HCV was discovered in 1989 and had previously been included in the Non-A, Non-B 
group of hepatitis.  The Fleming and Christiansen study timeline includes data collected between 
2000 and 2002, which may have influenced the number of persons recruited who were newly 
diagnosed with HCV.  Additionally, there may have been measurement issues in that the generic 
SF-36 (Ware, Snow, Kosinski, & Gandek, 1993) that was used for the Fleming and Christiansen 
study has been adapted for the HIV population with some of the questions reformulated and 
validated in an HIV-specific SF-tool (A. W.  Wu, 1996).  The limitation of the smaller sample 
size in the HIV-only group may be a potential concern for measurement error; the significance of 
the findings may have been misinterpreted without weighting the scores.  The short duration of 
diagnosis of HCV may have also influenced the results of this study.  
The impact of HIV/HCV co-infection on HRQOL is not well understood; the literature is 
contradictory. The gap in the knowledge is that HCV HRQOL has been described in multiple 
studies prior to and after treatment for HCV; however, increasing numbers of individuals are co-
infected with HIV; have significant depression, co-morbidities, and/or substance abuse; and are 
often excluded from such clinical trials, thus making their HRQOL unknown. Studies that are 
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theory-driven and use valid and reliable instruments that measure HRQOL in the co-infected 
population are needed. 
Adults perceive both mental and physical pain as a manifestation of liver disease and 
treatment side effects. Henderson and colleagues (2006) measured QOL in a chronic liver 
disease sample (n=80) and found that their decreased QOL scores were more significantly 
related to mental domains than physical functioning or bodily pain (see Chapter 3). Conversely, a 
study of emotional distress in patients with infectious liver disease not receiving antiviral therapy 
by Fontana et al. (2002) found that elevated perceived severity of disease was highly correlated 
with SF-36 summary scores of mental and physical function (p<.001). Thus, the interrelationship 
of symptom status with functional status in persons with HIV and liver disease is unclear. 
Henderson and colleagues (2006) conducted a cross-sectional secondary data analysis in 
persons living with HIV and taking highly active antiretroviral therapy as outpatients (see 
manuscript in Appendix A). The sample (N=215) included 119 persons with HIV and 96 persons 
with HIV and liver disease. Persons with HIV and liver disease had significantly lower MOS-
HIV cognitive function subscale scores (Wu, 1996) than persons with HIV and no known liver 
disease (Henderson et al., 2006).  The factor analysis supported the use of the MOS-HIV as a 
valid instrument in both the HIV group and the HIV and liver disease group. Two higher order 
factors were extracted from the ten subscales, including mental and physical factors. Cognitive 
function loaded highly on the mental function summary score and pain loaded highly on the 
physical function summary score. Thus, these findings justify that mental function symptoms are 
separate from ability to physically function and can therefore be operationalized in the Wilson 
and Cleary (1995) model of HRQOL as such.  
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Chronic hepatitis and its treatment regimens may directly cause altered cognitive function 
(Steiner, 2004). Conversely, Cordoba and colleagues (2003) studied mental symptom status and 
QOL in adults at differing stages of liver disease and found a decrease in QOL without major 
mental symptoms being noted. The aforementioned studies are limited given the convenience 
samples and exclusion of those failing the cognitive mental exams used for screening.   
In an attempt to address some of the identified limitations, Henderson et al. (2007) 
conducted a pilot study guided by the Wilson and Cleary (1995) model of HRQOL. The primary 
aim was to examine the differences between persons with HIV with and without liver disease by 
assessing the differences between groups in biological/physiological factors, symptom status, 
functional status, and selected socio-demographic characteristics.   The variables in the Wilson 
and Cleary (1995) model of HRQOL were operationalized as follows: biological/physiologic 
factors (documented liver disease/HIV viral load/CD4 count), symptom status (Beck Depression 
Inventory II [BDI-II], Medical Outcomes Survey [MOS-HIV] cognitive subscale), and functional 
status (missed HIV clinic appointments, MOS-HIV physical subscale). This cross–sectional 
analysis used baseline data from the parent study (R01 NR04749, Erlen).  Analysis included 
descriptive statistics, correlations, chi-square, independent sample t-tests, and path analysis.  The 
sample included 215 participants with HIV, 44.7% (n=96) with HIV and liver disease, 68% 
male, and 62% Caucasian. The average age was 40.63+7.60 years. There was a significant 
prediction of functional status (missed appointments) by presence of liver disease, χ2(1) = 5.598, 
p=.018, exp(B)=1.998, suggesting individuals with documented liver disease were approximately 
2 times more likely to report missed clinical appointments.  Documented liver disease was 
related to increased symptom status, as measured by lower self-reported MOS-HIV cognitive 
scores, z= -2.987, β=-.161, p=.017, and decreased functional status, as measured by the MOS-
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HIV physical subscale, z=4.850, β =.364, p<.001. There was a significant indirect relationship 
between functional status, as measured by self-reported missed appointments, and documented 
liver disease. There was a significant negative relationship between symptom status, as measured 
by the MOS-HIV cognitive subscale, and functional status, as measured by the MOS-HIV 
physical subscale. There were no significant differences between the groups with regard to age, 
race, or gender. There was no direct path from usual biological/physiological factors (HIV viral 
load or CD4 count) to symptom status (BDI-II, MOS-HIV cognitive subscale) as conceptualized 
in the model, regardless of group.  Thus, the pilot study supported the relationship between 
symptom status and functional status, but not between biological/physiological factors and 
symptom status as hypothesized  in the Wilson and Cleary (1995) Model of HRQOL.  These 
findings support the complexities associated with understanding the factors associated with 
HRQOL in patients with HIV and liver disease. Future research as described herein was needed 
with a larger, more diverse sample and more focused measures in order to better understand the 
multifaceted issues that affect individuals with HIV and documented liver disease. 
2.7.3 Relationship between Functional Status and General Health Perceptions 
Functional status is defined as an individual’s functional ability to carry out roles like attending 
school or work (Wilson & Cleary, 1995).  Functional status includes physical abilities to perform 
tasks such as activities of daily living and ability to attend medical appointments. General health 
perceptions are theoretically defined as the individual’s perception of the state of their own 
health, based on the integration of biological/physiologic factors, symptom status, and functional 
status combined with the effect of the particular disease or organ state on the individual.  The 
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following is a review of the empirical support for the relationship between functional status and 
general health perceptions.  
2.7.3.1 Results from HIV Studies 
Reynolds et al. (2004) conducted a multi-center study with a sample of individuals living with 
HIV (N=980). These researchers found that favorable general health perceptions scores were 
related to lower depression scores (p<.001) and higher functional status (p<.001). Similar 
findings were reported by Lorenz et al. (2006) in a study of (N=2,867) individuals living with 
HIV in the United States who participated in the HIV Cost and Services Utilization Study (1997-
1998). Decreased HIV health symptoms over-time, as measured by tabulating the number of 
selected symptoms out of a list of 13 potential HIV symptoms, strongly influenced individuals’ 
general health perceptions (p<.001) and overall QOL (p<.001), as measured by two single-item 
global questions, after adjusting for demographic and biological/physiological factors. These 
studies support the relationship between functional status and general health perceptions as 
hypothesized in the Wilson and Cleary (1995) model of HRQOL. 
2.7.3.2 Results from HIV and Liver Disease Studies 
A study of emotional distress in patients with infectious liver disease not receiving antiviral 
therapy by Fontana et al. (2002) revealed that elevated perceived severity of disease was highly 
correlated with SF-36 summary scores of mental and physical function (p<.001).  Given that this 
is the sole investigation located for this review, the interrelationship of functional status and 
general health perceptions in persons with HIV and liver disease remains unclear.   
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2.7.4 Relationship between General Health Perceptions and Overall Quality of Life 
General health perceptions are theoretically defined as how individuals perceive their own 
health, based on the integration of biological/physiologic factors, symptom status, and functional 
status combined with the effect of the particular disease or organ state on the individual (Wilson 
& Cleary, 1995).  Theoretically, overall QOL is described as how satisfied an individual is with 
all aspects of his or her life and is a subjective judgment. The following is a review of the 
empirical support for the relationship between general health perceptions and overall QOL. 
2.7.4.1 Results from HIV Studies 
In multiple studies among person with HIV, general health perceptions have been measured by 
the health transition single-item from the MOS-HIV (Wu, Revicki et al., 1997). As previously 
indicated, studies show a significant relationship between general health perceptions and overall 
QOL (Clingerman, 2004; Phaladze et al., 2005; Sousa et al., 1999; Wu, Revicki et al., 1997).  
These studies support the relationship between general health perceptions and overall QOL as 
hypothesized in the Wilson and Cleary (1995) model of HRQOL; however, the researchers used 
different measures for general health perceptions and overall QOL (see Table 1 in Chapter 2). 
2.7.4.2 Results from HIV and Liver Disease Studies 
There are limited studies that address the relationship between general health perceptions and 
overall QOL in persons with HIV and liver disease.  One noted study by Mrus et al. (2006) 
assessed whether individuals’ perception of illness as reflected in health values differed among 
three groups (N=203): persons with HIV, persons with HIV and HCV, and persons with HCV. 
The framework for this study was investigator-generated based on the Wilson and Cleary (1995) 
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model and the authors’ prior work (Tsevat, 2000).  Perceived health values measures included 
the standard gamble, time tradeoff, and a health values rating scale (Froberg & Kane, 1989; 
Torrance, 1986) Additional data were obtained for religiosity, risk attitude, social support (ISEL) 
(S. Cohen & Syme, 1985), symptom distress, depressive symptoms, health status SF-12 physical 
and mental summary scores (Ware et al., 1996), self-esteem, spirituality, and demographic and 
clinical data. Preliminary bivariate analysis with alpha set a priori at .10 was conducted, and 
significant variables were entered into the model. The analysis included backwards elimination 
modeling, with significant variables (p<.05) retained in the final models.  The health values 
rating scale is a computer-assisted, one-question, visual analog scale that asks participants to rate 
their health state from 0 (death) to 100 (excellent health).  The health status rating scale scores 
were associated significantly with sexual orientation, depressive symptoms, spirituality, and SF-
12 physical and mental summary scores and accounted for approximately 61% of the variance in 
HRQOL. Group membership, defined as infection type, was not significant in the main model.  
Therefore, there was no significant difference in the perception of illness as reflected in 
perceived health values among the three groups (HIV, HIV and HCV, or HCV). The model 
specifications based on the authors’ predictions may have been biased by the study’s small 
sample size in that the study may not have been adequately powered for the multi-method 
analysis. 
Bonkovsky and Woolley (1999) found an increase in HRQOL after 24 weeks of 
interferon treatment for 41 out of 642 patients with liver disease.  These 41 individuals had a 
sustained viral response to interferon treatment.  The authors also found that prior to treatment 
there were statistically significant differences (p<.001) in all eight categories of HRQOL, as 
measured by the SF-36 (Ware et al., 1993), when compared to healthy controls.  
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2.7.5 Relationship between Characteristics of the Individual and Other Model Concepts 
The characteristics of the individual have the potential to influence symptom status, functional 
status, general health perceptions, and overall QOL according to the Wilson and Cleary (1995) 
model of HRQOL.  Any of the characteristics of the individual (age, sex, ethnicity/race, and 
education) could potentially influence the model and its components, or any combination of 
characteristics of the individual (i.e., age and sex). 
2.7.5.1 Results from HIV Studies 
 
Age, sex, ethnicity/race, and number of years of education are potential influences on HRQOL of 
individuals living with HIV. Two recent studies report that younger individuals are more likely 
to miss HIV medical appointments, as a measure of functional status (Aloisi et al., 2002; Nacher 
et al., 2006). Women have been reported to be less likely to receive treatment for HIV/AIDS 
(OR=2.53, p=.001) (Giordano, White, Sajja, Graviss, Arduino, Adu-Oppong et al., 2003). 
2.7.5.2 Results from HIV and Liver Disease Studies 
Similarly, age, sex, ethnicity/race and number of years of education are potential influences on 
HRQOL in individuals living with HIV and liver disease. African Americans have the highest 
prevalence of liver disease in the United States, are poorly represented in clinical trials, are older 
and weigh more at initiation of treatment. For unknown reasons, African Americans with liver 
disease have a significantly poorer response to treatment (Howell, Jeffers, & Hoofnagle, 2000). 
An earlier diagnosis of liver disease has been positively correlated with better health outcomes 
(Dalgard et al., 2004). Independent associations with co-infection of HIV and liver disease 
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included low socioeconomic status at the level of poverty, less than 12 years of education, and a 
history of being separated or divorced (Alter et al., 1999).  
2.7.6 Relationship between Characteristics of the Environment and Other Model 
Concepts 
The characteristics of the environment have the potential to influence symptom status, functional 
status, general health perceptions, and overall QOL according to the Wilson and Cleary (1995) 
model of HRQOL.  Social support and income, as social inequalities, have been shown to have 
significant relationships with survival and disease progression in persons living with HIV (Dray-
Spira & Lert, 2003; McFarland, Chen, Hsu, Schwarcz, & Katz, 2003; Rapkin & Schwartz, 2004).   
2.7.6.1 Results from HIV Studies 
Social support and household income have been shown to potentially influence HRQOL in 
persons living with HIV (Clingerman, 2004; Gonzalez et al., 2004; Phaladze et al., 2005; Sousa 
et al., 1999; Sousa & Kwok, 2006; Sousa & Williamson, 2003; Vidrine et al., 2005, 2004; Wu, 
Revicki et al., 1997). The aforementioned studies have typically controlled for social support and 
income as covariates in the analyses.  
It has been well established that higher self-reported social support is related to lower 
self-reported depressive symptoms (S. Cohen & Wills, 1985). Specifically, Gonzalez and 
colleagues (2004) found in a sample of persons (n= 90, 67.8% male) living with HIV in Florida 
that depressive symptoms, as measured by the BDI, were significantly negatively related to 
social support (B=-.21, p<.01), as measured by the Social Provisions Scale (Cutrona & Russell, 
1985).  
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In a study conducted in India by Luszczynska, Sarkar, and Knoll (2007), the relationship 
of social support to positive general health perceptions and physical functioning was assessed in 
a sample of 104 (63.5% female) persons with HIV. More positive general health perceptions 
were found if individuals living with HIV found benefit in being infected with HIV and was 
measured with the Benefits Scale (Antoni et al., 2001). Positive general health perceptions were 
significantly related to social support (r=.34, p<.001).  In the same study, greater self-reported 
social support was found to be related to better self-reported physical functioning (r=.30, 
p<.001), as measured by the MOS-SF-20 physical functioning subscale (Wu, Hays, Kelly, 
Malitz, & Bozzette, 1997).  
However, Clingerman (2004), as previously indicated, did not control for social support 
but rather treated social support as an independent variable.  This researcher examined three 
dimensions of the Wilson and Cleary (1995) model including measures for social support, 
physical activity, and overall QOL.  Clingerman (2004) found that social support, as measured 
with the Norbeck Social Support Survey (Norbeck, 1995), and physical activity (weekly, 30-
minute participation in moderate to vigorous activity) were significantly related to HRQOL, 
(r=.49, p <.01), predicting 37% of the variability in HRQOL. 
Household income is an important characteristic of the environment, as many individuals 
living with HIV have limited financial resources (Worthington & Krentz, 2005). The Institute of 
Medicine reports that the majority of persons living with HIV in the United States have personal 
income levels below $20,000 annually (2001).  Worthington and Krentz (2005) found in a 
Canadian study of 308 (91% male) persons living with HIV that income was a significant 
independent predictor (p<.05) of HRQOL, as measured with the MOS-HIV mental health and 
health distress subscales (Wu et al., 1991).  This study used the eleven MOS-HIV subscale 
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scores without collapsing the subscales into summary scores as recommended by Revicki and 
colleagues (1998).  
2.7.6.2 Results from HIV and Liver Disease Studies 
Using the MOS-SF-36, Foster et al. (1998) found adults with chronic liver disease to have 
impaired social and physical functioning compared to population norms (Ware et al., 1993). 
Patients (N=72, 46% male) with liver disease indicated that the symptom of fatigue negatively 
affected their functional status both socially and physically.   
Tsui, Bangsberg, Ragland, Hall, and Riley (2007) studied 216 (17% female) marginally 
housed or homeless individuals living with HIV in or around San Francisco California, and 
found the prevalence of co-infection with HCV was 56%, as measured by a positive HCV 
antibody test and detectable HCV in serum.  The researchers found that both the HIV group and 
HIV with HCV groups had significantly lower self-reported social function, as measured with 
the MOS-SF-36 social functioning subscale scores, compared to normative US data (Ware, 
Kosinski, & Gandek, 2004). Furthermore, the HIV group had significantly higher MOS-SF-36 
social function subscale scores (M=71, SD±27) than the HIV with HCV group (M= 63, SD±29) 
[t(214)=2.15, p=.03]. Previous authors have shown  that a 3-5 point difference in SF-36 scores is 
minimally clinically significant and a difference of 10 points indicates moderate clinical 
significance (Samsa et al., 1999).   
2.7.7 Other Possible Relationships 
Ferrans, Zerwic, Wilbur, and Larson (2005) proposed a revision of the Wilson and Cleary (1995) 
model of HRQOL; they eliminated the directional arrows in the model and deleted non-medical 
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factors. By making the directional arrows bi-directional, the cause and effect or temporal 
relationships, as hypothesized by Wilson and Cleary (1995), would not exist. This revision may 
be somewhat controversial, as it has not yet been confirmed. Chia (2007) tested the proposed 
Ferrans et al. (2005) modification using a structural equation model in a sample of individuals 
(N=321) with type-2 diabetes and hypertension and or/ hyperlipidemia. The researcher found that 
the Ferrans et al. (2005) modification was only supported after significant model modifications 
were made to allow for other possible paths not included in the hypothesized model. Other 
previously mentioned studies (Sousa & Kwok, 2006) have found more parsimonious models for 
HRQOL. These models include a direct path from symptom status to general health perceptions 
and overall QOL, providing further support for this relationship set forth in the Wilson and 
Cleary (1995) model of HRQOL.   
2.8 SUMMARY 
HIV has clear effects on biological/physiologic indicators, symptom status, functional status, 
general health perceptions, and overall QOL.   However, liver disease has potentially similar but 
ultimately different effects. The literature is inconsistent in terms of differences in the HRQOL 
of persons with HIV without liver disease and persons with HIV and liver disease; however, 
clinically there is a clear difference in prognosis when persons have multiple co-morbidities, 
especially co-infection with HIV and liver disease.  Studies are needed to better evaluate the 
effects of co-morbidities such as the case with HIV and liver disease on an individual’s QOL 
(Jacobson, Murray, Zellos, & Schwarz, 2002).  The aforementioned differences in persons with 
HIV and persons with liver disease are noted but have not been tested all at one time with a 
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guiding theoretical framework. As the first goal of Healthy People 2010 is to help individuals of 
all ages increase life expectancy and improve their HRQOL, the challenge is to be aware of what 
specific area of the person’s HRQOL is being affected.  Thus, there is a significant gap in the 
literature as there are many and varied influences on HRQOL with no clear direction for 
researchers and clinicians.  This study addressed this gap by focusing on the known influential 
factors on HRQOL as guided by Wilson and Cleary’s (1995) model and testing the model in both 
persons living with HIV and liver disease and in persons living with HIV without liver disease.  
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3.0  QUALITY OF LIFE PILOT STUDY 
Cella’s (1994) conceptualization of quality of life (QOL) was empirically tested in a sample 
(N=80) of persons living with HIV and liver disease (HIV+LD) (Henderson et al., 2005). The 
domains that comprise overall QOL according to Cella (1994) include functional, social, 
physical and emotional well-being. The purpose of this pilot study was to use previously 
collected data from a parent study to determine the relationship between the domains (functional, 
social, physical and emotional well-being) of QOL according to Cella’s (1994) conceptualization 
in a subsample of persons with HIV+LD.  As a study using Cella’s (1994) conceptualization of 
QOL (hence forward referred to as Cella’s model) in persons with HIV+LD was not yet 
available, this study assessed the totality of the components that influence a potentially curable 
population (liver disease) with a population lives with the chronic condition of HIV (Wilson et 
al., 1997). The goal of measuring QOL and its domains within the population of those co-
infected with HIV+LD was to empirically identify those areas of QOL that are most affected and 
then tailor nursing interventions specific to the individual to assist in improving one’s overall 
QOL. 
Cella’s model is comprised of four domains (functional, social, physical and emotional 
well-being).  A possible pictorial representation of Cella’s model would consist of overlapping 
circles within the larger circle of QOL (see Figure 3). All domains contribute to overall QOL and 
are subjective or self-perceived in nature. The domain of functional well-being is defined by 
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Cella (1994) as the subjective perspective regarding one’s ability to perform daily tasks or 
activities of daily living.  This domain could also be related to roles at work, or with family or 
friends.  Specifically, Cella defines this domain as it pertains to “one’s personal needs, 
ambitions, or social role(s)” (Cella, 1994, p. 188). The domain of social well-being is perceived 
by the individual and encompasses social support, close relations with family or friends, and 
intimacy.  The domain of physical well-being pertains to the individuals’ perceptions of their 
own bodily function, which includes disease symptomomatology, side effects of medication, or 
general physical well-being. The last domain is emotional well-being.  This domain is defined by 
Cella (1994) as being bipolar with both positive and negative affect relations.  This domain could 
include, but is not limited to, optimism, depression, or anxiety. Overall QOL is defined as one’s 
self perceived overall well-being. The domains of importance that predict overall QOL in one 
patient population may not necessarily be the same as those of another population.   
Cella’s (1994) model was chosen to be pilot tested in a subgroup of persons with 
HIV+LD because it had been previously applied to hepatocellular carcinoma populations. 
Additonally, Cella’s (1994) model  had also been applied to other specific diseases including, but 
not limited to, many cancers (breast, bladder, brain, colorectal, central nervous system, cervical, 
esophageal, endometrial, head and neck, hepatobiliary, lung, leukemia, lymphoma, ovarian, and 
prostate), and symptoms (fatigue, anemia, neutropenia, incontinence, lymphedema, and 
cachexia) (Cella, 2004).  
The scope of Cella’s (1994) model could be considered large as it may be applied to all 
persons capable of indicating their personal perceptions. The relational statements within the 
theory are such that the domains of QOL are the necessary building blocks contributing to the 
dynamic concept of QOL, thereby allowing the researcher to quantify the relationships of the 
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constructs to the concept.  All domains of QOL within Cella’s conceptualization (functional, 
social, physical, and emotional) make up the person’s perceived QOL status.  The domains 
thereby have the potential to directly influence the individual’s overall QOL. 
 Physical
Functional
Emotional
                Social
Overall Quality of Life
 
 
 
Figure 3. Interpretation of Cella’s (1994) Model 
 
There are multiple interpretations and conceptual frameworks for QOL (see Chapter 2), 
most of which consider QOL to be multidimensional phenomenon in which the components 
make up the whole, similar to Cella’s model (1994). QOL measures have been used in many 
settings and disease processes as noted previously.  Being able to quantify QOL outcomes is of 
great interest to many researchers because it is important to be able to explain whether different 
treatments or interventions are positively affecting the patient’s overall QOL.   
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3.1.1 Design 
This cross-sectional secondary data analysis assessed QOL of persons living with HIV and co-
morbid LD who were recruited to a parent study funded by the National Institutes of Health. The 
parent study (R01 NR04749, PI, J. A. Erlen) was designed to improve medication adherence in 
persons living with HIV taking highly active antiretroviral medication. The investigator analyzed 
retrospective data from individuals with HIV who self-reported liver problems; however, the 
particular liver problem was not always known because those data were not systematically 
collected as part of the parent study. Exempt Institutional Review Board authorization was 
gained from the University of Pittsburgh prior to initiation of the study (see Appendix B). Data 
were extracted by an honest broker and participants’ personal health information was de-
identified. Data were compiled from baseline data collection before any adherence promoting 
interventions occurred.  Chart review for clinical indicators of liver comorbidities was also 
performed by the honest broker.   
3.1.2 Sample 
The inclusion criteria for the parent study were: a diagnosis of HIV and currently being treated 
with highly active antiretroviral medication, males and females of all races and ethnicities, 
telephone access, and consent to participate in the parent study.  Exclusion criteria included 
failure on the HIV Dementia Scale (Power, Selnes, Grim, & McArthur, 1995), currently 
incarcerated, living with someone else already in the study, or not presently administering one’s 
own medications.  
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The sample for this secondary data analysis included 80 persons with HIV+LD who were 
predominately male (70%) and Caucasian (63.8%); 48.8% had chronic or permanent hepatitis. 
The average age was 40.95 + 7.03 years; and the average number of years of education was 
13.01 + 2.77.   
3.1.3 Measures 
Cella’s (1994) model guided this preliminary study. The concepts of the model were 
operationalized as follows: functional (Medical Outcomes Study HIV Health Survey (MOS-
HIV) role function subscale [MOSRF]); social (Interpersonal Support Evaluation List [ISEL]); 
physical (Symptom Distress Scale [SDS]); and emotional (Beck Depression Inventory II, [BDI 
II]).  Overall QOL was measured by the Ferrans and Powers (1992) Quality of Life Index (QLI).   
3.1.4 Functional Well-Being 
Functional well-being was measured with the MOS-HIV role function subscale (MOSRF). This 
tool was used to assess self-perceived functionally. The MOS SF-36 (Ware et al., 1993) has been 
adapted for use with the HIV population (MOS-HIV). The ordinal level responses to questions 
vary from answers such as “all the time” to “none of the time” (Wu, Revicki et al., 1997). The 
100-item subscale is standardized with a range of scores from 0-100 with higher scores 
signifying better function.  The MOSRF has a Cronbach’s alpha of .50 (N=117, HIV). The MOS-
HIV subscales have been validated in persons living with HIV+LD (Henderson et al., 2006; 
Henderson et al., 2007). A detailed description is available in Appendix A.   
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3.1.5 Social Well-Being 
The Interpersonal Support Evaluation List (ISEL) was used to measure social support as an 
indicator of the social domain of QOL within Cella’s model (1994). The ISEL is an ordinal 
instument that asks participants to subjectively rate the support they receive from others as 
definitely false (0) to definitely true (3). There are 40 items: 20 true and 20 false. Higher scores 
equate with higher perceived social support.  Cohen, Mermelstein, Kamarck, and Hoberman 
(1985) report the reliability for the total scale of the ISEL to be a Cronbach’s alpha of .88-.90 in 
a sample of healthy adults (N=64) without chronic disorders. 
3.1.6 Physical Well-Being 
The domain of physical well-being was evaluated in terms of physical symptom distress using 
the Symptom Distress Scale (SDS), a reliable instrument used to assess 13 particular symptoms 
in persons living with HIV (Ragsdale & Morrow, 1990). There are five choices on each of the 13 
ordinal items, which are ranked 1 to 5 (no distress to severe distress); the higher the score the 
more distress one is experiencing.  Ragsdale and Morrow (1990) report a Cronbach’s alpha for 
the SDS as .92 (N=95, HIV patients). 
3.1.7 Emotional Well-Being 
The  Beck Depression Inventory II (BDI-II) (Beck et al., 1996) was used to assess the emotional 
component of QOL.  The BDI-II is a 21-item ordinal tool for which each question has four 
statements ordered according to depressive symptom severity (maximum score is 63). Higher 
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scores indicate more depressive symptoms. The BDI-II has a Cronbach’s alpha of .92 (N=500, 
psychiatric outpatients) (Beck et al., 1996).  
3.1.8 Overall Quality of Life 
The Ferrans and Powers (1992) Quality of Life Index (QLI) was used to assess overall QOL. The 
QLI assesses both importance and satisfaction with life. The total scale of this 66-item ordinal 
index has been shown to have a Cronbach’s alpha of .84 when assessed in the HIV population 
(Mellors, Riley, & Erlen, 1997). 
3.1.9 Analysis 
The analysis included descriptive statistics, parametric and non-parametric techniques as 
appropriate, correlations, and multiple regression tests.  Multiple regression analysis measured 
QOL as the dependent variable and the four measured domains of QOL as potential predictors 
(see Figure 4).  Confirmatory factor analysis was preformed to test the goodness of fit of the data 
to Cella model (1994).  Statistical significance was set a priori at .05. SPSS version 13.0 (SPSS 
Inc., Chicago, Illinois) was used to manage and analyze the data.  Confirmatory factor analysis 
was preformed with EQS software package version 6.1 (Multivariate Software, Inc., Encino, 
California). 
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3.1.10 Results 
All four domains were moderately associated with correlations ranging from .303 to .651 with 
appropriate negative correlations with inversely related domains (see Table 4). For example, 
BDI-II scores were negatively correlated with ISEL scores, in that, the more self-reported 
depressive symptoms the lower the amount of self-perceived social support. Similarly, higher 
SDS scores were negatively correlated with MOSRF scores indicating that the higher the self-
reported symptoms the lower the self-perceived role function ability (see Figure 4).   
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 Table 4. Correlational Matrix of Measures. 
Variable QLI MOSRF ISEL SDS BDI-II
QLIa 1.000  
MOSRF .552 1.000  
ISEL .629 .430 1.000  
SDS -.470 -.651 -.303 1.000 
BDI-II -.497 -.494 -.486 .482 1.000
Note. QLIa = Constant; QLI = Quality of Life Index; MOSRF = Medical Outcomes 
Survey HIV Role Function Subscale; ISEL = Interpersonal Support Evaluation List; SDS = 
Symptom Distress Scale; and BDI-II = Beck Depression Inventory II. 
 
Multiple regression analysis with QLI as the dependent measure and the four dimensions 
as predictors resulted in significant prediction by the emotional, social, and physical domains 
explaining approximately 50% of the variance of QLI (R2=.532). Cella’s domains were 
significantly associated with QOL as measured by the QLI: functional (MOSRF), r=.329, p< .01; 
social (ISEL), r=.636, p<.01; emotional (BDI-II), r=-.549, p<.01; and physical (SDS), r=-.480, 
p<.01 (See Table 5).  However, the functional domain, as measured by the MOSRF subscale 
made no unique contribution to the regression model.   
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Figure 4. Correlation Model of Operationalized Cella Quality of Life Model 
  
Relationships of overall QOL as measured by the QLI with functional well-being (MOSRF); 
social well-being (ISEL); physical well-being (SDS); and emotional well-being (BDI-II); QLI = 
Quality of Life Index; MOSRF = Medical Outcomes Survey HIV Role Function Subscale; ISEL 
= Interpersonal Support Evaluation List; SDS = Symptom Distress Scale; and BDI-II = Beck 
Depression Inventory II. 
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 Table 5. Regression Analysis Summary for Measures Predicting Quality of Life (N=80) 
 
Measure      B  SE B    p  partial r2 
 
QLIa    14.450  4.30  .001    - 
MOSRF      .440    .63  .490  .003 
ISEL       .125    .03  .001  .161 
SDS      -.170    .08  .040  .028 
BDI-II      -.140    .07  .040  .028 
 
Note. R2 = .53. QLIa = Constant; QLI= Quality of Life Index; MOSRF = Medical 
Outcomes Survey HIV Role Function Subscale; ISEL = Interpersonal Support Evaluation List; 
SDS = Symptom Distress Scale; and BDI-II = Beck Depression Inventory II. 
 
The description of Cella’s conceptualization of QOL (1994) suggests a second order 
factor called QOL which underlies the sub-domains (well-being domains).  Multiple regression 
analyses performed in the pilot study demonstrated predictive validity in that the sub-domains 
predicting QOL suggested that the use of the QLI was valid in this sample.  However, this 
analysis did not directly test Cella’s hypothesis that all the domains make up the totality of QOL.   
Therefore, a confirmatory factor analysis was performed based on the correlation among the sub-
domains (MOSRF, ISEL, SDS, and BDI-II) all loading on one factor (QOL as measured by the 
QLI).  All 4 factor loadings were significant (see Table 6), ranging in magnitude from .522 to 
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.829.  The overall model fit was good even though the model chi-square was significant, 
χ2(2)=7.591, p=.022; CFI=.939, GFI=.956, SRMR=.058.  The communalities ranged from .272 
for ISEL to .687 for MOSRF.  The QOL domain as measured by the QLI had good reliability, 
Cronbach’s alpha =.783. 
    
Table 6. Confirmatory Factor Analysis  
 
Measure   Factor loading  z-value     SE  
QLIa   
 MOSRF   .829   7.784   .107 
ISEL    .522   4.525   .115  
SDS    .754   6.972   .108 
BDI-II    .643   5.788   .111 
 
Note. χ2(2) = 7.591, p = .022; CFI = .939, GFI = .956, SRMR = .058. QLIa = Constant; 
QLI= Quality of Life Index; MOSRF = Medical Outcomes Survey HIV Role Function Subscale; 
ISEL = Interpersonal Support Evaluation List; SDS = Symptom Distress Scale; and BDI-II = 
Beck Depression Inventory II.  
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3.1.11 Discussion 
The results of this preliminary study supported the Cella Model (1994); however the functional 
and physical domains were highly correlated in the sample of persons with HIV+LD studied.  
Interestingly, these findings were similar to results of a study by Wu et al. (1991).  Role function 
weakly correlated with physical function, but did not act as a predictor of overall QOL as 
measured by the QLI (N=80, HIV and liver disorders, Henderson et al., 2004).  Self-reported role 
function, as measured by the MOSRF, was not a predictor of overall QOL, as measured by the 
QLI.  These findings may be due to individuals with HIV+LD viewing themselves as not having 
a social or working role; possibly these findings may have been moderated by participants’ 
employment status (over 70% were unemployed or disabled). The MOSRF demonstrated a 
Cronbach’s alpha=.50 in this sample, suggesting that this particular tool may not be appropriate 
for this population or the use of a subscale of the MOS-HIV is not as reliable as using the MOS-
HIV summary scales. The results do not, however, refute Cella’s model (1994), as he does not 
speculate on the level of association between the two domains;  Cella claims that the domains are 
related. The findings of this study supported that claim.   
The quality of one’s life with HIV and liver disease and the perceived roles in one’s life 
or on a daily basis may differ.  Functioning on a daily basis may be very different from having a 
perceived role. Functional well-being is an antecedent to functional status (Fawcett, 1999).  
Functional status is important because better understanding of the factors that directly affect an 
individual’s ability to function in daily life could guide implicit and explicit supportive care.  
While Cella’s model (1994) did show a good prediction of QOL, functional status dropped out of 
the regression model.   
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It is difficult to ascertain what could be done to aid these individuals toward the life they 
desire if all that is known is that their QOL is decreased.  The components that are most 
important to the individual and their health within these domains may hold the key to potential 
interventions in the future.  Therefore, the next logical step is to use a more sophisticated model 
that has causal pathways and includes symptoms in order to further assess the phenomenon of 
QOL within the population of individuals with co-morbid HIV and liver disease.  The Wilson 
and Cleary (1995) model of HRQOL has the potential to bridge the gap between well-being 
verses health-defined models.  Not only is QOL theoretically defined in such a way that it 
includes health and well-being, but also the directional theoretical framework gives guidance and 
specification toward potential causation for decreased overall QOL.  Ultimately, the Wilson and 
Cleary (1995) model of HRQOL is a feasible and empirically supported theoretical framework 
by which to guide research in the HIV area.  As individuals living with HIV are more likely to 
die from their liver disease related complications than from HIV itself, testing the Wilson and 
Cleary (1995) model of HRQOL is warranted.  
3.1.12 Limitations 
There are several reasons for why Cella’s conceptualization of QOL (1994) did not aid in 
identifying a point of intervention to improve QOL in persons with HIV+LD. The first reason is 
a possible measurement error and lack of a causal framework. The second relates to the way the 
model defines QOL, which is overall “well-being”. Physical well-being is an antecedent to 
physical status and physical status can be highly related to particular health and physical 
symptoms that go along with chronic conditions. Additionally the retrospective nature of the 
study with QOL measures that were predetermined and a relatively small sample size limit the 
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generalizability of these study findings.  A more reliable measure of role function is needed to 
better assess role function in this population. Future research is warranted with potentially 
different measures of the functional domain.   
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4.0  METHODS 
4.1 RESEARCH DESIGN 
4.1.1 Introduction 
This secondary data analysis tested the fit of the Wilson and Cleary (1995) model of HRQOL in 
persons living with HIV without liver disease and persons living with HIV and liver disease.  
Data from persons living with HIV and liver disease from the parent study (1R01 NR04749, 
Principal Investigator, J. A. Erlen) were combined with data from persons living with HIV and 
liver disease who participated in the continuation study (2R01 NR04749, Principal Investigator, 
J. A. Erlen). These two studies are henceforth referred to as Study 1 and Study 2.  The current 
analysis was a secondary data analysis of the larger parent studies and was a cost-effective and 
time-efficient means to examine the multiple components of HRQOL and test the relationships 
in the Wilson and Cleary (1995) model of HRQOL in the two patient populations.   
 
4.1.2 Parent Study Overview 
The parent study tested a nurse-delivered, telephone-based, cognitive-behavioral medication 
adherence intervention designed to improve adherence to antiretroviral therapy in persons living 
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with HIV (R01 NR04749, Principal Investigator, J. A. Erlen). The primary aim of the parent 
study was to determine the effect over time of a nurse-delivered telephone adherence 
intervention compared to usual care on adherence to antiretroviral therapy in persons living with 
HIV. The secondary aims included testing the relationship between adherence and quality of life 
and between adherence and clinical response over time. The sample included persons living with 
HIV who were taking antiretroviral therapy; evidenced no cognitive dysfunction as assessed by 
the HIV Dementia Scale (Power, Selnes, Grim, & McArthur, 1995) at baseline; were over 18 
years of age; spoke English; and lived in the community with telephone access. No one was 
excluded based on race, gender, or ethnicity.  Exclusion criteria included living with someone 
who was currently in the study, or not presently self-administering medications.  The parent 
study used Teleform™, a Windows-based software program, for automated data entry, 
processing, and verification of the data. The parent study (N=215) began in 1998 and was 
renewed for an additional five years in 2003, at which time a third arm (individualized adherence 
intervention) was added. The continuation study enrolled 352 participants.  
4.2 SETTING AND SAMPLE 
4.2.1 Setting 
Parent study participants were recruited from western Pennsylvania and eastern Ohio community 
hospitals, university-based clinics, and comprehensive HIV care centers, as well as self-referral. 
The study was conducted by investigators at the University of Pittsburgh. If participants were 
randomized to an intervention arm, they received telephone-based behavioral interventions 
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aimed at improving their adherence to antiretroviral therapy plus their usual care. Participants not 
randomized to interventions received their usual care only. A private conference room at the 
clinic or university was used for enrollment and baseline and subsequent data collections. 
4.2.2 Sample 
Inclusion criteria for this secondary data analysis included all persons living with HIV who were 
eligible based on the aforementioned criteria and consented to participate in the parent study.   
The total sample of persons living with HIV was divided into those with and without liver 
disease.  Liver disease was confirmed via medical record review or self-report and included but 
was not limited to hepatitis (A, B, C, other), cirrhosis, steatosis, and hepatocellular carcinoma. 
The subsample of persons living with HIV and liver disease from the preliminary analysis of the 
initial parent study sample (N=215) found 45% of the persons living with HIV had liver disease 
(N=96) of whom 31% were female and 60% were Caucasian (Henderson et al., 2006).   
4.3 MEASURES 
The assessment of HRQOL and its components were limited to the measures that were used in  
the parent study. These measures included standardized and disease-specific questionnaires that 
were deemed to assess components of HRQOL.  A minimum of two measures per component 
were selected. This study operationalized the five main components of the Wilson and Cleary 
(1995) model of HRQOL as follows: biological/physiological factors (CD4 count, HIV viral 
load), symptom status (BDI-II, MOS-HIV mental summary scale), functional status (missed 
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appointments, MOS-HIV physical summary scale), general health perceptions (Perception of 
Illness, MOS-HIV health transition score), and overall QOL (MOS-HIV Overall QoL, 
Satisfaction with Life Scale). All measures are included in Appendix C.  
4.3.1 Biological/Physiologic Factors 
Biological and physiological factors were examined using HIV viral load and CD4 counts. HIV 
viral load and CD4 counts were collected by self-report and medical record review obtained at 
baseline. HIV viral load was reported categorically as detectable or undetectable  (below 
laboratory norms for analysis) as suggested by Sousa and Chen (2002).  CD4 counts were the 
number of CD4 cells counted as a continuous measure per milliliter of human blood. The range 
for CD4 counts was from zero to approximately 1,600. Continuous measures of CD4 cell counts 
have been shown to predict HRQOL in persons living with HIV by researchers using the Wilson 
and Cleary model (Holzemer, Corless et al., 1999).  
4.3.2 Symptom Status 
Symptom status was assessed using the Beck Depression Inventory II (BDI-II) score and the 
MOS-HIV mental function summary score obtained at baseline. Although some models include 
anxiety in symptom status, anxiety was not initially assessed in the parent study and therefore 
was not included. The  BDI-II (Beck et al., 1996) was used to reflect the emotional component 
specific to depressive symptoms that contributed to HRQOL. The BDI-II is a 21-item ordinal 
tool for which each question has four statements indicative of depressive symptom severity 
(maximum score is 63). Scores of 14-19 indicate mild depressive symptoms; 20-28 indicate 
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moderate depression; and 29-63 indicate severe self-reported depressive symptoms.  The higher 
the score, the greater the degree of depressive symptoms (Beck et al., 1996). Previous research 
has revealed that the BDI-II has a coefficient alpha of .92 (n=500, psychiatric outpatients) and 
.91 (n=215, HIV outpatients, 1R01 NR04749, parent study).  
The MOS-HIV (Wu, 1996) mental function summary score (Revicki et al., 1998) was 
used to assess mental well-being.  Because the MOS-HIV had not been validated in a persons 
with HIV and liver disease, an exploratory factor analysis of ten of the eleven total subscales of 
the MOS-HIV was performed (Henderson et al., 2006).  The transititonal item that queries 
change in mental and physical status is not included in the factor analysis. A two-factor model 
(mental, physical) was found and corresponded with a national normative HIV study (Revicki et 
al., 1998). The two-factor solution is presented in Appendix A and describes the factor loading 
for the two factors. Cronbach’s alphas for each of the components that comprised the two 
summary scores (physical and mental) of the MOS-HIV have generally been reported above .70 
(Wu, 1996) and have been shown to predict outcomes and discriminate between HIV groups.  
4.3.3 Functional Status 
Functional Status was measured with the MOS-HIV (Wu, 1996) physical function summary 
score and missed clinic appointments.  The baseline MOS-HIV (Wu, 1996) physical function 
summary score was used to report perceived function. The factor loadings for the physical 
summary score are presented in Appendix A. Missed clinic appointments were quantified using 
chart review data from the medical record review and were categorized as missed or not missed.  
This method was previously used as a measure of functional ability to achieve tasks in a sample 
of persons living with HIV (Holzemer et al., 1999).   
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4.3.4 General Health Perceptions 
General health perceptions was measured by the Perception of Illness Visual Analog Scale 
(VAS) developed for the parent study by Erlen (J. A. Erlen, personal communication, February 
1, 2006) and the MOS-HIV (Wu, 1996) health transition score obtained at baseline. The 
Perception of Illness VAS is a series of five questions asking participants to place a vertical line 
through a 100 mm horizontal scale at a point that indicated the extent to which HIV was 
burdening his or her life.  An example of the anchoring points on the horizontal scales is “no 
effect” to “major effect”.  After standardizing the coding of the items, higher scores indicated 
higher perceived burden of HIV disease (J. A. Erlen, personal communication, February 1, 
2006). The mean score was used. The MOS-HIV health transition scale is a single-item that asks 
how much on a scale from one to five HIV has affected one’s life; a higher score indicates a 
poorer view of health (Wu, 1996). 
4.3.5 Overall Quality of Life 
Overall QOL was measured with the Satisfaction with Life Scale (Diener et al., 1985) and the 
single MOS-HIV item that measures overall QOL (Wu, 1996) obtained at baseline. The 
Satisfaction with Life Scale is a series of five questions using a Likert scale ranging from one to 
seven that asks participants to indicate their level of agreement with positively-referenced life 
questions.  Scores may range from 5-35, with higher scores indicating increased life satisfaction. 
Internal consistency reliability for this scale in community-dwelling adults has been reported as 
Cronbach’s alpha=.87 and two-month test-retest reliability r=.82 (N=176) (Diener et al., 1985).  
The overall QOL item from the MOS-HIV tool asks how the participant would rate his or her 
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overall QOL during the past four weeks. This is a five-point Likert scale question, with 
responses that range from very good to very bad, and include a neutral midpoint (Wu, 1996). 
Responses were reverse-coded so that a higher score indicated better perceived QOL.  
4.3.6 Characteristics of the Individual 
Baseline measures used to assess the characteristics of the individual included age (measured in 
years), sex (categorized as male or female), ethnicity/race (categorized as white and non-white 
and further categorized based on self-report), and number of years of education. These data were 
obtained from the data collected at baseline using the Socio-demographic Questionnaire 
developed by the CRCD, University of Pittsburgh School of Nursing (1999). 
4.3.7 Characteristics of the Environment 
The characteristics of the environment were measured by the total score of the Inventory  
Support Evaluation List (ISEL) (S. Cohen et al., 1985) and annual gross household income, both 
ascertained at baseline in the parent study.  The ISEL is an ordinal instument that asks 
participants to subjectively rate the support they receive from others as definitely false (0) to 
definitely true (3). There are 40 items, 20 true and 20 false. Higher scores indicate higher 
percieved social support.  Cohen and colleagues (1985) report an alpha coefficient of .88-.90 for 
the ISEL.  The annual gross household income was collected as self-report data at baseline using 
the Socio-demographic Questionnaire developed by the CRCD, University of Pittsburgh School 
of Nursing (1999). Annual gross household income was collected categorically ranging from 
under $10,000 to greater than $50,000.  These instruments are included in Appendix C. 
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4.4 DATA COLLECTION PROCEDURES 
4.4.1 Overview of Data Collection Procedures 
 The first step in the conduct of this dissertation was to seek approval as an “exempt” study from 
the Institutional Review Board at the University of Pittsburgh (see Appendix B). Data from the 
parent study were then extracted and de-identified by the data manager before being used by this 
researcher for this secondary data analysis.  Data were compiled from the baseline data 
collection and medical record review across the two study cohorts. Then all variable values were 
extracted and organized in SPSS version 15.0 (SPSS Inc., Chicago, Illinois). Next, this 
researcher cleaned the data and performed data screening procedures as described in the next 
section.  After organizing and cleaning the data, preliminary analysis was conducted.   
In order to identify persons living with HIV and liver disease and persons living with 
HIV without liver disease, a screening of participants’ self-reports of liver disease was extracted 
from their baseline data from the parent study. For the purposes of this study, liver disease was 
defined broadly as any liver problem or pathology known to and self-reported by the person 
living with HIV with the Co-morbidity Questionnaire (CRCD, University of Pittsburgh School 
of Nursing, 1999) or recorded in their Medical Record Review (CRCD, 2003) or Co-morbidity 
Conditions Problem list (CRCD, 2000). All persons living with HIV who self-reported a “liver 
problem” were included in the HIV and liver disease group regardless of available objective 
medical record data.  All persons living with HIV who had a liver disease noted in their baseline 
medical record were also included in the liver disease group. All others were considered persons 
living with HIV without liver disease.  A trained research assistant confirmed group placement. 
This researcher, the researcher’s mentor, and the parent study’s project manager met bi-weekly 
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to monitor the progress of the study.  A statistician with expertise in structural equation modeling 
was consulted to aid in the formulation of the covariance matrix and to ensure proper model 
construction.  The study’s hypotheses were tested as indicated below.   
4.5 DATA SCREENING PROCEDURES 
The data were screened for missing data, outliers, and normality.  The data screening procedures 
are described below. 
4.5.1 Missing Data 
The data for this secondary data analysis were screened for missing data. The degree to which 
the missing data were problematic was assessed by examining the pattern of the missing data 
within and across variables. There are multiple techniques to deal with missing data depending 
on the pattern of missingness including listwise deletion, pairwise deletion, mean imputation, 
and regression imputation. However, in structural equation modeling a deletion or imputation 
technique is not necessary. A separate procedure estimated the model parameters without 
imputing data.  The full information maximum likelihood (Jamshidian & Bentler, 1999; Yuan & 
Bentler, 2000) computation based on the log-likelihood function was used; this approach 
assumes multivariate normality, and produces a model chi-square. If non-parametric methods are 
warranted due to not meeting the assumptions of multivariate normality then bootstrapping via 
naïve bootstrap or model-based bootstrapping was used as a re-sampling technique using the 
sample in place of a population parameter (Bentler & Yuan, 1999). 
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4.5.2 Univariate and Multivariate Outliers 
Preliminary data analysis included computation of means, modes, medians, frequencies, ranges 
of scores, standard deviations, and tests for normality, as well as the generation of scatter plots to 
examine influential data points.   
4.5.3 Data Screening for Normality, Linearity, and Multi-collinearity 
Attempts were made to normalize data with transformation, if indicated.  If certain data could not 
be normalized, then these variables were dichotomized or divided by a constant. For example, 
CD4 is positively skewed with a standard deviation of approximately 300 in both the HIV 
without liver disease and HIV with liver disease groups (see Results in Chapter 5). Standard 
transformations were unable to normalize the data. Therefore, continuous CD4 counts were 
divided by a constant of 100 and robust SEM measures were used.  Exploratory factor analysis 
scree plots were used to test for factor loadings and factor structures within each measure, as 
necessary. Correlation matrices were constructed to assess for collinearity diagnostics. 
4.6  DATA MANAGEMENT/ANALYSIS 
A statistical consultant assisted with developing the plan for the statistical analysis.  The parent 
study used Teleform™ reader to enter data from the instruments (Appendix C). These scanned 
data were double checked by a trained research assistant. The data were entered into an Oracle™ 
database. The data manager saved and stored the data. The data files were compiled and stored 
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until further cleaning and transformation of the data were performed.  The data manager 
reassigned the de-identified data so that the participants could not be identified in this study. The 
data manager transferred de-identified data to a secure, separate Unix™-based University of 
Pittsburgh private internet server that was accessible only by the research staff working on the 
study.  SPSS version 15.0 (SPSS Inc., Chicago, Illinois) was used to further manage and analyze 
the data.   
4.7 
4.8 
DESCRIPTIVE STATISTICS 
Each variable was examined for its distribution, range, mean, median, mode, and standard 
deviation. Assessment was done to test for normality specific to the type of variable. For 
dichotomous variables, frequencies were explored to identify whether cell sizes were relatively 
equal. Chi-square and the independent-samples t-test were used to examine differences between 
the initial and continuation studies and the two groups: persons living with HIV and liver disease 
and persons living with HIV without liver disease. Correlations between the variables were 
analyzed for systematic entry into the SEM. The SEM Wilson and Cleary model (1995) was 
tested (Figure 5) as well as the step-wise Wilson and Cleary model (Figure 6). 
STRUCTURAL EQUATION MODELING 
The primary aim was to test the null hypothesis, wherein the hypothesized model held true with 
the components (biological/physiological factors, symptom status, functional status, general 
 79 
health perceptions, and overall QOL) in two groups; persons living with HIV and liver disease 
and in persons living with HIV without liver disease (i.e., correctly explain the relationship 
among the variables).  A multi-group structural equation modeling (SEM) was used to test the fit 
of the Wilson and Cleary (1995) model of HRQOL in the two groups. A maximum likelihood 
estimation method used EQS software package version 6.1 (Multivariate Software, Inc., Encino, 
California) to perform the statistical analyses (Bentler & Wu, 2002).  
SEM analysis is a sophisticated statistical method designed to determine whether specific 
hypotheses about the nature and interrelationships among underlying factors (or dimensions, 
often called latent constructs) proposed in the theoretical model are consistent with the observed 
data collected from the sample (Bentler & Bonett, 1980).  Thus, SEM can be used to assess the 
complex relationships among the components in the Wilson and Cleary (1995) model of 
HRQOL in a sample of persons living with HIV and liver disease and in persons living with HIV 
without liver disease. Direct and indirect effects on nonadjacent components in the model were 
tested with SEM simultaneously (Vidrine et al., 2005).  The final analysis of the SEM showed an 
associated regression coefficient called a model parameter.  A path diagram and path analysis 
was used to represent a model based on a theory and test the secondary aims of the study, which 
included latent variables or factors (see Figure 6).  
The exploratory aim was to identify whether there were different relationships with 
regard to the characteristics of the individual (age, sex, ethnicity/race, and number of years of 
education) and the environment (social support and household income) between and among 
persons living with HIV without liver disease and persons living with HIV and liver disease. 
This model was more powerful (i.e., the effects of the Wilson and Cleary components were 
stronger in magnitude) than without covariates. The relevant covariates were determined by 
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model comparisons and/or LaGranage Multiplier tests. Only relevant covariates were kept in the 
model for reasons of parsimony. In other words, only covariates that significantly improved the 
model logically and statistically were included. 
Biological and 
Physiological 
Factors
Symptom Status Functional Status Overall Quality of Life
General Health 
Perceptions
Age Sex Race/ethnicity Education
Household Income Social Support
 
Figure 5. SEM Operationalized Wilson and Cleary Model 
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4.9 PATH MODEL 
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Figure 6. Operationalized Step-wise Wilson and Cleary (1995) Model of HRQOL 
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 4.10 MODEL SPECIFICATIONS 
For this study the Wilson and Cleary (1995) model of HRQOL was tested a priori, as it was 
theorized by its authors. The model was evaluated using the model chi-square and fit indices.  
The model chi-square is known to be sensitive to the sample size; it is not recommended for a 
model evaluation.  Instead, fit indices were used, which are like “effect” sizes.  There are 
different classes of fit indices (incremental and absolute).  The current recommendation is to use 
at least 2 different fit indices from two different classes (Hu & Bentler, 1998, 1999).  The 
comparative fit index (CFI) (Bentler, 1990) is an incremental fit index.  A model is considered 
“good” if the value is greater than or equal to .95.  The root-mean-square-error-of-approximation 
(RMSEA) is an absolute fit index (Steiger & Lind, 1980), which measures the amount of error 
(differences between an observed and a model covariance matrix).  A model is considered 
“good” if the value of RMSEA is less than or equal to .06.  Once a “good” model is identified 
with path coefficients (i.e., the size or strength of the relationship between underlying latent 
variables) and factor loadings (i.e., the size or strength between scale items and construct to be 
measured by the items) the overall model is assessed.  The model parameters (i.e., factor 
loadings and path coefficients) are then tested using the z-test at alpha equal to .05 (two-tailed). 
The model specification and results of model testing are described in Chapter 5. 
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4.11 POWER ANALYSIS 
4.11.1 Sample Size Justification: 
Study 1 was powered to require a total sample size of approximately 200.  For the parent study, 
the sample size was calculated for those with poor adherence and was estimated to have adequate 
statistical power (.80) to test for differences in mean adherence between the two treatment 
groups over time at a significance level of .05.  The initial parent study (Study 1) enrolled a total 
of 215 persons with HIV. Study 1 added a third arm (individualized adherence intervention) and 
was renewed for an additional 5 years. The continuation study (Study 2) was powered to require 
a total sample size of 300 participants and enrolled a sample of 352 persons with HIV, with 
baseline data for the measures included in this dissertation. After removing data from Study 1 on 
35 individuals who were also enrolled in Study 2, the overall sample size for this secondary data 
analysis was 532. 
4.11.2  Sample Size 
The total number of persons living with HIV and liver disease after combining Study 1 (revised 
N=180) and Study 2 (N= 352) was 227 (42.6%) of the overall sample (N=532) with baseline 
parent study data; demographic findings are reported in Chapter 5. The parent study invited 
control participants from Study 1 to enroll in Study 2 and be randomized.  Thirty-five individuals 
in Study 1 who did not receive the adherence intervention were enrolled in Study 2.  Study 2 
baseline data from these individuals was used rather than their Study 1 data. These criteria were 
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established a priori to allow for more recent data regarding liver disease status. The results of the 
merger of the initial study and the continuation study are described in Chapter 5.  
4.11.3 Feasible Sample Size 
Given Study 2 recruitment goals and the goals of this dissertation, the estimated sample size for 
this secondary data analysis was approximately 300, with 150 participants in each of the two 
groups (persons living with HIV with and without liver disease).  The total number of individuals 
who were available for this study (N=532) exceeded the required number for the planned 
analysis. 
4.11.4 SEM Power Analysis 
To estimate necessary sample size in SEM four fit indices were used to compute a noncentrality 
paramenter.  These included the root mean square error of approximation (RMSEA), 
Comparative fit index (CFI), Steiger’s gamma, and McDonald’s Fit Index (K. H. Kim, 2005). A 
maximum of 66 parameters were estimated to allow all variables to correlate with a total of 12 
variables. However, when applying SEM to Wilson and Cleary’s (1995) model (see Figure 6), 20 
parameters were estimated.  (Note that all variables were allowed to correlate and all possible 
combinations of relationships are not shown in Figure 6) Given the degrees of freedom 
approximated at 620, power of .80 and alpha equal to .05, the critical noncentrality parameter 
was 26.13. Given these calculations, a minimum total sample size was 264 participants. Because 
there were baseline parent study data from over 150 participants in each group, yielding a total 
sample size of over 300, there was more than adequate power for the analysis.   
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4.12 AIMS OF THE STUDY 
4.12.1  Primary Aim 
The primary aim was to test the null hypothesis, wherein, the hypothesized model held true with 
the components (biological/physiological factors, symptom status, functional status, general 
health perceptions, and overall quality of life) in persons living with HIV without liver disease 
and in persons living with HIV with liver disease.  
 
4.12.2 Secondary Aim 
The secondary aim was to test the relationships proposed within Wilson and Cleary’s directional 
model of HRQOL between biological/physiological factors, symptom status, functional status, 
general health perceptions, and overall quality of life among persons living with HIV without 
liver disease and persons living with HIV and liver disease. The hypotheses for the secondary 
aim were as follows: 
4.12.2.1 Secondary Hypothesis 2.1 
 Biological/physiological factors have a direct effect on symptom status in persons living with 
HIV without liver disease and in persons living with HIV and liver disease. 
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4.12.2.2 Secondary Hypothesis 2.2  
Symptom status has a direct effect on functional status in persons living with HIV without liver 
disease and in persons living with HIV and liver disease. 
4.12.2.3 Secondary Hypothesis 2.3  
Functional status has a direct effect on general health perceptions in persons living with HIV 
without liver disease and in persons living with HIV and liver disease. 
4.12.2.4 Secondary Hypothesis 2.4  
General health perceptions has a direct effect on overall quality of life in persons living with HIV 
without liver disease and in persons living with HIV and liver disease. 
4.12.3 Exploratory Aim 
The exploratory aim was to identify whether there were different relationships with regard to the 
characteristics of the individual (age, gender, ethnicity/race, and number of years of education) 
and the environment (social support and household income) between and among persons living 
with HIV without liver disease and persons living with HIV and liver disease. 
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4.13 PROTECTION OF HUMAN RIGHTS 
4.13.1 Human Subjects 
This descriptive study met criteria for an exempt study by the Institutional Review Board 
because it was a secondary data analysis that used data collected at baseline and through medical 
record review for the parent study. No identifying information was used.  For the study no one 
was excluded on the basis of gender, race, or ethnic background. This study involved the use of 
existing data/documents/records. Data were provided to the investigator in such a manner that 
subjects could not be identified directly or through identifiers linked directly to the subjects. 
4.13.2 Potential Risks 
The potential risk to the parent study participants was minimal.  Information about HIV and liver 
disease status was used; however, to ensure complete anonymity prior to its use by this 
researcher, the parent study data manager de-identified the data. The data were compliant with 
the most current guidelines of the Complete Health Insurance Portability and Accountability Act 
(HIPAA) of 1996; there was no way in which to link health status to any particular participant.  
No potential physical, psychological, social, legal, or other risks occurred. Prior to the start of the 
study, approval was obtained from the Institutional Review Board of the University of 
Pittsburgh. 
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4.13.3 Protection Against Risk   
Fully de-identified, HIPAA-compliant data were accessible only on password-protected 
computers on a private University of Pittsburgh internet server maintained by trained personnel 
at the University of Pittsburgh. This researcher completed the University of Pittsburgh education 
and certification program in research and practice fundamentals and monitored access to the data 
by ensuring only authorized access to the secure server. Access to the server was password-
protected.  Any additional records kept by this researcher were double-locked in a file cabinet in 
the researcher’s office.  
4.13.4 Inclusion of Women, Minorities, and Children over the Age of 18 
 The parent study included women, minorities, and children over 18 years of age. The numbers 
for each subgroup included in this secondary data analysis are reported in Chapter 5.  
 
4.14 LIMITATIONS 
There were limitations to this study because it was a secondary analysis of data collected for a 
larger study.  The parent study was not designed to make predictions about a subgroup of 
persons living with HIV and liver disease.  The level of logical rigor in a study is highly 
dependent upon the level of credibility/validity and dependability/reliability of the measures used 
within the context of the specified population of persons living with HIV with and without liver 
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disease.  HRQOL measures have been adapted for use in many settings and disease processes; 
however, several of the selected measures did not have demonstrated reliability and validity in a 
sample of persons living with HIV and liver disease (e.g., Perception of Illness (J. A. Erlen, 
personal communication, February 1, 2006) and the Satisfaction with Life Scale (Diener et al., 
1985)). Predicting influencing factors on HRQOL is of great interest to researchers and 
clinicians, but measuring HRQOL at one time point may not be sufficient.  There are multiple 
interpretations and conceptual frameworks for HRQOL (see Chapter 2), most of which consider 
HRQOL to be a multidimensional phenomenon wherein the components make up the whole. 
The significant difference in these conceptualizations is that Wilson and Cleary’s (1995) 
model of HRQOL is a causal directional model that allowed for identification of potential causal 
factors in the overall HRQOL paradigm.  Furthermore, the model links biomedical and social 
science paradigms and thereby has the potential to bridge the gap between physiological 
indicators and patient perceptions of overall quality of life in patients living with HIV and liver 
disease. Testing this model using SEM is only one approach to understanding HRQOL. HRQOL 
may be a phenomenon in which its predictors are too highly interrelated and thereby over 
saturate any model.  The components of importance that predict overall HRQOL in persons with 
HIV without liver disease may not necessarily correlate with the perceptions of persons with 
HIV and liver disease.  
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5.0  RESULTS 
After an initial review of the data sampling procedures, this chapter provides the results of the 
sample demographic characteristics, reliability of the measures, and results of the primary aim, 
the four secondary aims, and the exploratory aim.  Because this is a secondary data analysis, the 
number of persons with HIV and HIV and liver disease (HIV+LD) in Study 1 and Study 2 that 
met criteria for this analysis were not known a priori. Therefore, the procedure and results of the 
inclusion criteria are outlined below.  
5.1 PROCEDURES 
5.1.1 Determining the Sample 
The procedure for determining the overall sample involved multiple steps to merge data from 
Study 1 and Study 2.  The following criteria had to be met prior to combining the two studies.  
The first criterion involved uniqueness of the participants in both studies. Given the history of 
the parent study having an initial phase (Study 1) and a continuation phase (Study 2), it was 
necessary to ensure that each study participant was unique, in that the person was only included 
in the overall data set one time. Persons living with HIV that participated in Study 1 and were 
randomized to the control group (i.e., did not receive any intervention in Study 1) were invited to 
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enroll in Study 2 and be randomized to one of three arms of the study.  Baseline data from Study 
1 were collected between April of 1999 and October of 2002. Baseline data from Study 2 were 
collected between March of 2004 and March of 2007.  As previously indicated, the a priori 
condition was set in that if persons living with HIV from Study 1 also participated in Study 2 
(i.e., they were controls in Study 1), the data from Study 2 would be used rather than the data 
from Study 1 (see Figure 7). There were 35 individuals who were randomized to the control 
group in Study 1 and were subsequently enrolled in Study 2. The use of data from these Study 2 
participants (n=35) reflected more recent liver disease and QOL status.  The final overall sample 
size was 532 persons living with HIV after combining Study 1 (n=180) and Study 2 (n=352).   
In order to differentiate individuals with HIV without liver disease from those individuals 
with HIV+LD it was necessary to merge identifying liver disease data from four instruments (see 
Appendix C). In Study 1, determination of liver disease was based first on the Co-Morbidity 
Conditions Problem List and then on the self-reported Co-morbitidity Questionnaire.  In Study 2 
the same procedure for identifying persons living with HIV+LD was completed along with two 
other measures. The first was a liver disease-specific Medical Record Review Addendum A that 
collected HCV diagnosis, HCV viral load, and HCV genotype.  The second was an additional 
self-reported questionnaire that included history of hepatitis A, B, C or other hepatitis. Positive 
documented history of liver disease from the medical record review data took priority over self-
reported data.  If positive history of liver disease from medical record review data was missing, 
then self-report data were merged into the missing liver disease data field.  In other words, any 
positive history of liver disease, first from objective data (medical record review) and then from 
subjective data (self-report), was classified as HIV+LD. The classifications of merged co-morbid 
types of liver diseases are noted in Table 7.  All others were classified as HIV. The data merge 
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was conducted twice: once by hand and then with confirmation by a computer-based merger of 
data. 
 
Table 7.  Classification of Co-morbid Types of Liver Disease (n=227) 
HIV & Type of Liver Disease N  Cumulative total  Percentage (%) 
HIV+ Hepatitis A only 15 15 6.6 
HIV + Hepatitis B only 32 47 14.1 
HIV + Hepatitis C only 88 135 38.8 
HIV + Hepatitis A & B 7 142 3.1 
HIV + Hepatitis A & C 1 143 0.4 
HIV + Hepatitis B & C 13 156 5.7 
HIV + Hepatitis A, B & C 5 161 2.2 
HIV + Unknown Hepatitis 52 213 22.9 
HIV + Other liver disease 12 225 5.3 
HIV + Other liver disease + Hepatitis C 1 226 0.4 
HIV + Other liver disease + Hepatitis A, B, & C 1 227 0.4 
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 A new variable was created for liver disease and data were indicator/dummy coded as “0” 
for no positive liver disease data and “1” for positive liver disease data. After following the 
aforementioned criteria for discriminating persons with HIV from persons with HIV+LD in the 
overall sample (N=532), the data revealed 305 persons with HIV and no evidence of liver disease 
(57.3%) and 227 persons with HIV+LD (42.7%) (see Figure 7).   
 
 
Not 
Unique
n= 35
Study 1
N=215
Study 2
N=352
Unique
n= 180
Overall Sample
N=532
HIV Group
N=305
HIV+LD Group
N=227
 
Figure 7. Overall Study Grouping Algorithm 
Note. LD= liver disease 
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5.2 DATA EXPLORATION STATISTICS 
Exploratory statistical analyses were conducted to screen for missingness, outliers, normality, 
collinearity and homeoscedasticity. The exploratory statistics for the physiological/biological 
factors (CD4 count, HIV viral load), symptom status (BDI-II, MOS-HIV mental summary scale), 
functional status (missed appointments, MOS-HIV physical summary scale), general health 
perceptions (Perception of Illness, MOS-HIV health transition score), and overall QOL 
(Satisfaction with Life scale) are reported in Table 8.  Significant outliers were found for CD4 
count (n=3) and BDI-II total score (n=3).  The three CD4 counts that were statistical outliers 
were also above normal laboratory values (maximum 1612). The three highest BDI-II total 
scores were 53, 54, and 60. In addition, CD4 count and BDI-II total score were both positively 
skewed, and Perception of Illness was negatively skewed. Because of the large sample size and 
the distribution of the data, robust SEM adjusts for these violations of non-normality.  Therefore, 
a maximum likelihood robust regression was performed.  
Approximately 13% of the CD4 count and 10% of HIV viral load data were missing. Of 
the 90% with data coded for CD4 count and HIV viral load more than 70% came from objective 
medical review data. The remaining CD4 count and HIV viral load data were self-reported. 
There were detectable HIV viral load levels in approximately 41% of the overall sample.  With 
the exception of biological/physiological data (as noted above), there was less than three percent 
missing data for the other four primary model variables. Means and standard deviations 
conformed to expected values for a sample of persons living with HIV (see Table 8).  Missed 
appointments were categorized as missed or not missed, with 33% of the overall sample having 
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missed clinic appointments. The Perception of Illness was assessed with a visual analogue (0-1) 
and scores ranged from .06-1.0.  The MOS-HIV health transition score and Satisfaction with Life 
Scale were both measured with Likert scales with average scores of 3.33 and 3.57, respectively. 
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Table 8. Data Screening Descriptive Statistics for Measures 
Variable 
    Measure 
N Number 
Missing 
Percentage 
Missing 
(%)/M (SD) Range Outliers 
Biological/Physiological Factors       
    CD4 count 459 71 13.4 455.94 (303.97) 44-1540 3 
    HIV Viral Load Detectable 484 49 9.2 (41.1) n/a 0 
Symptom Status       
    Beck Depression Inventory-II 524 6 1.1 14.92 (11.54) .0-52.0 3 
    MOS-HIV Mental Summary Score 519 11 2.1 45.45 (12.08) 10.38-67.78 0 
Functional Status       
    Missed Appointments-yes 522 11 2.1 (33.0) n/a 0 
    MOS-HIV Physical Summary Score 519 11 2.1 41.83 (11.60) 14.65-63.37 0 
General Health Perceptions       
    Perception of Illness 523 7 1.3 0.74 (.18) 0.06-1.00 0 
    MOS-HIV Health Transition Score 523 7 1.3 3.33 (1.02) 1-5 0 
Overall Quality of Life       
    Satisfaction with Life Scale 516 14 2.6 3.57 (1.49) 1-7 0 
Note. n/a= not applicable 
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 5.3 RELIABILITY STATISTICS OF THE MEASURES 
Internal consistency of each of the measures assessing the model’s components (e.g., BDI-II, 
MOS-HIV, etc.) is shown in Table 9.  Acceptable to excellent reliability was noted for all 
applicable measures in the overall sample (N=532) and in both subgroups (HIV n=305 vs. 
HIV+LD n=227).  In the overall sample, Cronbach’s alpha statistics for those measures with 
more than two questions ranged from 0.628 to 0.953 showing acceptable to excellent reliability 
across the instruments. When the sample was split into the subgroups (HIV and HIV+LD 
groups) Cronbach’s alpha statistics ranged from 0.617 to 0.954, again showing acceptable to 
excellent reliability.  
The MOS-HIV mental and physical summary scores were generated by computing 
weighted HIV population-based scores for the individual subscales (e.g., pain, role function; see 
Appendix A).  Therefore, individual MOS-HIV mental and physical summary score Cronbach’s 
alphas were the same. Cronbach’s alpha reliability statistics were performed on instruments with 
more than two questions that comprised the measure.   
It should be noted that the final primary model component, overall QOL, has only one 
measure. Overall QOL was initially operationalized to include assessment using the MOS-HIV 
overall QOL score and the Satisfaction with Life Scale. After an exploratory factor analysis of 
the total MOS-HIV tool (see manuscript in Appendix A), the MOS-HIV overall QOL subscale 
score was found to be included in both the physical and mental summary scores of the MOS-
HIV. Therefore, the MOS-HIV overall QOL subscale score perfectly correlated to one of the 
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measures of symptom status (MOS-HIV mental summary score) and one of the measures of 
functional status (MOS-HIV physical summary score).  This would have unjustly biased the 
analysis in favor of finding a good fitting model. Therefore, the MOS-HIV overall HRQOL was 
excluded and the Satisfaction with Life Scale was used as the only measure for the primary 
model variable overall QOL.  
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 Table 9.  Reliability Estimates for the Measures Assessing the Model Components 
Cronbach’s Alpha 
 
Variable 
 
    Measure 
Description Number 
of Items
Overall HIV group 
(N=305) 
HIV +LD Group 
(N=227) 
Biological /Physiological Factors 
 
     
    CD4 Count  1 n/a n/a n/a 
 
    HIV Viral Load  1 n/a n/a n/a 
 
Symptom Status 
 
     
    Beck Depression Inventory-II Total Score 21 .934 
N=515 
.940 
N=294 
.924 
N=221 
 
    MOS-HIV Mental Summary Score  
 
11 .849 
N=522 
.844 
N=301 
.850 
N=221 
Functional Status 
 
     
    Missed Appointments 
 
 1 n/a n/a n/a 
    MOS-HIV Physical Summary Score  
 
11 .849 
N=522 
.844 
N=301 
.850 
N=221 
General Health Perceptions 
 
     
    Perception of Illness 
 
 4 .628 
N=525 
.639 
N=301 
.617 
N=224 
 
    MOS-HIV Health Transition Score 
 
 1 n/a n/a n/a 
Overall Quality of Life 
 
     
    Satisfaction with Life Scale  5 .859 
N=527 
.847 
N=303 
.868 
N=224 
Characteristic of the Environment 
 
     
    Interpersonal Support Evaluation List Total Score 40 .953 
N=502 
.952 
N=287 
.954 
N=215 
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5.4 CORRELATIONS AMONG MEASURES 
 
Before merging data from Study 1 and Study 2 there was a need to ensure that there were no 
gross differences in the overall relationships among the measures.  Specifically, the relationships 
between the measures across disease groups (HIV vs. HIV+LD) as a function of Study 1 or 
Study 2 were examined.  Fisher’s r-to-z transformation of correlation coefficients was performed 
to test for significant differences in the bivariate relationships across disease groups between 
Study 1 and Study 2. The raw correlation coefficients with two group comparisons are presented 
in Table 10 for the HIV group and in Table 11 for the HIV+LD group with significance levels of 
Fisher’s r-to-z transformation noted with asterisks.  Most of the group comparisons showed no 
significant differences when comparing the two studies.  Five of the 36 sets of correlations were 
different when comparing variable correlations in persons with HIV from Study 1 (n= 93) to 
Study 2 (n=151). Seven of the 36 sets of correlations were different when comparing variable 
correlations in persons with HIV+LD from Study 1 (n= 66) to Study 2 (n=130). However, the 
few correlations that were statistically different reflected appropriately in the strength of the 
association.  For example, the correlation between Beck Depression Inventory-II (BDI-II) scores 
and Satisfaction with Life scores in the HIV groups were -.213 and -.503 in Study 1 and Study 2, 
respectively, indicating a statistically significant difference in the strength of the relationship 
when applying the Fisher’s r-to-z transformation (z=2.52; p<.05).  However, this finding was 
reflected in the negative correlations found in both studies in which the more self-reported 
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depressive symptoms, as measured by the BDI-II, the lower the Satisfaction with Life scores (see 
Table 10).  
Similarly, the correlation between HIV Medical Outcomes Survey (MOS-HIV) Mental 
Summary Score and MOS-HIV Physical Summary score in HIV+LD was .525 and .716 in Study 
1 and Study 2, respectively, indicating a statistically significant difference in the strength of the 
relationship when applying the Fisher’s r-to-z transformation (z=-2.05; p=.04). The correlations 
indicate that the MOS-HIV Mental and Physical Summary scores were positively correlated in 
both studies; however the strength of the relationship was different (see Table 11). After an 
evaluation of the correlational matrices in Study 1 and Study 2 across persons with HIV without 
LD and persons with HIV+LD the data and correlational matrices supported merging Study 1 
and Study 2 data. 
 Table 10. Correlations Among Measures of Variables of the Model for HIV Group Study 1 (n=93) and Study 2 (n=151) 
 
Variables 
    Measure 
 
1 2 3 4 5 6 7 8 9 
Biological/ Physiological Factors 
    
    1. CD4 Count 
- 
 
 
        
 
    2. HIV Viral Load 
 
.334 
(.228) 
 
-        
Symptom Status 
 
    3. Beck Depression Inventory-II 
-.065 
(-.067) 
-.220 
(-.011) 
 
-       
 
    4. MOS-HIV Mental Summary Score 
 
.173 
(.155) 
.331* 
(.031)*
-.743 
(-.782) 
 
-      
Functional Status 
 
    5. Missed Appointments 
.158 
(.115) 
.157 
(.107) 
-.025 
(-.159) 
-.023 
(.178) 
 
-     
 
    6. MOS-HIV Physical Summary Score 
  
.118 
(.204) 
.173 
(.062) 
-.501 
(-.505) 
.677 
(.623) 
-.101 
(.026) 
 
-    
General Health Perceptions 
 
    7. Perception of Illness 
.318 
(.264) 
.299* 
(.006)*
-.467 
(-.419) 
.522 
(.526) 
-.039 
(.108) 
.423 
(.310) 
 
-   
 
    8. MOS-HIV Health Transition Score 
 
.074 
(.070) 
.003 
(.018) 
-.461 
(-.458) 
.569 
(.428) 
-.098 
(.023) 
.425 
(.384) 
.514* 
(.292)* 
 
-  
Overall Quality of Life 
 
    9. Satisfaction with Life Scale 
-.106 
(.150) 
-.041 
(.029) 
-.213* 
(-.503)*
.186** 
(.521)**
-.002 
(.064) 
.099 
(.297) 
.050 
(.295) 
.066 
(.152) 
 
- 
Note.  Fisher’s r to z values *p< .05; **p<.01; ***p<.001. Study 2 correlations are in parenthesis. 
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Variables 
    Measure 
 
1 2 3 4 5 6 7 8 9 
Biological/ Physiological Factors 
    
    1. CD4 Count 
- 
 
 
        
 
    2. HIV Viral Load 
 
.352 
(.286) 
 
-        
Symptom Status 
 
    3. Beck Depression Inventory-II 
-.176 
(.127) 
.002 
(-.129) 
 
-       
 
    4. MOS-HIV Mental Summary Score 
 
.282 
(.009) 
-.011 
(.205) 
-.765 
(-.803) 
 
-      
Functional Status 
 
    5. Missed Appointments 
.046 
(.058) 
-.094 
(.002) 
.046 
(-.086) 
.006 
(.067) 
 
-     
 
    6. MOS-HIV Physical Summary Score 
  
.434** 
(.017)** 
-.037 
(.203) 
-.454 
(-.573) 
.525* 
(.716*) 
-.073 
(.081) 
 
-    
General Health Perceptions 
 
    7. Perception of Illness 
.114 
(-.073) 
.041 
(.140) 
-.548 
(-.389) 
.647* 
(.404*) 
-.239 
(.037) 
.419 
(.360) 
 
-   
 
    8. MOS-HIV Health Transition Score 
 
.189 
(-.075) 
.048 
(.142) 
-.217 
(-.463) 
.398 
(.427) 
.187 
(.125) 
.094 
(.278) 
.219 
(.169) 
 
-  
Overall Quality of Life 
 
    9. Satisfaction with Life Scale 
-.104 
(-.018) 
.076 
(.219) 
.069*** 
(-.499)***
-.068*** 
(.483)***
-.105 
(.098) 
.017* 
(.313)*
.066 
(.340) 
-.083* 
(.251)* 
 
- 
Table 11. Correlations Among Measures of Variables of the Model for HIV+LD Group Study 1 (n=66) and Study 2 (n=130) 
Note.  Fisher’s r to z values *p< .05; **p<.01; ***p<.001. Study 2 correlations are in parenthesis.
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5.5 DEMOGRAPHIC CHARACTERISTICS STUDY 1 VS. STUDY 2 
As a preliminary data screening to the secondary data analysis, the selected demographic 
characteristics between Study 1 and Study 2 were determined (see Table 12).  There were a 
greater number of males than females in both Study 1 (70% male; 30% female) and in Study 2 
(69.6% male; 30.4%). There was no significant difference between the two studies with regard to 
percentage of male and female participants χ2(1) =.009, p=.925.  There were differences in the 
percentage of individuals that self-reported being “white” in the two studies.  There were 
significantly more participants who self-reported their race as “white” in Study 1 (65.5%) than in 
Study 2 (40.6%) χ2(1) =29.62, p=.001. Participants who self-reported their race as anything other 
than “white” were considered “non-white.”  Those in the “non-white” category were primarily 
African-American due to recruitment in Study 2 in urban areas in Western Pennsylvania and 
Northeastern Ohio. The self-reported total gross household incomes between Study 1 and Study 
2 (χ2(5) =22.16, p<.001) were significantly different. The average age across the two studies was 
42.4 ±7.86 years.  Study 1 participants were significantly younger (t(530) =-4.71, p<.001) than 
those in Study 2 (40.26 ± 7.64 vs. 43.66 ±7.73 years of age respectively).   Participants in Study 
1 self-reported an average of 13.36 ±2.64 years of formal education, whereas 12.96 ±2.85 years 
were reported in Study 2.  There was no significant difference between the two studies with 
regard to number of years of education (t(529) =1.59, p=.112).  Overall, participants in Study 2 
were older and more likely to be non-white; a greater proportion in Study 2 reported incomes 
below $10,000 (see Table 12). 
Group 
 
Variable  
Overall 
(N=532) 
Study 1 (N=180) Study 2 (N=352) 
 
 
 
Statistic 
Chi-Sq/ t-test 
 
  n (%)/M (SD) n (%)/M (SD) n (%)/M (SD) 
df value 
p value 
Sex     1 .009 .925 
 Male 371    (69.7) 126    (70.0) 245    (69.6)  
 Female 161    (30.3)  54    (30.0) 107    (30.4)  
Race     1 29.62 .001 
 White 261    (49.1) 118    (65.6) 143    (40.6)  
 Non-white 271    (50.9)   62    (34.4) 209    (59.4)  
Total gross household 
income 
    5 22.16 <.001 
 Under  
10,000 
262    (49.2) 68    (37.8) 194    (55.1)  
 10,000 to 
13,000 
90    (16.9) 37    (20.6)   53    (15.1)  
 13,000 to 
20,000 
60    (11.3) 21    (11.7)   39    (11.1)  
 20,000 to 
30,000 
39    (7.3) 13    (7.2)   26    (7.4)  
 30,000 to 
50,000 
34    (6.4) 18    (10.0)  16    (4.5)  
 Over 
 50,0000 
32    (6.0) 18    (10.0)  14    (4.0)  
 Missing 15    (2.8)  5    (2.8)  10    (2.8)  
      
Age  42.40 (7.86) 40.26 (7.64) 43.66 (7.73) 530 -4.71 <.001 
      
Number of years of 
formal education 
 13.21 (2.76) 13.36 (2.64) 12.96 (2.85) 529 1.59 .112 
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Table 12. Selected Sample Characteristics for Study 1 and Study 2 
 5.6 STUDY 1 VS. STUDY 2 MEASURE COMPARISONS 
A comparison was made among the measures selected to assess the five model components 
between Study 1 and Study 2. The Wilson and Cleary (1995) model components include: 
biological/physiological factors (CD4 count, HIV viral load), symptom status (Beck Depression 
Inventory II [BDI-II], Medical Outcomes Study HIV Health Survey [MOS-HIV] mental 
summary score), functional status (missed appointments, MOS-HIV physical summary score), 
general health perceptions (Perception of Illness visual analogue scale, MOS-HIV health 
transition score), and overall HRQOL (Satisfaction with Life Scale).  
The frequencies, means, standard deviations, and effect parameters are noted in Table 13.  
Cohen’s d was determined for parametric effect size and Φ for non-parametric effect size for 
standardized differences between Study 1 and Study 2. These analytic techniques were used in 
place of independent sample t-tests and chi-square tests given the difference in sample sizes 
between Study 1 (n=180) and Study 2 (n=352).  A small Φ or Cohen’s d effect size is equivalent 
to approximately .200, whereas  .500 is a medium effect, and .800 is a large effect (J. Cohen, 
1988).  
When assessing the biological/physiological factors, there was no significant difference 
in the CD4 count (Cohen’s d=.165) between Study 1 (487.41 ± 325.19 cells/ml) and Study 2 
(437.44 ± 289.75 cells/ml).  Additionally, there was no significant difference in percentage of 
detectable HIV viral load.  In Study 1 there were 45.9% of the participants with detectable HIV 
viral load reported compared to 38.5%  in Study 2 (Φ = .073).  
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There was no significant difference in symptom status (MOS-HIV mental summary 
score, [Cohen’s d=.208]), functional status (missed appointments [Φ = .000, no effect], MOS-
HIV physical summary score [Cohen’s d=.345]), general health perceptions (Perception of 
Illness visual analogue scale [Cohen’s d=.081], MOS-HIV health transition score [Cohen’s 
d=.182]), and overall HRQOL (Satisfaction with Life Scale, [Cohen’s d=.061]). 
Other than the total BDI-II scores, there were no significant differences between the 
measures from the two studies. Persons in Study 2 had higher total self-reported depressive 
symptoms (M=16.05) than persons in Study 1 (M=12.80). The clinical significance of this 
difference may not be noteworthy as both mean scores are below the moderate depressive 
symptom cutoff score of 20 (Beck et al., 1996).  For example, the BDI-II scores from the two 
studies had approximately 85% distribution overlap with a small Cohen’s d effect of .284.  
Therefore, after considering the correlational matrices and the distribution of the data from Study 
1 and Study 2, the data were appropriately combined and used in the structural equation model 
(SEM). 
Group  
Variable 
    
    Measure 
 
Overall 
 
Study 1
(n=180) 
Study 2 
(n=352) 
 
 
Statistic 
 
 
Biological/Physiological Factors 
 n (%)/M (SD) n (%)/M (SD) n (%)/M (SD) Cohen’s d/ phi 
 
    CD4 Count  455.94 (303.97) 487.41 (325.19) 437.44 (289.75) .165 
      
    HIV Viral load Detectable 199 (41.1) 79 (45.9) 120 (38.5) .073 
 Undetectable 285 (58.9) 93 (54.1) 192 (61.5)  
Symptom Status 
 
     
    Beck Depression Inventory-II  14.94 (11.54) 12.80 (9.29) 16.05 (12.42) .284 
      
    MOS-HIV Mental Summary Score 
 
 45.44 (12.06) 47.10 (11.87) 44.59 (12.08) .208 
Functional Status 
 
     
     Missed Appointments Yes 172    (33.0) 57    (32.9) 115    (33.0) .000 
 No 350    (67.0) 116    (67.1) 234    (67.0)  
      
     MOS-HIV Physical Summary Score 
  
 41.80 (11.62) 39.18 (10.36) 43.14 (12.02) .345 
General Health Perceptions 
 
     
    Perception of Illness  0.74 (.19) 0.75 (.18) 0.73 (.19) .081 
      
    MOS-HIV Health Transition Score 
 
 3.34 (1.02) 3.46 (.98) 3.27 (1.03) .182 
Overall Quality of Life 
 
     
    Satisfaction with Life Scale  3.57 (1.49) 3.63 (1.53) 3.54 (1.47) .061 
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Table 13. Differences of Study Measures for Study 1 and Study 2 
 5.7 DEMOGRAPHIC CHARACTERISTICS HIV VS. HIV+LD  
The participants in both groups (HIV and HIV+LD) were relatively homogeneous with regard to 
the selected demographic characteristics. There was a larger proportion of men in the overall 
sample (69.7%), as well as the subgroup of HIV (67.5%) and the subgroup of HIV+LD (72.7%).  
There were no significant difference between these percentages (χ2(1) =1.63, p=.201).  The 
overall sample and the subgroups were split almost equally (range 47.6-53.4%) between white 
and non-white race (χ2=1.79 (1), p=.181).  The majority of persons across both groups had a total 
gross annual household income under $10,000 (45.9-52.9%; χ2(5) =8.08, p=.152).  Overall, only 
12% had annual household income over $30,000. Persons in the HIV group (M=41.51, SD±8.29) 
were significantly younger than persons in the HIV+LD group (M=43.87, SD±7.14; t= -3.44 
(530), p=.001). There was also a significant difference in years of education between the HIV 
group (M=13.35, SD±2.83) and the HIV+LD group (M=12.77, SD±2.66; t(529) =2.37, p=.018).  
In summary, there were no significant differences between persons with HIV with and with out 
LD as a function of sex, ethnicity/race, or income. Persons with HIV+LD were older and less 
educated than persons with HIV without LD (see Table 14).   
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 Table 14. Sample Characteristics for HIV and HIV and Liver Disease Groups 
Group Variable  
Overall 
(N=532) 
 
HIV
 (N=305) 
HIV+LD 
(N=227) 
 
 
 
Statistic 
 
Chi-Sq/ t-test 
 
  n (%)/M (SD) n (%)/M (SD) n (%)/M (SD) 
df Value 
p value 
Sex     1 1.63 .201 
 Male 371    (69.7) 206    (67.5) 165    (72.7)   
 Female 161    (30.3) 99    (32.5)  62    (27.3)   
Race     1 1.79 .181 
 White 261    (49.1) 142    (46.6) 119    (52.4)   
 Non-white 271    (50.9) 163    (53.4) 108    (47.6)   
        
Total Gross 
Annual 
Household 
Income 
    5 8.08 .152 
 Under  
10,000 
262    (49.2) 140   (45.9) 122    (52.9)   
 10,000 to 
13,000 
90    (16.9) 53    (17.4)   37    (16.3)   
 13,000 to 
20,000 
60    (11.3) 35    (11.5)  25    (11.0)   
 20,000 to 
30,000 
39    (7.3) 29    (9.5)  10    (4.4)   
 30,000 to 
50,000 
34    (6.4) 23    (7.5)   11    (4.8)   
 Over 
 50,0000 
32    (6.0) 17    (5.6)   15    (6.6)   
 Missing 15    (2.8) 8    (2.6)  7     (3.1)   
       
Age  42.40 (7.86) 41.51 (8.29) 43.87 (7.14) 530 -3.44 .001 
       
Number of 
Years of 
Education 
 13.21 (2.76) 13.35 (2.83) 12.77 (2.66) 529 2.37 .018 
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5.8 CORRELATIONAL MATRIX  
Because the primary aim of this secondary analysis was to test the Wilson and Cleary (1995) 
model of HRQOL in persons with HIV without LD and in persons with HIV and LD, a 
correlational matrix was run separately for the two groups and the combined overall sample 
(N=532). Moderate to high correlations were noted (Spearman’s rho= .30 to greater than .60) 
for all of the measures with the exception of missed appointments.  Missed appointments had 
very low correlations with the other measures, Spearman’s rho ranged from .002 to .140 in 
the overall sample and in the two subgroups. The correlational matrices are presented in 
Tables 15, 16 and 17.  
 Table 15. Correlations Among Measures by Model Variable for Overall HIV Group (n=305) 
Variables 
    Measure 
 
1 2 3 4 5 6 7 8 9 
Biological/ Physiological Factors 
    
    1. CD4 Count 
 
 
- 
        
 
    2. HIV Viral Load 
 
 
.257 
 
- 
       
Symptom Status 
 
    3. Beck Depression Inventory-II 
 
-.084 
 
-.073 
 
- 
      
 
    4. MOS-HIV Mental Summary Score 
 
 
.178 
 
.150 
 
-.767 
 
- 
     
Functional Status 
 
    5. Missed Appointments 
 
.140 
 
.114 
 
-.123 
 
.104 
 
- 
    
 
    6. MOS-HIV Physical Summary Score 
  
 
.141 
 
.120 
 
-.464 
 
.617 
 
-.035 
 
- 
   
General Health Perceptions 
 
    7. Perception of Illness 
 
.286 
 
.113 
 
-.445 
 
.526 
 
.056 
 
.335 
 
- 
  
 
    8. MOS-HIV Health Transition Score 
 
 
.074 
 
.004 
 
-.463 
 
.489 
 
-.016 
 
.372 
 
.377 
 
- 
 
Overall Quality of Life 
 
    9. Satisfaction with Life Scale 
 
.040 
 
.004 
 
-.377 
 
.370 
 
.039 
 
.225 
 
.191 
 
.115 
 
- 
Note.  Spearman’s rho values  
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 Table 16. Correlations Among Measures by Model Variable for Overall HIV+LD Group (n=227) 
 
Variables 
    Measure 
 
1 2 3 4 5 6 7 8 9 
Biological/ Physiological Factors 
    
    1. CD4 Count 
 
- 
        
 
    2. HIV Viral Load 
 
 
.312 
 
- 
       
Symptom Status 
 
    3. Beck Depression Inventory-II 
 
.035 
 
-.084 
 
- 
      
 
    4. MOS-HIV Mental Summary Score 
 
 
.102 
 
.125 
 
-.793 
 
- 
     
Functional Status 
 
    5. Missed Appointments 
 
.049 
 
-.026 
 
-.034 
 
.032 
 
- 
    
 
    6. MOS-HIV Physical Summary Score 
  
 
.157 
 
.139 
 
-.529 
 
.644 
 
.052 
 
- 
   
General Health Perceptions 
 
    7. Perception of Illness 
 
.005 
 
.115 
 
-.428 
 
.484 
 
-.057 
 
.379 
-   
 
    8. MOS-HIV Health Transition Score 
 
 
.019 
 
.106 
 
-.390 
 
.417 
 
.125 
 
.211 
 
.186 
-  
Overall Quality of Life 
 
    9. Satisfaction with Life Scale 
 
-.051 
 
.164 
 
-.335 
 
.300 
 
.002 
 
.204 
 
.241 
 
.168 
 
- 
Note.  Spearman’s rho values  
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Variables 
    Measure 
 
1 2 3 4 5 6 7 8 9 
Biological/ Physiological Factors 
    
    1. CD4 Count 
 
- 
        
 
    2. HIV Viral Load 
 
 
.282 
 
- 
       
Symptom Status 
 
    3. Beck Depression Inventory-II 
 
-.064 
 
-.103 
 
- 
      
 
    4. MOS-HIV Mental Summary Score 
 
 
.172 
 
.170 
 
-.780 
 
- 
     
Functional Status 
 
    5. Missed Appointments 
 
.084 
 
.062 
 
-.114 
 
.093 
 
- 
    
 
    6. MOS-HIV Physical Summary Score 
  
 
.165 
 
.164 
 
-.520 
 
.636 
 
.018 
 
- 
   
General Health Perceptions 
 
    7. Perception of Illness 
 
.159 
 
.100 
 
-.407 
 
.483 
 
.005 
 
.332 
 
- 
  
 
    8. MOS-HIV Health Transition Score 
 
 
.067 
 
.052 
 
-.395 
 
.442 
 
.043 
 
.299 
 
.228 
 
- 
 
Overall Quality of Life 
 
    9. Satisfaction with Life Scale 
 
.011 
 
.101 
 
-.388 
 
.379 
 
.069 
 
.236 
 
.224 
 
.150 
 
- 
 115 
Table 17. Correlations Among Measures by Model Variable for Overall Sample (n=532) 
Note.  Spearman’s rho values  
  
 
5.9 HIV AND HIV+LD GROUP MEASURE COMPARISONS 
Descriptive statistics and measure comparisons between the HIV group and HIV+LD group are 
presented in Table 18.  Frequencies were used to calculate percentages of categorical measures 
(e.g., HIV viral load and missed appointments).  Means and standard deviations were used to 
describe continuous measures. Pearson chi-square was used to test for statistical differences 
between the two groups on categorical data; independent sample t-tests were used to test for 
statistical differences between the two groups on continuous measures. A non-parametric t-test 
(Mann-Whitney) was used to assess for statistical differences in CD4 counts, a continuous 
measure, due to the positively skewed nature of the data.  
There was a statistically significant difference between the HIV group and the HIV+ LD 
group on CD4 counts. When compared to the HIV group (M=492.25, SD±341.98), the HIV+LD 
group had statistically significant lower CD4 counts (M=435.43, SD±316.30; t= -2.01, p=.044). 
CD4 counts were inversely related to HIV viral load so that when the HIV viral load goes up 
CD4 counts go down. There was a higher percentage of persons with HIV+LD (45.8%) who had 
detectable HIV viral load than persons with HIV without liver disease (37.5%).  However, this 
difference was not statistically significant (χ2(1) = 3.35, p=.067).  
Persons in the HIV group self-reported significantly fewer depressive symptoms (t(525) 
=-2.42, p=.016), as measured by the BDI-II (mean total score 13.89 ± 11.68) compared to 
HIV+LD group (M=16.34, SD ±11.22). Additionally, persons in the HIV group had higher self-
reported mental function (t(520) =2.96, p=.003), as measured by the MOS-HIV mental summary 
score (M=46.77, SD ±12.24) compared to the HIV+LD group (M=43.63, SD ± 11.59). There was 
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a significant difference in functional status between the two groups as measured by the MOS-
HIV physical summary score (t(520) =3.90, p<.001), although both groups had relatively poor 
self-reported physical function.  The HIV group mean scores for the MOS-HIV physical 
summary score were 43.47 with a standard deviation of 11.28 compared to the HIV+LD group 
with a mean score of 39.51 with a standard deviation of 11.72.  Although the categorical measure 
of missed appointments for the variable of functional status was not included in the SEM model 
due to very weak correlations among the variables, no differences were found between the 
groups. The HIV group data indicated that 31.3% had missed clinic appointments annually and 
35.1% missed appointments in the HIV+LD group (Pearson χ2(1) =.835, p=.361).  
There were no significant differences between the HIV and HIV+LD groups with regard 
to the measures of the variables for general health perceptions.  Even though there were 
significant differences among most of the other measures between the groups, both groups have 
similar general health perceptions, as measured by the Perception of Illness visual analog scale 
(t=.72 (524), p=.470).  Similarly, both groups self-reported on the MOS-HIV health transition 
scale that their perception of their physical and emotional health was about the same to a little 
worse compared to 4 weeks prior (t(524) =1.34, p=.182). 
Both groups also reported being somewhat dissatisfied with their overall QOL, as 
measured by the Satisfaction with Life Scale.  There was no significant difference between the 
groups (t(517)=1.08, p<.280). The HIV group had a mean score of 3.63 with a standard deviation 
of 1.44 and the HIV+LD group had a mean score of 3.49 with a standard deviation of 1.56. The 
mean scores in both groups for the Satisfaction with Life Scale were slightly below the mid-
point. 
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Overall the data from persons with HIV+LD showed statistically significant lower CD4 
counts, more self-reported depressive symptoms, and significantly lower self-reported mental 
and physical function compared to persons with HIV without LD. There were no other 
statistically significant differences noted between the HIV and HIV+LD groups.   
Group Variable 
    Measure 
 
Overall 
(n=532) 
HIV
(n=305) 
HIV+LD
(n=227) 
 
 
Statistic 
 
Chi-Sq/ t-test   n (%)/M (SD) n (%)/M (SD) n (%)/M (SD) 
df value p value 
Biological/Physiological Factors 
 
    CD4 Count 
  
 
455.94 (303.97) 
 
 
492.25 (341.98) 
 
 
435.43 (316.30) 
 
Mann-
Whitney 
 
 
-2.01 
 
 
.044 
        
    HIV Viral load Detectable 199    (41.1) 102    (37.5) 97    (45.8) Pearson (1) 3.35 .067 
 Undetectable 285    (58.9) 170    (62.5) 115    (54.2)    
Symptom Status 
 
       
    Beck Depression Inventory-II  14.94 (11.54) 13.89 (11.68) 16.34 (11.22) 525 -2.42 .016 
       
    MOS-HIV Mental Summary Score  45.44 (12.06) 46.77 (12.24) 43.63 (11.59) 520 2.96 .003 
 
Functional Status  
 
      
  Missed Appointments Yes 172    (33.0) 94    (31.3) 78    (35.1) Pearson (1) .835 .361 
 No 350    (67.0) 206    (68.7) 144    (64.9)   
       
 MOS-HIV Physical Summary Score 
  
 41.80 (11.62) 43.47 (11.28) 39.51 (11.72) 520 3.90 <.001 
General Health Perceptions 
 
      
    Perception of Illness  0.74 (0.19) .74 (.18) .731 (.19) 524 .72 .470 
       
     MOS-HIV Health Transition Score  3.34 (1.02) 3.39 (1.01) 3.27 (1.02) 524 1.34 .182 
 
Overall Quality of Life 
      
    
   Satisfaction with Life Scale 
  
3.57 (1.49) 
 
3.63 (1.44) 
 
3.49 (1.56) 
 
517 
 
1.08 
 
.280 
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Table 18. Measure Comparisons by Model Variable for HIV and HIV+LD Groups 
 5.10 PRIMARY AIM 
The primary aim was to test the null hypothesis, wherein, the hypothesized model will hold true 
with the components (biological/physiological factors, symptom status, functional status, general 
health perceptions, and overall quality of life) in persons living with HIV without liver disease 
and in persons living with HIV with liver disease.  
5.10.1 Primary Aim Research Questions 
(1.) Does the Wilson and Cleary (1995) model of HRQOL hold true in persons living with 
HIV without  liver disease?  
(2.) Does the Wilson and Cleary (1995) model of HRQOL hold true in persons living with 
HIV and liver disease (HIV+LD)?  
(3.) Is there a difference in the models between persons living with HIV without liver disease 
and in persons living with HIV+LD? 
The baseline hypothesized Wilson and Cleary model was assessed with SEM and found to 
hold true in both groups, persons living with HIV without liver disease and in persons living with 
HIV+LD, when a Lagrange multiplier modification was applied.  
The baseline model parameters and subsequent model modifications are noted in Table 
19.  Model 1 parameters were found after releasing model constraints and allowing additional 
pathways from symptom status to general health perceptions and overall quality of life, and from 
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biological/physiological factors to general health perceptions.  The second constrained model 
(Model 2) allowed for correlations between the biological/physiological factors (CD4 count, HIV 
viral load) and the error terms. There were no significant differences in the HIV group model and 
the HIV+LD model.  A multi-sample robust SEM was performed.  Because there were no 
significant differences between the structural models in the two groups the data were constrained 
to fit the same model.  The constrained model estimates one set of parameters for both groups. 
SEM was run on both the constrained and unconstrained models and found that the constrained 
model had a better fit. The model parameters were not significantly different (See Table 19) 
when comparing the Satorra-Bentler model chi-squares.   
 
Table 19. Goodness of Fit Summary for Model Selection 
 SB χ2 df CFI RMSEA Δ SB χ2 df p value
Baseline 
 
22.68 20 .997 .028 - - - 
Model 1 
Regression 
Coefficent 
Constrained 
 
39.31 36 .997 .020 16.61 16 .411 
Model 2 
Regression 
Coefficent 
Constraints with 
Parsimony 
40.31 38 .998 .017 17.57 18 .484 
Note.  SB χ2= Satorra-Bentler scaled Chi-square; df= degrees of freedom; CFI= 
Comparative Fit Index; RMSEA= Root mean-square error of approximation; Δ= difference. 
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 The standardized full information maximum likelihood solution with robust methods is 
presented for the HIV group (n=305) in Figure 8 and for the HIV+LD group (n=227) in Figure 9. 
The feasibility of the parameter estimates was accomplished by assessing each model parameter 
and ensuring that the parameter exhibited the correct size and sign (positive or negative relation) 
consistent with the underlying measure of the variable component. For example, the BDI-II to 
MOS-HIV health transition score parameter was -.210 which is logically feasible in that higher 
self-reported depressive symptoms have a negative relationship with self-reported health status. 
The standardized solution reflected the slight difference in sample size between the two groups 
otherwise the unstandardized model parameters were identical. 
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CD4 Count
MOS-HIV Physical
Satisfaction with Life Scale
Perception of Illness
MOS-HIV Mental
.011
.023
.065
HIV Viral Load
BDI-II
.669
.122 .410
-.097
MOS-HIV Health 
Transition
.021
.343
-.204
.387
-.055
.120 -.074
.103.009
 
Figure 8. Standardized Full Information Maximum Likelihood Solution in HIV Group 
(n=305) 
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CD4 Count
MOS-HIV Physical
Satisfaction with Life Scale
Perception of Illness
MOS-HIV Mental
.012
.022
.062
HIV Viral Load
BDI-II
.644
.103 .369
-.094
MOS-HIV Health 
Transition
.021
.319
-.203
.358
-.051
.113 -.072
.107.008
 
Figure 9. Standardized Full Information Maximum Likelihood Solution in HIV+LD 
Group (n=227) 
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The multi-group maximum likelihood robust SEM solution is detailed in Table 20 with 
each of the 16 model parameter estimates identified with the level of significance noted with an 
asterisk. The unstandardized model parameters were the same for both the HIV group and the 
HIV+LD group as both groups were constrained to the same model parameters.  The 
standardized full information maximum likelihood solutions of HRQOL were slightly different 
(not statistically different) due to the small differences in the sample sizes of the groups (HIV 
group, n=305; HIV+LD group, n=227).  The significantly modeled pathways are noted below in 
the secondary aims section 5.11 and depicted in Figure 10. Because the modified model fit both 
the HIV group and the HIV group there were no significant differences between any of the 
model parameters. 
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Table 20. Multi-group Maximum Likelihood Robust SEM Solution 
 HIV Group 
n=305 
HIV+LD Group 
n=227 
Path Unstandardized. Standardized z score Unstandardized Standardized z score 
1. CD4 → BDI .029 .009 -.18 .029 .008 -.18 
2. CD4 → MHS .423 .120 2.44* .423 .113 2.44*
3. CD4 → POI .006 .122 2.97** .006 .103 2.97**
4. VLD → BDI -1.640 -.074 -1.51 -1.640 -.072 -1.51 
5. VLD → MHS 2.561 .103 2.10* 2.561 .107 2.10*
6. BDI → PHS .012 .011 .20 .012 .012 .20 
7. BDI → POI .002 -.097 -1.25 .002 -.094 -1.25 
8. BDI → HTS -.019 -.204 -2.94** -.019 -.203 -2.94**
9. BDI → SLS .051 .387 -6.84*** .051 .358 -6.84***
10. MHS → PHS .631 .669 11.52*** .631 .644 11.52***
11. MHS → POI .006 .410 4.63*** .006 .369 4.63***
12. MHS → HTS .028 .343 4.12*** .028 .319 4.12***
13. PHS → POI .000 .023 .38 .000 .022 .38 
14. PHS → HTS .002 .021 .41 .002 .021 .41 
15. POI → SLS .528 .065 1.28 .528 .062 1.28 
16. HTS → SLS -.078 -.055 -1.07 -.078 -.051 -1.07 
Note. *p< .05; **p<.01; ***p<.001. CD4 = CD4 Count; VLD = HIV Viral Load;  
BDI = Beck Depression Inventory-II; MHS = MOS-HIV Mental Summary Score; PHS = MOS- 
HIV Physical Summary Score; POI = Perception of Illness; HTS = MOS-HIV Health Transition 
Score; SLS = Satisfaction with Life Scale. 
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CD4 Count
MOS-HIV Physical
Satisfaction with Life Scale
Perception of Illness
MOS-HIV Mental
HIV Viral Load
BDI-II
p <.001
p =.003 p <.001
MOS-HIV Health 
Transition
p <.001
p =.003
p <.001
p =.015
p =.036
 
Figure 10. SEM with Significant Measured Modeled Pathways Retained (n=532) 
 127 
5.11 SECONDARY AIM 
The secondary aim was to test the relationships proposed within Wilson and Cleary’s (1995) 
directional model of HRQOL between biological/physiological factors, symptom status, 
functional status, general health perceptions, and overall QOL among persons living with HIV 
without liver disease and persons living with HIV+LD. Four hypotheses were tested. 
5.11.1 Secondary Hypothesis 2.1 
Hypothesis: Biological/physiological factors have a direct effect on symptom status in persons 
living with HIV without liver disease and in persons living with HIV+LD. 
There was a significant direct effect of biological/physiological factors on symptom 
status in both persons with HIV and persons with HIV and liver disease. CD4 count, as a 
measure of biological/physiological factors, significantly predicted symptom status, as measured 
with the MOS-HIV mental summary score in both the HIV (B=.120, z=2.44, p=.015).and 
HIV+LD groups (B=.113, z=2.44, p=.015). HIV viral load, as a measure of 
biological/physiological factors, significantly predicted symptom status, as measured with the 
MOS-HIV mental summary score in both the HIV (B=.103, z=2.10, p=.036) and HIV+LD 
groups (B=.107, z=2.10, p=.036).  An additional significant path was identified using the 
LaGrange Multiplier from biological/physiological factors to general health perception (CD4 
count to Perception of Illness) in both the HIV group (B=.122, z=2.97, p=.003) and the HIV+LD 
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group (B=.103, z=2.97, p=.003).  CD4 count and HIV viral load, as measures of 
biological/physiological factors, did not predict symptom status, as measured by the BDI-II. 
5.11.2 Secondary Hypothesis 2.2 
Hypothesis: Symptom status has a direct effect on functional status in persons living with HIV 
without liver disease and in persons living with HIV+LD. 
There was a significant direct effect of symptom status on functional status in both 
groups. However, categorized missed appointments (“yes” or “no”) was not related to the study 
measures and was therefore not included in the SEM / path analysis. The MOS-HIV mental 
summary score, as a measure of symptom status, significantly predicted functional status, as 
measured with the MOS-HIV physical summary score, in both the HIV (B=.669, z=11.52, 
p<.001) and HIV+LD groups (B=.644, z=11.52, p<.001). BDI-II, as a measure of symptom 
status, did not predict functional status, as measured by the MOS-HIV physical summary score. 
There were four significant additional paths identified by using the Lagrange Multiplier 
linking symptom status, as measured by the BDI-II and the MOS-HIV mental summary score, to 
distal components of the Wilson and Cleary (1995) model of HRQOL. Three of the identified 
paths linked symptom status directly to general health perceptions and one linked symptom 
status directly to overall quality of life (see Figure 10). The MOS-HIV mental summary score, as 
a measure of symptom status, significantly predicted general health perceptions, as measured 
with the Perception of Illness visual analogue scale in both the HIV (B=.410, z=4.63, p<.001) 
and HIV+LD groups (B=.369, z=4.63, p<.001). The MOS-HIV mental summary score, as a 
measure of symptom status, significantly predicted general health perceptions, as measured with 
the MOS-HIV health transition score, in both the HIV (B=.343, z=4.12, p<.001) and HIV+LD 
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groups (B=.319, z=4.12, p<.001). The BDI-II, as a measure of symptom status, significantly 
predicted general health perceptions, as measured with the MOS-HIV health transition score in 
both the HIV (B=.-.204, z=-2.94, p=.003) and HIV+LD groups (B=.-.203, z=-2.94, p=.003).  The 
final added path included the BDI-II, as a measure of symptom status, which significantly 
predicted overall QOL, as measured with the Satisfaction with Life Scale, in both the HIV 
(B=.387, z=-6.84, p<.001) and HIV+LD groups (B=.358, z=-6.84, p<.001). 
5.11.3 Secondary Hypothesis 2.3 
Hypothesis: Functional status has a direct effect on general health perceptions in persons living 
with HIV without liver disease and in persons living with HIV+LD. 
There was no significant direct effect of functional status, as measured with the MOS-
HIV physical summary score, on general health perceptions, as measured with either the 
Perception of Illness visual analogue score or the MOS-HIV health transition score, in persons 
with HIV without liver disease or in persons living with HIV+LD. 
5.11.4 Secondary Hypothesis 2.4  
Hypothesis: General health perceptions have a direct effect on overall QOL in persons living 
with HIV without liver disease and in persons living with HIV+LD. 
There was no significant direct effect of general health perceptions, as measured by either 
the Perception of Illness visual analogue score or the MOS-HIV health transition score, on 
overall QOL, as measured by the Satisfaction with Life Scale, in either group. 
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5.12 EXPLORATORY AIM 
The exploratory aim was to identify whether there were different relationships with regard to the 
characteristics of the individual (age, gender, ethnicity/race, and number of years of education) 
and the environment (social support and household income) between and among persons living 
with HIV without liver disease and persons living with HIV+LD. 
The SEM was tested to explore the covariates including characteristics of the individual 
(age, gender, ethnicity/race, and number of years of education) and characteristics of the 
environment (social support [measured with the mean score on the Inventory Support Evaluation 
List (ISEL)], and household income (measured as total gross annual household income).  This 
was an exploratory aim as this research study was not statistically powered to test these 
relationships. Because there was no difference between the HIV model and the HIV and liver 
disease model, the final constrained multi-sample SEM was applied with the covariates included.  
The exogenous variable biological/physiological factors was not hypothesized by Wilson and 
Cleary (1995) to be predicted by the characteristics of the individual or characteristics of the 
environment and therefore was not included in the covariance matrix tested.  In order to test for 
the covariates, multiple pathways were added.  Model paths included the following: paths from 
each of the four selected demographic characteristics to the four endogenous variables (symptom 
status, functional status, general health perceptions and overall QOL) (16 paths); correlations 
among the four selected demographic characteristics (6 paths) and paths from each of the four 
endogenous variables to the two characteristics of the environment (household income and social 
support), along with the correlation between those two characteristics (9 paths).  These paths are 
depicted graphically in Figure 11. 
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BDI-II
Age Sex Race/ethnicity Education
Household Income Social Support
MOS-HIV Mental
MOS-HIV Physical Perception of Illness
Satisfaction with 
Life Scale
MOS-HIV Health 
Transititon
 
Figure 11. Additional 36 Covariate Relationships Tested in Exploratory SEM 
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 The findings of the 36 additive covariance pathways did not improve the multi-sample 
SEM nor did the added pathways better explain the relationships between the primary model 
variables.  Therefore, none of the covariates (age, sex, race/ethnicity, years of education, ISEL, 
or household income) were added to the model.  Some of the characteristics of the individual and 
environment had significant independent relationships without affecting the overall model fit.  
The significant independent relationships are noted below and listed in Table 21. 
In the Wilson and Cleary (1995) model of HRQOL the covariate of age, as a measure of 
characteristics of the individual, only predicted the endogenous variable of functional status, as 
measured by the MOS-HIV physical summary score (B=.069, z=-1.984, p=.047). Age was not 
related to measures of symptom status, general health perceptions, or overall QOL. Sex as a 
covariate in the model did not correlate or predict any of the endogenous variables in the model.  
Race as a covariate in the model was found to have three independent significant paths.  The first 
path that race predicted was symptom status, as measured by the MOS-HIV mental summary 
score (B=.091, z=2.204, p=.028). The second path predicted by race was functional status, as 
measured by the MOS-HIV physical summary score (B=.125, z=3.350, p=.001). The last path 
predicted by race was general health perceptions, as measured by the MOS-HIV health transition 
score (B=.148, z=3.443, p=.001). Race was not related to symptom status, as measured by the 
BDI-II, or overall QOL, as measured by the Satisfaction with Life Scale. Years of education did 
not correlate or independently predict any of the endogenous variables in the identified model.    
The characteristics of the environment as measured by the ISEL (social support) and 
household income had significant independent covariant relationships to the model parameters. 
Specifically, self-reported social support, as measured with the ISEL, had an independent effect 
 133 
on symptom status at significance levels of <.001 as measured by both the BDI-II (B=.517, z=-
11.936, p<.001) and MOS-HIV mental summary score (B=.525, z=11.685, p<.001). The ISEL 
score as a covariate in the model also independently predicted general health perceptions, as 
measured by the Perception of Illness visual analogue scale (B=.228, z=4.180, p<.001).  Lastly, 
overall QOL, as measured by the Satisfaction with Life Scale, was independently predicted by 
the ISEL (B=.155, z=2.707, p=.007). The ISEL score was not independently related to measures 
of functional status.  Gross annual household income, as a measure of characteristics of the 
environment, had three significant independent paths.  First, gross annual household income as a 
covariate in the model predicted symptom status by both the BDI-II (B=.104, z=-2.392, p=.017) 
and the MOS-HIV mental summary score (B=.113, z=2.488, p=.013).  Gross annual household 
income also independently predicted functional status, as measured by the MOS-HIV physical 
summary score (B=.165, z=4.024, p<.001), but did not predict measures of general health 
perception or overall QOL.  The significant retained independent multi-group SEM covariate 
pathways are depicted in Figure 12.   
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Table 21. Covariate z-scores and p-values as Related to Measures Assessing Primary Model 
Variables 
                           Covariates 
Variable Characteristics of the 
 Individual 
Characteristics of the 
Environment 
 
    Measure Age 
z-score  
(p-value) 
Sex 
z-score 
(p-value) 
Race 
z-score 
(p-value) 
Education 
z-score  
(p-value) 
ISEL 
z-score 
(p-value) 
Income 
z-score 
(p-value) 
Symptom Status       
    BDI -1.400 
(.162 ) 
.511 
( .609 ) 
-1.284 
( .199 ) 
-.330 
( .741) 
-11.936 
( <.001) ***
-2.392 
(  .017) *
    MHS 1.136 
 
( .256 ) 
-1.562 
 
( .118 ) 
2.204 
 
( .028 ) *
-.466 
 
( .641 ) 
11.685 
 
( <.001) ***
2.488 
 
(  .013) *
Functional Status       
    PHS -1.984 
( .047 ) *
.216 
( .829 ) 
3.350 
(  .001) **
-.165 
(.869 ) 
-1.198 
( .231 ) 
4.024 
( <.001 ) ***
General Health Perceptions       
    POI -1.009 
( .313 ) 
1.016 
( .310 ) 
-.522 
( .602 ) 
1.234 
( .217 ) 
4.180 
( <.001 ) ***
-1.224 
(.221 ) 
    HTS -1.710 
 
( .087 ) 
1.138 
 
( .255 ) 
3.443 
 
( .001 ) **
-.749 
 
( .454 ) 
.911 
 
(.362 ) 
-.420 
 
( .674 ) 
Overall Quality of Life       
    SLS .416 
( .677 ) 
.384 
( .701 ) 
.328 
(.743) 
-1.539 
( .124) 
2.707 
( .007 ) **
.634 
(.526) 
Note. *p< .05; **p<.01; ***p<.001. Measures: BDI= Beck Depression Inventory-II; MHS= MOS-
HIV Mental Summary Score; PHS= MOS-HIV Physical Summary Score; POI= Perception of 
Illness; HTS= MOS-HIV Health Transition Score; SLS= Satisfaction with Life; Age= age in 
years; Sex= male or female; Race= white/non-white; Education= years of education; ISEL= 
Inventory Support Evaluation List; Income= Total gross annual household income. 
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BDI-II
p<.001
p=.047
p=.013
Age Sex Race/ethnicity Education
Household Income ISEL
p<.001
p=.007
MOS-HIV Mental
MOS-HIV Physical Perception of Illness
Satisfaction with 
Life Scale
MOS-HIV Health 
Transititon
p=.017
p<.001
p=.028 p=.001
p<.001
p=.001
 
Figure 12. SEM with Significant Covariate Model Pathways Retained 
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6.0  DISCUSSION AND IMPLICATIONS 
Over the past decade, persons with human immunodeficiency virus (HIV) are living longer  and 
therefore are more likely to suffer significant comorbidities due to a number of liver related 
factors (e.g., anemia, infectious hepatitis, lipodystrophy, and hepatocellular carcinoma), many of 
which may ultimately result in significant morbidity or mortality (Tedaldi et al., 2003). Both 
HIV and liver disease have been shown to have a significant effect on one’s health-related 
quality of life (HRQOL) (Fleming et al., 2004; Foster et al., 1998; Hickman et al., 2004; 
Nicholas et al., 2005; Pojoga et al., 2004).  Research suggests that persons living with HIV and 
liver disease (HIV+LD), a growing number of individuals (W. R. Kim, 2002), may have a poorer 
HRQOL than persons with HIV who do not have liver disease (Tsui et al., 2007).  
Wilson and Cleary (1995) have hypothesized a model of HRQOL that has been tested in 
several studies of persons living with HIV (Clingerman, 2004; Phaladze et al., 2005; Sousa et al., 
1999; Sousa & Kwok, 2006; Vidrine et al., 2005).  However, after conducting  a search of the 
literature using Medline, Ovid, Pubmed, and Web of Science from 1995-2007, the researcher 
concluded that the Wilson and Cleary (1995) model of HRQOL had not been tested in persons 
with HIV+LD.  Thus, the research presented herein was novel as it assessed the multi-faceted 
variables, as hypothesized by Wilson and Cleary (1995), that potentially impact an individual’s 
HRQOL in a total sample (N=532) of persons living with HIV and further divided into persons 
living with HIV without liver disease (n=305) and persons with HIV+LD (n=227). This chapter 
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reviews and discusses the main findings of this dissertation, describes the implications this work 
has for future research, and identifies limitations of the study. 
6.1 SUMMARY OF THE STUDY 
The purpose of this secondary analysis was to test the fit of the Wilson and Cleary (1995) model 
of HRQOL in two groups of patients: persons living with HIV without liver disease and persons 
living with HIV+LD. Wilson and Cleary have theorized that HRQOL has five components: 
biological/physiological factors, symptom status, functional status, general health perceptions, 
and overall quality of life (QOL) and proposed a directional model. 
The primary aim was to test the null hypothesis, wherein, the hypothesized model will 
hold true with the components (biological/physiological factors, symptom status, functional 
status, general health perceptions, and overall QOL) in persons living with HIV without liver 
disease and in persons living with HIV+LD.  The null hypothesis was that there would be no 
difference in the model in persons living with HIV without liver disease and in persons living 
with HIV+LD. 
The Wilson and Cleary (1995) model of HRQOL was tested with the five components 
operationalized as follows: 1) biological/physiological factors (HIV viral load, CD4 count), 2) 
symptom status [Beck Depression Inventory II (Beck et al., 1996), Medical Outcomes Study 
HIV Health Survey MOS-HIV, (Wu et al., 1997) mental summary score] 3) functional status 
[missed appointments, (MOS-HIV) physical summary score], 4) general health perceptions 
[Perception of Illness visual analog scale, (J. A. Erlen, personal communication, February 1, 
2006), MOS-HIV health transition score], and 5) overall QOL [Satisfaction with Life Scale 
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(Diener et al., 1985), MOS-HIV overall QOL]. In addition, characteristics of the individual (age, 
sex, race/ethnicity, and years of education) and characteristics of the environment (Inventory  
Support Evaluation List (ISEL), (S. Cohen et al., 1985), gross annual household income) were 
also explored as covariates after initial model testing.   
This secondary analysis used de-identified baseline and medical record review data from 
a parent study testing interventions to improve medication adherence to antiretroviral therapy in 
persons living with HIV (R01 NR04749, Principal Investigator, J. A. Erlen).  The initial parent 
study’s (Study 1) baseline data were collected between April 1999 and November of 2002 
(n=215). The continuation of the parent study (Study 2) had baseline data collected between 
March 2004 and March 2007 (n=352). For the purposes of this dissertation, data from Study 2 
collected before January 19, 2007 were included in the analysis.  Exempt approval was obtained 
from the University of Pittsburgh Institutional Review Board (IRB) for a retrospective secondary 
analysis (IRB #0603071, see Appendix B).  
Control participants from Study 1 (persons who were not randomized to the intervention 
arm) were invited to enroll in Study 2.  Baseline data collected at the time of their enrollment in 
Study 2 were used for the secondary data analysis (n=35) rather than the Study 1 baseline data. 
The overall sample for this analysis was 532 persons living with HIV.  The overall study 
algorithm is depicted in Figure 7 of Chapter 5. 
6.2 SUMMARY OF THE FINDINGS 
The Wilson and Cleary (1995) model of HRQOL stipulates that the five primary model 
components (biological/physiological factors, symptom status, functional status, general health 
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perceptions, and overall QOL) build upon one another in a set order.  The current study tested 
the null hypothesis that Wilson and Cleary’s model (1995) of HRQOL would hold true for both 
persons living with HIV without liver disease as well as persons with HIV+LD.   
The data were initially screened for missing data, outliers, and normality. Then 
individuals with comorbid liver disease were identified.  Liver disease status was merged first 
from medical records then from self-reported data. In addition, the primary model measures for 
the five variables were assessed for internal consistency in both groups and found to have 
adequate to good reliability (see Table 9 in Chapter 5). The fifth component of the Wilson and 
Cleary (1995) model of HRQOL, overall QOL, was initially operationalized to include the MOS-
HIV overall QOL score and the Satisfaction with Life Scale. After an exploratory factor analysis 
of the total MOS-HIV tool (see manuscript in Appendix A), the MOS-HIV overall QOL subscale 
score was found to be included in both the physical and mental summary scores of the MOS-
HIV. Therefore, the MOS-HIV overall QOL subscale score perfectly correlated to one of the 
measures of symptom status (MOS-HIV mental summary score) and one of the measures of 
functional status (MOS-HIV physical summary score).  Because this association would have 
biased the analysis in favor of finding a good fitting model, the MOS-HIV overall HRQOL was 
excluded and the Satisfaction with Life Scale was used as the only measure for the primary 
model variable overall QOL.  
Next, the relationships between the measures were assessed separately in persons with 
HIV without liver disease and in persons with HIV+LD between Study 1 and Study 2 (see 
Tables 10 and 11 in Chapter 5).  The relationships between the grouped data for HIV+LD were 
similar enough to warrant combining the two studies. Selected demographic characteristics were 
assessed for the samples from Study 1 and Study 2.  Participants in Study 2 were older and more 
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likely to be non-white; a greater proportion reported incomes below $10,000 as compared to 
Study 1. The differences in the study measures across Study 1 and Study 2 were also assessed. 
The only noteworthy difference in the study measures was self-reported depressive symptoms, as 
measured with the BDI-II. Persons in Study 2 had a score averaging 3.25 points higher on the 
BDI-II than persons in Study 1.  
After the data from Study 1 and Study 2 were merged, the HIV group and HIV+LD 
groups were identified once again. Selected demographic characteristics were assessed and the 
two groups (HIV group and HIV+LD group) were found to be relatively homogeneous with 
regard to sex, race/ethnicity and number of years of formal education (see Table 12 in Chapter 
5). Persons in the HIV+LD group were significantly older than those in Study 1 (t=-4.71 (530), 
p=<.001), on average approximately two and a half years older 40.26 ±7.64 (Study 1) vs. 43.66 
±7.73 (Study 2). A significantly greater percentage of persons in Study 2 (55.1%) reported 
incomes below $10,000 as compared to Study 1 (37.8%) (χ2=22.16 (5), p<.001). 
The final step before running the structural equation model (SEM) was to assess the 
correlations and descriptive statistics among the measures for the overall HIV group (n=305), the 
overall HIV+LD group (n=227), and the overall sample (N=532). Each of the five primary model 
variables was assessed: biological/physiological was measured with HIV viral load, and CD4 
count; symptom status was measured with the BDI-II and MOS-HIV mental summary score; 
functional status was measured with missed appointments (missed “yes” vs. “no”) and the MOS-
HIV physical summary score; general health perceptions were measured with the Perception of 
Illness visual analog score and the MOS-HIV health transition score; and overall QOL was 
assessed with a single tool (as previously indicated), the Satisfaction with Life Scale.  Missed 
appointments was found to have a weak association with the other model measures in both the 
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HIV and HIV+LD groups (see correlational matrices in Chapter 5, Tables 15-17). Thus, because 
a structural equation model (SEM) assesses the relationships between variables, the lack of even 
a moderate correlation between missed appointments and other variables in the model resulted in 
this measure being eliminated from the analysis. Therefore, the functional status variable in the 
model was assessed using only the MOS-HIV physical summary score.   
The measures for the variables of the Wilson and Cleary (1995) model of HRQOL were 
compared between the HIV group and the HIV+LD group (see Table 18 in Chapter 5).  Overall, 
the data showed that persons with HIV+LD had significantly lower CD4 counts (M=492.25, 
SD±341.98 vs. M=435.43, SD±316.30; t=-2.01, p=.044), and more self-reported depressive 
symptoms (M=13.89±11.68 vs. M=16.34, SD±11.22; t=-2.42 (525), p=.016) than the HIV group, 
as measured with the BDI-II.  Additionally persons in the HIV group had higher self-reported 
mental function (t=2.96 (520), p=.003), as measured by the MOS-HIV mental summary score 
(M=46.77, SD±12.24) compared to the HIV+LD group (M=43.63, SD±11.59) and significantly 
higher functional status, as measured with the MOS-HIV physical summary score (M=43.47, 
SD±11.28 vs. M=39.51, SD±11.72; t=3.90 (520), p<.001). There were no other significant 
differences in the model measures between the two groups. 
6.2.1 Primary Aim Findings 
In this study, the null hypothesis was found to hold true; all model components 
(biological/physiological factors, symptom status, functional status, general health perceptions, 
and overall QOL) were necessary to make up HRQOL in the total sample of persons living with 
HIV (N=532).  A single group robust SEM was performed for both the HIV group without liver 
disease and the HIV+LD group. Although the initial baseline operationalized Wilson and Cleary 
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(1995) model of HRQOL did not fit the data well in either group, a good-fitting model was found 
with relatively few modifications (Satorra-Bentler χ2=40.307 (38), Comparative Fit Index=.998, 
Root mean-square error of approximation=.017). Interestingly, there were no significant 
differences in the SEM between the two groups when using the chi-square difference test.  The 
modified model fit the data in both the HIV group without liver disease and the HIV+ LD group.  
That is, all five model components were necessary in both groups, such that they followed the 
same path and had similar fit indices. However, the path from CD4 count to Perception of Illness 
was different between the HIV group and the HIV+LD group.  In the HIV+LD group, the path 
was not initially identified with the LaGrange Multiplier as making a significant difference in the 
model chi-square.  That is, in the HIV group without liver disease, there was a positive 
association between CD4 counts and Perception of Illness scores such that higher CD4 counts 
(better indicator of health) was associated with higher scores on the Perception of Illness scale 
(better perceived control over managing their illness).  In those persons with HIV+LD, this 
relationship was not found to be as significant based on the change in model chi-square. 
To determine if this path (CD4 count to Perception of Illness) existed in the HIV+LD 
group, the SEM was run again constraining, or forcing this path, to determine model fit.  The 
constrained path from CD4 count to Perception of Illness fit the HIV+LD data and was therefore 
included. The final multi-group SEM with model parameters constrained allowed for 
identification of significant pathways influencing HRQOL. Therefore, the null hypothesis was 
not rejected.  
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6.2.2 Secondary Aims Findings 
The secondary aims were to test if each of the five variables was directly linked as hypothesized 
by Wilson and Cleary (1995).   
There was a significant direct effect of biological/physiological factors on symptom 
status in both persons with HIV and persons with HIV+LD. CD4 count, as a measure of 
biological/physiological factors, significantly predicted symptom status, as measured with the 
MOS-HIV mental summary score in both the HIV (B=.120, z=2.44, p=.015) and HIV+LD 
groups (B=.113, z=2.44, p=.015). HIV viral load, as a measure of biological/physiological 
factors, significantly predicted symptom status, as measured with the MOS-HIV mental 
summary score in both the HIV (B=.103, z=2.10, p=.036) and HIV+LD groups (B=.107, z=2.10, 
p=.036).  The MOS-HIV mental summary score, as a measure of symptom status, significantly 
predicted functional status, as measured with the MOS-HIV physical summary score, in both the 
HIV (B=.669, z=11.52, p<.001) and HIV+LD groups (B=.644, z=11.52, p<.001).  In both the 
HIV and HIV+LD groups, the biological/physiologic factors had a significant direct effect on 
symptom status, which in turn had a significant direct effect on functional status.  However, there 
were no significant direct effects of functional status on general health perceptions or general 
health perceptions on overall QOL.  Thus, only two of the four direct links were found to be 
significant in this sample of persons living with HIV and HIV+LD.  
Additional significant paths were identified using the LaGrange Multiplier from 
biological/physiological factors to general health perception (CD4 count to Perception of Illness) 
in both the HIV group (B=.122, z=2.97, p=.003) and the HIV+LD group (B=.103, z=2.97, 
p=.003), and four paths linking symptom status, as measured by the BDI-II and the MOS-HIV 
mental summary score, to distal components of the Wilson and Cleary (1995) model of HRQOL. 
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Three of the identified paths linked symptom status directly to general health perceptions and 
one linked symptom status directly to overall quality of life (see Figure 10 in Chapter 5). The 
MOS-HIV mental summary score, as a measure of symptom status, significantly predicted 
general health perceptions, as measured with the Perception of Illness visual analog scale in both 
the HIV (B=.410, z=4.63, p<.001) and HIV+LD groups (B=.369, z=4.63, p<.001). The MOS-
HIV mental summary score, as a measure of symptom status, significantly predicted general 
health perceptions, as measured with the MOS-HIV health transition score, in both the HIV 
(B=.343, z=4.12, p<.001) and HIV+LD groups (B=.319, z=4.12, p<.001). The BDI-II, as a 
measure of symptom status, significantly predicted general health perceptions, as measured with 
the MOS-HIV health transition score in both the HIV (B=-.204, z=-2.94, p=.003) and HIV+LD 
groups (B=-.203, z=-2.94, p=.003).  The final added path included the BDI-II, as a measure of 
symptom status, which significantly predicted overall QOL, as measured with the Satisfaction 
with Life Scale, in both the HIV (B=.387, z=-6.84, p<.001) and HIV+LD groups (B=.358, z=-
6.84, p<.001). 
Because the LaGrange Multiplier identified the most influential paths across all of the 
measures, additional pathways were identified.  These additional paths identified links between 
biological/physiological factors to general health perceptions and symptom status to both general 
health perceptions and overall QOL.  Thus while biological/physiological factors did influence 
the model, the vast majority of the variability in the model was explained by self-reported 
depressive symptoms and mental health status regardless of group membership.  
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6.2.3 Exploratory Aims Findings 
The exploratory aim was to assess the relationships between characteristics of the individual 
(age, sex, race/ethnicity, and years of education) and characteristics of the environment 
(Inventory Support Evaluation List [ISEL], gross annual household income) as covariates in the 
SEM. The addition of these covariates did not improve the overall model fit. However, of the 36 
covariance pathways that were added to the good-fitting model, 11 individual parameters were 
found to be significant.  There were four significant pathways found stemming from the 
characteristics of the individual. Three of the four significant pathways came from race/ethnicity 
and the remaining path related age to functional status. The covariate of age, as a measure of 
characteristics of the individual, predicted the endogenous variable of functional status, as 
measured by the MOS-HIV physical summary score (B=.069, z=-1.984, p=.047). Age was not 
related to measures of symptom status, general health perceptions, or overall QOL. Race as a 
covariate in the model was found to have three independent significant paths.  The first path that 
race predicted was symptom status, as measured by the MOS-HIV mental summary score 
(B=.091, z=2.204, p=.028). The second path predicted by race was functional status, as measured 
by the MOS-HIV physical summary score (B=.125, z=3.350, p=.001). The last path predicted by 
race was general health perceptions, as measured by the MOS-HIV health transition score 
(B=.148, z=3.443, p=.001).  Sex and years of education were not significantly related to the main 
Wilson and Cleary (1995) model components (biological/physiological factors, symptom status, 
functional status, general health perceptions, and overall QOL).  
The characteristics of the environment as measured by the ISEL (social support) and 
household income had significant independent covariant relationships to the model parameters. 
Four paths linked from social support and three paths linked from gross annual household 
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income. Specifically self-reported social support, as measured with the ISEL, had an independent 
effect on symptom status at a significance level of <.001 as measured by both the BDI-II 
(B=.517, z=-11.936, p<.001) and MOS-HIV mental summary score (B=.525, z=11.685, p<.001). 
The ISEL score as a covariate in the model also independently predicted general health 
perceptions, as measured by the Perception of Illness visual analogue scale (B=.228, z=4.180, 
p<.001).  Lastly, overall QOL, as measured by the Satisfaction with Life Scale, was 
independently predicted by the ISEL (B=.155, z=2.707, p=.007). Gross annual household 
income, as a measure of characteristics of the environment, had three significant independent 
paths.  First, gross annual household income as a covariate in the model predicted symptom 
status by both the BDI-II (B=.104, z=-2.392, p=.017) and the MOS-HIV mental summary score 
(B=.113, z=2.488, p=.013).  Gross annual household income also independently predicted 
functional status, as measured by the MOS-HIV physical summary score (B=.165, z=4.024, 
p<.001). The significant retained independent multi-group SEM covariate pathways are depicted 
in Figure 12 of Chapter 5.   
6.3 CONCLUSIONS 
This study applied a sophisticated statistical analysis, SEM, to test a theoretical model of 
HRQOL as described by Wilson and Cleary (1995). The assessment of HRQOL is useful not 
only for capturing important facets of a person’s self-perception of how illness affects everyday 
functioning, but also as a valid measure of clinical outcome when assessing interventions 
(Lorenz et al., 2006; Tsui et al., 2007).  This model, as initially conceptualized by Wilson and 
Cleary (1995), has been found useful to describe HRQOL in persons living with HIV (Phaladze 
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et al., 2005; Sousa & Kwok, 2006; Vidrine et al., 2005). However, persons living with HIV have 
an increased risk of developing liver disease as related to toxic effects of antiretroviral therapy 
yielding hepatitis and other liver disease (Lorenz et al., 2006; NIH, 2002; Tsui et al., 2007). No 
study to date has tested the Wilson and Cleary (1995) model in persons living with HIV+LD. 
Testing the Wilson and Cleary (1995) model of HRQOL offered information regarding both the 
nature and direction of the relationships and the structure of the components that make up 
HRQOL in persons with HIV without liver disease and in persons with HIV+LD. Based on the 
aforementioned findings it was concluded that a modified Wilson and Cleary (1995) model of 
HRQOL fit the data in a group of persons living with HIV, as well as persons living with 
HIV+LD.  These findings are similar to other studies that have used the Wilson and Cleary 
(1995) model in clinical samples with heart failure (Heo et al., 2005), gastrointestinal bleeding 
(Sousa & Williamson, 2003), diabetes (Chia, 2007), and Hodgkin’s lymphoma (Wettergren et 
al., 2004).  Therefore, the model proposed by Wilson and Cleary has now been supported in a 
sample of individuals with HIV+LD. 
6.4 DISCUSSION OF THE FINDINGS 
The findings of this research show that both health-related factors, such as CD4 count and HIV 
viral load, and social factors, such as self-reported mental health and depressive symptoms, were 
important indicators of HRQOL in this sample of persons living with HIV (N=532). These 
findings imply that symptom status, specifically depressive symptoms and altered mental 
function, are key issues in determining HRQOL in person with HIV without liver disease and in 
persons with HIV+LD.   
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6.4.1 Relationship to the Existing Literature 
This study supports prior theoretical work by researchers who tested the Wilson and Cleary 
Model (1995) of HRQOL in persons living with HIV (Clingerman, 2004; Phaladze et al., 2005; 
Sousa et al., 1999; Sousa & Kwok, 2006; Vidrine et al., 2005).   Although each of the 
aforementioned researchers used different measures (see Table 1 in Chapter 2) to measure 
overall QOL, and not all of the researchers tested the model in its entirety, the results were 
similar in that the Wilson and Cleary (1995) model of HRQOL was found to predict 
relationships among the variables.  The predictions as hypothesized in the model were found 
when using a series a multiple regressions (Clingerman, 2004; Phaladze et al., 2005; Sousa et al., 
1999) and when using SEM (Sousa & Kwok, 2006; Vidrine et al., 2005).  In this study, the 
theoretical framework of HRQOL defined by Wilson and Cleary (1995) was found to be useful 
in identifying the core relationships that influenced HRQOL in persons with HIV with and 
without LD as a comorbidity.  The current analysis was more sophisticated than a series of 
multiple or simple linear regressions, since SEM allowed for simultaneous testing of all the 
relationships among the hypothesized components of HRQOL according to Wilson and Cleary 
(1995). 
Biological/physiological factors (CD4 count, HIV viral load) did have a direct effect, 
although limited, in the overall analysis, which supports prior findings from HIV studies (Murri 
et al., 2003).  Murri and colleagues (2003) included 809 persons with HIV with a similar 
percentage of males (68%) as this study who were also taking highly active antiretroviral 
therapy. However, the current findings from this study do not necessarily support or refute 
research assessing the relationship between chronic liver disease and specific 
biologic/physiologic factors and symptom status (Hauser et al., 2004), as this dissertation did not 
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include a specific measure of biological/physiological liver function (e.g., liver function tests or 
biopsy). The parent study was not designed to test specific comorbid patient populations who 
also had HIV infection. Furthermore, as persons living with HIV are living longer CD4 counts 
may no longer be the best indicator for biological/physiological function.  Duration of illness or 
duration on antiretroviral therapy may be more indicative of disease progression. 
There was a significant direct effect of symptom status on functional status in both 
groups. Symptom status was represented in the model by scores on the BDI-II and the MOS-HIV 
mental summary score. Furthermore, symptom status had significant effects in the SEM on 
multiple components of HRQOL. The additional pathways between symptom status and other 
components, such as overall QOL, have been noted by other researchers (Albert et al., 1995; 
Anandan, Braveman, Kielhofner, & Forsyth, 2006; Breitbart et al., 1996; Crystal, Fleishman, 
Hays, Shapiro, & Bozzette, 2000; Henderson, Erlen, & Kim, 2007; Hudson, Lee, & Portillo, 
2003; Hughes, 2004; Murri et al., 2003; Phaladze et al., 2005; Sousa et al., 1999; Sousa & Kwok, 
2006; Vidrine et al., 2005; Voss, 2005; Wilson & Cleary, 1995; Wu et al., 1997), and suggest 
that self-reported depressive symptoms and mental function are important indicators of HRQOL.  
The findings of such a relationship were similar to those of Sousa and colleagues (1999); 
however, they used different measures, including a HIV symptom specific checklist, and they 
assessed persons with HIV (N=142) that had an AIDS diagnosis prior to the use of highly active 
antiretroviral therapy.  The findings in this study also support those of Reynolds et al. (2004) 
who found a negative relationship between depressive symptoms and positive general health 
perceptions in a sample of persons with HIV (N=980). Self-reported depressive symptoms were 
found in both the HIV and HIV+LD groups; this is a common finding in both persons living with 
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HIV and persons with HIV+LD (Mrus et al., 2006; NIH, 2002; Shiffman, 1998; Soriano et al., 
2005).   
The measure of missed appointments was not related to the other measures in the primary 
SEM.   Therefore, categorized missed appointments (“yes” or “no” did not miss HIV medical 
appointments) was not included in the SEM/path analysis. These findings do not support those of  
Holzemer and colleagues (1999) in which lower CD4 counts and higher HIV viral loads were 
related to more missed appointments in a sample (N=420, 80% male) living with HIV. The 
average CD4 count in the sample in Holzemer and colleagues study (1999) was 321 cells/ml 
which is considerably lower than this study (average CD4 count of 455 cells/ml). Missed 
appointments were measured continuously by Holzemer and colleagues (1999) with the number 
of missed appointments quantified annually, which was likely a more powerful measure than the 
categorical measure used in this study. Moreover, self-reported depressive symptoms were not 
related to missed appointments as others have reported (Aloisi et al., 2002; Beach et al., 2006; 
Berg et al., 2005; Giordano et al., 2003; Nacher et al., 2006; Weiser et al., 2006). The lack of a 
relationship with missed appointments was likely due to the categorical nature of the measure 
and an inconsistent definition or procedure for what was defined as missed appointments across 
differing data collection sites.   
There was no significant direct effect of functional status on general health perceptions 
nor was there a significant direct effect of general health perceptions on overall QOL as others 
have demonstrated in diverse HIV samples (Phaladze et al., 2005; Sousa et al., 1999; Wu, 
Revicki et al., 1997).  The overall SEM did include general health perceptions and overall QOL 
as they were related to other model variables yielding a more parsimonious model including a 
direct path from symptom status to general health perceptions and overall QOL as Sousa and 
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colleagues found (N=917) in a recent HIV study (Sousa, Tann, & Kwok, 2006).  This was one of 
the added relationships/pathways that was statistically identified by the LaGrange Multiplier that 
helped to improve the final SEM model in this dissertation.  Sousa and colleagues (2006) found 
the Wilson and Cleary (1995) model of HRQOL to hold true in persons living with HIV but 
found similar results as the majority of the model was influenced by symptom status rather than 
the other model variables.   
Other possible factors influencing HRQOL were assessed with the exploratory analyses.  
Specifically, characteristics of the individual and of the environment were investigated as to their 
relationship to the model measures.  Given the covariates that were considered, an additional 36 
parameters were assessed simultaneously.  While the scope of this study did not allow for 
adequate statistical power for these analyses, the exploratory findings did identify that sex and 
years of education were not significantly related to the five main Wilson and Cleary (1995) 
model components (biological/physiological factors, symptom status, functional status, general 
health perceptions, and overall QOL).  Although the overall model was not improved by the 
addition of the covariates, several of the covariates were found to be significantly related to 
several of the individual measures. The lack of a relationship according to sex may be related to 
the disproportionate numbers of males and females in the study (70% male, 30% female). 
Race/ethnicity as a characteristic of the individual was associated with MOS-HIV mental 
summary scores, MOS-HIV physical summary scores, and MOS-HIV health transition scores.  
Examining the standardized z-scores (see Chapter 5, Table 21) for these associations, being 
“non-white” significantly predicted higher scores on these measures.  This is an interesting 
finding as the data and z-transformation scoring was based on white males in the United States 
with HIV in the early to mid 1990’s (Wu, 1996; Wu, Hays et al., 1997; Wu, Revicki et al., 1997; 
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Wu et al., 1991).  In a review of the literature addressing African Americans with liver disease, 
Howell et al. (2000) found outcomes for African Americans to be poorer than Caucasians across 
a number of measures, including response to treatment, but no studies reported assessing 
HRQOL.  Thus, future studies addressing race and HRQOL would seem to be warranted. Age 
was related only to MOS-HIV physical summary scores and demonstrated that older age was 
associated with lower self-reported physical function. 
 Social support, as measured with the ISEL, was associated with both general health 
perceptions, as measured by the Perception of Illness visual analog scale, and overall QOL, as 
measured with the Satisfaction with Life Scale. Social support, as measured with the ISEL, was 
also significantly related to symptom status, as measured with the BDI-II and MOS-HIV mental 
summary score.  Total gross annual household income was related to MOS-HIV mental and 
physical summary scores.  Thus, characteristics of the environment, as others have shown, have 
relevance to the components of HRQOL (Dray-Spira & Lert, 2003; McFarland et al., 2003; 
Rapkin & Schwartz, 2004).  
6.5 LIMITATIONS 
The following section addresses the limitations of the presented research. These include 
limitations related to the design, sample, measures, analytical approach, and generalizability.  
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6.5.1 Design 
A significant limitation to this analysis was the secondary nature of the study.  The parent study 
was not designed to test the Wilson and Cleary (1995) model of HRQOL. Thus, the measures 
selected were those available and may not have been the best means of assessing the variables. 
There are causal relations within the Wilson and Cleary  (1995) model of HRQOL suggesting 
that one variable may come before and build on the next.  To assess the causal relationships, a 
longitudinal study would be necessary with data gathered from different time points.  The data 
used in this study were cross-sectional and therefore the causal relationships were not able to be 
assessed. 
6.5.2 Sample 
Combining data from Study 1 and Study 2 was a potential strength as it better powered the study; 
however, there were some differences between the samples in the two studies.  The timeline of 
the two studies may have influenced those categorized as having HIV without liver disease and 
those with HIV+LD as mandatory laboratory reporting of the Hepatitis C virus did not begin 
until 2002 (NIH, 2002).  In addition, persons living with HIV on highly active antiretroviral 
therapy for a longer duration may have been more likely to suffer liver related complications as 
their medication regimes can be liver toxic (Sax & Gathe, 2005; Tsui et al., 2007).  Duration on 
highly active antiretroviral therapy was not included as a measure for this analysis as this 
information was that available from the parent study. Also, treatment issues were not measured 
in this study. Some of the persons living with HIV+LD may have been or were currently being 
treated for infectious hepatitis with chemotherapy types of medications that are known to have 
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effects on depressive symptoms and possibly result in fatigue/anemia and altered cognitive 
function. Furthermore, liver disease could potentially be a proxy measure of substance abuse, as 
the hepatitis C virus is most commonly contracted from intravenous drug use and has not been 
shown to be sexually transmitted (NIH, 2002). This study did not include lipodystropy as a 
comorbidity that typically goes hand in hand with hyperlipidemia, which is classified as a liver 
disorder.  The category of “other liver diseases” was not very specific; “other liver diseases” was 
one option that an individual could self-report and was possibly individually defined.  
There were additional differences between the samples of Study 1 and Study 2.  Overall, 
participants in Study 2 were older and more likely to be non-white; a greater proportion reported 
incomes below $10,000 (see Table 12 in Chapter 5). There were higher numbers of non-white 
minorities enrolled in Study 2 as recruitment sites were added that had different demographics 
from the Pittsburgh sites used in Study 1. The additional sites (i.e., Cleveland and Akron) had a 
higher proportion of non-white participants and lower income levels. The difference in age may 
be spurious.  The higher proportion of non-white participants and lower income levels may aid in 
making this study more generalizable as these differences are more reflective of the overall 
United States population of persons living with HIV (IOM, 2001).  
6.5.3 Measures 
The measures used were those available from the parent study and may not have been the best 
choice for each of the components; however, they were found to have adequate to good 
reliability in both groups (HIV group and HIV+LD group). Another potential limitation to this 
study was that the majority of the data were self-reported. Self-reported data are suitable for 
QOL research as QOL is defined as a subjective perception of the individual.  The current study 
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had mostly self-report measures with the exception of the majority (70% from medical record 
review) of the biological/physiological factors data.  It could be argued that self-reported 
depressive symptoms may be biased in that scores may be exaggerated or minimized by the 
participant. It is considered optimal to have both objective and subjective measures of a latent 
construct for more precise measurement (Byrne, 2006, pp. 261-277). The main findings of a 
significant relationship between depressive symptoms and other measures could be limiting as 
there was no objective measure of depression.   
Additional measurement limitations were the processes in which all of the data were 
gathered.  There were likely issues of how missed appointments were defined at the various 
clinics/data collection sites.  It may not be clear if a rescheduled appointment was also a missed 
appointment or if a missed appointment was designated as not calling to cancel the day prior to 
the appointment.  The categorized missed appointment variable was used as this same measure 
was collected in both Study 1 and Study 2.  Continuous measures of annual missed appointments 
were instituted in Study 2 and would be considered a better measure, but were not available for 
Study 1 data.  Furthermore, there was a potential for bias if missed appointments were not 
defined in the same way in the various clinics/data collection sites.  There may have been issues 
regarding how the data were recorded, coded, and entered as there were multiple data collectors 
and research assistants across the nine-year duration of the parent study.  
The parent study protocol required that all participants use an electronic medication 
adherence monitoring device and pen and paper medication diary for 4 weeks prior to the 
baseline data collection in order to obtain baseline adherence data. This observation period may 
have influenced the data. That is, most of the self-reported measures asked participants to rate 
their symptom status, functional status, general health perceptions, and overall QOL for the prior 
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4 weeks. Possibly the participants may have focused more on their own health during that 4-
week period. 
6.5.4 Analytical Approach 
Analytic issues that may limit the generalizability of the study findings included the possibility 
that the study was over-powered.  If the sample size is large, differences between groups are 
likely to be found that may not actually exist.  Furthermore, SEM is designed to find statistical 
relationships among the variables.  However, these statistical relationships may not be theoretical 
or actual associations. The findings may be due to the random relationships of the variables or 
the data fitting those hypothesized relationships (Bentler, 1990; Bentler & Bonett, 1980; Bentler 
& Yuan, 1999; Byrne, 2006; K. H. Kim, 2005). SEM tests the relationships among the variables. 
LaGrange Multiplier tests for all possible solutions to aid the researcher in using theoretical 
wisdom to identify which additional pathways for model fit are appropriate to allow the best 
fitting solution to the data (Bentler & Wu, 2002; Byrne, 2006). However, these relationships may 
not be present. Furthermore, even though statistical significance and a good-fitting model were 
found, these results may not be clinically meaningful to persons living with HIV with or without 
LD.  On the other hand, SEM is useful in testing a theoretical model of HRQOL, as it allows the 
researcher to test the multiple components simultaneously.   
6.5.5 Generalizability 
Health-related quality of life (HRQOL) is a subjective perception; however, this study only 
provided a baseline perspective of the participants at that one particular point in time. The results 
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of this analysis are not necessarily generalizable to other HIV or HIV+LD populations (Becker, 
1998; IOM, 2001; NIH, 2002). This sample had CD4 counts that were not in the low range (i.e., 
means for both groups were above 400 per/ml, indicating that the average immune status for both 
the HIV and HIV+LD group was relatively good. The participants in this sample had to be taking 
antiretroviral therapy, which is indicated for persons with HIV whose CD4 counts are below 350 
per/ml. Therefore, the results of this study may not be generalizable to other groups of persons 
with HIV who are not being treated with highly active antiretroviral therapy.   
Care should be taken in interpreting the findings, as persons living with HIV without 
liver disease and persons living with HIV+LD may or may not have access to state funding for 
HIV medications and clinic appointments free of charge. There are such state-funded HIV 
programs available to individuals living in the states in which the data for this study were 
collected.  Additionally, individuals who agreed to participate in the parent study may not have 
been representative of the population as a whole.  HIV disclosure issues or fears of 
stigmatization may have kept some individuals from participating in the parent studies if they 
had not disclosed their HIV status to others or if they were uncomfortable talking about their 
HIV to strangers.  In order to be considered for inclusion in the parent study the participant had 
to have telephone access to receive nurse delivered telephone interventions. Not having access to 
a telephone may have further biased the sample recruited.   
Furthermore, these results may or may not be applicable to different areas of the country 
or the world.   Persons with HIV living in different areas of the United States, such as urban vs. 
rural, may have other issues, such as limited access to HIV care, lack of social support resources, 
or increased stigmatization. Culture and cultural differences may be a factor if one tries to apply 
these findings beyond North America or even within sectors of North America. One’s HRQOL 
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may have a cultural component; what makes one’s perceptions of their HRQOL good in one 
culture may be different in another culture or environment. 
6.6 IMPLICATIONS 
The first important goal of this study was to make a novel contribution to the literature regarding 
HRQOL in persons with HIV+LD.  Individuals are living longer; multiple factors affect their 
HRQOL.  The findings provide potential support for the use of the Wilson and Cleary (1995) 
model of HRQOL in individuals with multiple comorbidies or clusters of symptoms (e.g., 
depression and altered mental function). The findings of this research increase the theoretical 
understanding of HRQOL and offer guidance to healthcare professionals in regard to potentially 
modifiable symptoms such as depression.  These modifiable symptoms may then be targeted 
with disease-specific interventions designed to ultimately improve HRQOL in persons with 
multiple comorbidities.   
The Wilson and Cleary (1995) model is useful as it links clinical indicators to patient-
related outcomes, thus, bridging the gap between health-related and socially-identified variables. 
Therefore, this study has clear clinical applications as the findings indicate that 
biological/physiological factors and symptom status play important roles in the outcome of 
HRQOL.   
 
 159 
6.6.1 Directions for Future Research  
This study should be replicated within the HIV+LD population, as well as other chronic diseases 
as a prospective longitudinal study with both objective and subjective measures across all of the 
variables in the Wilson and Cleary (1995) model of HRQOL. Such work will allow for 
identification of potential causality with theoretical models. 
There is no cure for HIV. Therefore, persons living with HIV with or without LD are no 
longer just trying to survive day to day – but are seeing the future of living with HIV as a chronic 
disease with debilitating long-term consequences. Direction for a future study needs to include 
better measures of biological/physiological factors that specifically assess current disease status.  
Specifically, work needs to focus on a specific liver disease that may significantly impact 
persons living with HIV such as the Hepatitis C virus or on specific symptoms that affect the 
individual most, such as depressive symptoms. 
Depressive and mental symptoms had the strongest relationship to the other model 
measures suggesting that a focus for clinical intervention would be to more closely address these 
issues in persons living with HIV+LD. These findings also suggest that a more complete 
understanding of the symptom experience in persons living with HIV+LD is fundamental to 
achieve optimal patient outcomes. It may be that specific symptoms, such as depressive 
symptoms, need to be controlled for in model testing. Future research should consider a 
symptom-specific tool to look for clusters of symptoms in both HIV and liver disease. This study 
also found that race, social support, and income were important covariates.  Therefore another 
direction for future research would be to assess differences between racial and socioeconomic 
status on HRQOL in persons with HIV+LD. 
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In summary, there are multiple interpretations of HRQOL (see Chapter 2), many of 
which consider HRQOL to be multidimensional wherein the components make up the whole. 
The Wilson and Cleary (1995) model of HRQOL is different in that it is a causal model that 
allowed for identification of the potential causal factors in the overall HRQOL paradigm.  
Testing the model with SEM was useful as it allowed for testing all of the components of 
HRQOL simultaneously.  A limitation to the approach used in this study was that the symptoms 
that the researchers operationalized in the symptom status variable (depressive and mental 
symptoms) may not be the most bothersome symptoms to the person living with HIV+LD.  As 
was found in pilot testing Cella’s model of QOL (1994) the variables were too highly correlated 
and thus oversaturated the model (See Chapter 3). HRQOL variables in general may be too 
highly correlated and interrelated.  It may be difficult to identify one modifiable factor in any 
analysis as HRQOL is multidimensional.  
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APPENDIX A 
A.1 PILOT #2 MANUSCRIPT 
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Abstract 
Title. Validity of the MOS-HIV as a Measure of Health-Related Quality of Life in 
Persons Living with HIV and Liver Disease 
 
Aim. The purpose of this study was to validate the HIV Medical Outcomes Survey in 
persons with human immunodeficiency virus and liver disease.   
Background.  Persons living with human immunodeficiency virus are living longer and 
therefore more likely to suffer significant morbidity due to potentially treatable liver diseases.  
Liver Disease alone has been shown to have a significant effect on one’s health-related quality of 
life.  Clinical evidence suggests that persons living with human immunodeficiency virus and 
liver disease, a growing number of individuals, may have a poorer health-related quality of life 
than persons with human immunodeficiency virus who do not have liver disease.   
Method. To accurately assess health-related quality of life requires the use of a valid 
instrument for this population.  The sample included 215 persons living on antiretroviral therapy 
(n=119 without and n=96 with liver disease).  
Findings.  The validity of the HIV Medical Outcomes Survey was supported by testing 
construct, convergent, discriminative, and predictive validity. The HIV Medical Outcomes 
Survey was shown to be able to discriminate between those persons living with human 
immunodeficiency virus with and without liver disease on the basis of the cognitive function 
subscale scores (p=.018).   
Conclusion. This study found the HIV Medical Outcomes Survey to be a valid 
instrument in persons with human immunodeficiency virus and liver disease.  
Key words. health-related quality of life, HIV, liver disease, MOS-HIV, nursing 
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SUMMARY  
 
 
What is already known about this topic 
 
• Persons living with human immunodeficiency virus are living longer and are dying from 
liver related complications. 
• Human immunodeficiency virus affects individuals’ health-related quality of life. 
• The Human Immunodeficiency Virus Medical Outcomes Survey has been tested in a 
multitude of studies involving persons living with human immunodeficiency virus. 
 
 
What this paper adds 
 
• The findings support the validity of the Human Immunodeficiency Virus Medical 
Outcomes Survey in persons living with human immunodeficiency virus and co-morbid 
liver disease. 
• The Human Immunodeficiency Virus Medical Outcomes Survey may be useful in 
clinical practice to assess HRQOL in individuals living with human immunodeficiency 
virus and co-morbid liver disease. 
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Introduction 
A diagnosis of human immunodeficiency virus (HIV) is now considered a chronic 
disease requiring complex medication regimes with multiple co-morbidities that influence all 
aspects of an individual’s well-being.  Persons living with HIV are living 20 to 30 years beyond 
the time of diagnosis (Tedaldi et al. 2002).  Aggressive treatment of HIV has prolonged the lives 
of these patients; however, they are more likely to suffer significant morbidity and mortality 
from liver related disorders and their complications (anemia, end stage liver disease (LD), and 
hepatocellular carcinoma) than from their HIV (Cosby et al. 2000, Tedaldi et al. 2002).  Because 
of the toxic effects of antiretrovirals on the liver and co-infection with chronic viral hepatitis, the 
number of persons with HIV and liver diseases is increasing (Foster et al. 1998, Kim 2002, Sax 
& Gathe 2005). 
More than 50% of persons with HIV are co-infected with chronic viral hepatitis, 
primarily hepatitis C virus (HCV).  Estimates are that the number of cases of HCV in the United 
States may be four to five times greater than the number of cases of HIV (Alter et al. 1999, 
National Institutes of Health 2002, United States Census Bureau 2000).  Factors that predict a 
worse prognosis for patients with HCV include co-infection with HIV, obesity, nonalcoholic 
steatohepatitis syndrome, viral genotype, and advanced age at infection (Lawrence 2000, Soriano 
et al. 2005). 
The co-morbidity of HIV and LD includes various liver conditions (infectious, chronic, 
steatosis, and cirrhosis). The etiologies of LD in persons with HIV are 85% hepatitis C virus, 
20% hepatitis B virus, 7% drug toxicity, and 3% other rare pathologies.  Approximately 85% of 
those with acute LD go on to develop chronic LD.  Long-term consequences of chronic LD 
include decreased health-related quality of life (HRQoL), chronic fatigue and anemia, chronic 
 166 
viral hepatitis, hepatocellular carcinoma, and it is the primary cause for liver transplant in the 
United States.  These potentially treatable liver conditions have been shown to have a significant 
effect on a person’s HRQoL. (Buti et al. 2006, Fleming et al. 2004, Foster et al. 1998, Hauser et 
al. 2004, Hickman et al. 2004, Ortiz et al. 2002, Pojoga et al. 2004, Soriano et al. 2005). 
However, there is no measure of HRQoL that has been validated in the co-infected population. 
The empirical support measuring HRQoL in the population with LD has, more often than 
not, been reported as overall HRQoL or is collapsed into mental and physical summary scores of 
the Short Form Health Survey (SF-36).  Many current studies that have HRQoL as a primary 
outcome variable are focused on one chronic disease.  For example, research has shown that 
adults with HIV alone, as well as those with chronic LD have impaired physical, mental, and 
social functioning compared to population norms.  There also is a body of literature describing 
the separate effects of HIV and LD on HRQoL, fatigue, and depression. (Foster et al. 1998, 
Henderson et al., 2005, Phaladze et al. 2005, Revicki et al. 1995, Sousa et al. 1999, Vidrine et al. 
2005, Wilson et al. 1997).  One recent study reports that HIV specific instruments need to be 
redesigned for patients with co-infection with HCV (Buti et al. 2006). 
As the first goal of Healthy People 2010 (United States Department of Health and Human 
Services 2000) is to help individuals of all ages increase life expectancy and improve their 
HRQoL, the challenge for researchers and practitioners is to determine what aspects of HRQoL 
are affected for those with multiple co-morbid chronic diseases (Henderson et al., 2006).  The 
domains of importance that predict the overall HRQoL in one population are not necessarily the 
same for another population.  There are few systematic studies evaluating the validity of HRQoL 
instruments in persons with HIV and LD (Fleming et al. 2004).  A study using the MOS-HIV in 
this population is not yet reported.  Thus, there is a need for a valid HRQoL tool that can be used 
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with persons with HIV and LD.  An instrument that assesses the complex nature of HRQoL may 
assist in identifying and developing specific interventions to improve the well-being of persons 
with HIV and LD.  A validated tool in this population could also provide a patient related 
outcome measure.  The purpose of this study was to examine the validity of the HIV Medical 
Outcomes Survey (MOS-HIV) (Wu 1996, 1999) as a measure of HRQoL in persons with HIV 
and LD. 
Methods 
This study assessed the validity of the two-factor model of the MOS-HIV (Wu 1996, 
1999, Wu et al. 1997).  This secondary data analysis used cross-sectional data including the 
MOS-HIV comparing the HRQoL of persons with HIV and persons with HIV and LD from a 
parent study (number removed for review).  The aims of the parent study were to improve 
medication adherence in persons with HIV on antiretrovirals.  Previously de-identified baseline 
data were extracted by the data manager.  The data were collected prior to any adherence 
interventions.  Chart review for clinical indicators and a problem list of medical co-morbidities 
was completed by project staff.  All MOS-HIV questionnaires, medical record reviews, and 
sociodemographic survey measures were collected as a component of the parent study. 
For the parent study, the sample size of 200 participants with poor adherence was 
estimated to have adequate statistical power (.80) to test for difference in mean adherence 
between the two treatment groups over time at a significance level of .01.  An additional 15 
subjects with good medication adherence (>95%) were also enrolled.  The inclusion criteria for 
the parent study were a positive diagnosis by a health care provider of HIV, currently being 
treated with antiretroviral therapy, males and females of all races and ethnicities, and consent to 
participate in the parent study.  All included participants required telephone access for the 
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administration of the behavioral adherence intervention.  Exclusion criteria included failure of 
the HIV Dementia Scale (Power et al. 1995) screening, living with someone else already in the 
study, blindness or motor impairment of the upper extremities, or not presently administering 
their own medications. 
This current secondary analysis study compared baseline data from persons with HIV and 
persons with HIV and LD who self-reported having liver problems or had a history of LD as 
recorded in the medical record.  The particular type of liver problem was not available in all 
cases.  Persons with HIV with self-reported or chart review history of LD were deemed to be 
persons with HIV and LD.  This descriptive study was granted Institutional Review Board 
approval as an exempt study.  This study involved the use of existing data/documents/records 
that were provided to the investigator in such a manner that subjects could not be identified, 
directly or through identifiers linked directly to the subjects.  No one was excluded on the basis 
of gender, race, or ethnic background.  Individuals under the age of 18 were excluded. 
Measures 
The MOS-HIV has been used widely in HIV related clinical trials as an outcome measure 
(Wu et al., 1997).  The two factors or latent constructs that comprise the HRQoL are physical 
function and mental function.  The MOS-HIV was developed from the MOS-Short Form 20 
(Stewart et al. 1988). Additional concepts that were pertinent to persons with HIV, such as 
energy/fatigue, cognitive functioning, health distress, and quality of life were added.  The 
subscales are scored on a 0-100 scale with higher scores yielding better perceived health.  
Generation of the mental and physical health summary scores, the two factors or latent constructs 
that comprise HRQoL, was based on an analysis of the subscale scores of over 2,500 persons 
with HIV in the late 1990’s (Revicki et al. 1995).  Subscales that loaded highly on the mental 
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health summary score included mental health, quality of life, health distress, and cognitive 
function.  Subscales that loaded highly on the physical health summary score included physical 
function, pain, and role function.  The remaining three subscales (energy/fatigue, overall health, 
and social function) loaded on both the mental and physical summary scores. 
The social and demographic information was collected with the Sociodemographic 
Questionnaire, which was developed by the Center for Research in Chronic Diseases (CRCD). 
The specific self-reported data that were gathered included age (years), gender (male or female), 
race (collapsed into white or non-white), and education (number of years).  Employment status 
was dichotomized as currently employed or not employed. 
The Co-morbidity Conditions/Problem List is a CRCD developed survey that includes a 
list of medical problems as documented in the most recent medical record reviewed.  Medical 
record reviews were performed within 3 months of the self-reported baseline data collection.  
The medical co-morbidities were listed and coded.  The total number of medical co-morbities 
was calculated. 
Data Analysis 
The two factor structure of the MOS-HIV with the components (mental and physical) in 
both groups was tested.  Convergent, discriminative, and predictive validity of the MOS-HIV 
(Wu 1996 1999, Wu et al. 1991, Wu et al. 1997) are reported in two groups of person with HIV; 
those with and without LD.  The sample’s demographic characteristics as measured by the 
CRCD Sociodemographic Questionnaire are described.  The relationship between selected 
sociodemographic factors and HRQoL in persons with HIV only and persons with HIV and LD 
was examined.  Descriptive statistics, group comparisons, correlations, and exploratory factor 
analysis with oblique rotation principal components extraction were conducted using SPSS 
 170 
version 13.0 (SPSS Inc., Chicago, Illinois).  Eigenvalues greater than 1 were retained.  
Convergent validity was assessed with analysis of variance.  Statistical significance was pre-
determined at p≤.05 two tailed. 
Results 
Sample 
As summarized in Table 1, the sample (N=215) included 119 persons with HIV and 96 
persons with HIV and LD.  There were no significant differences between the two groups on age, 
gender, race, education, employment status, or number of medical co-morbidities.  The sample of 
HIV and LD tended to be less educated and have a higher level of unemployment. {Insert Table 
1} 
MOS-HIV 
Table 2 presents the group comparisons across the MOS-HIV subscales.  There was a 
significant difference between the two groups on the cognitive function subscale (p=.018) with 
the HIV and LD group having significantly lower cognitive function than those with HIV only.  
The HIV and LD group also showed lower mean scores as compared to those with HIV on role 
function, pain, overall health, and energy/fatigue subscales (p<.10).  There were no other 
significant differences between the groups with regard to subscale scores.  Pearson product 
moment correlations demonstrated a moderate correlation between income and all MOS-HIV 
subscale scores for both groups (r>.300). {Insert Table 2} 
Exploratory factor analysis of the MOS-HIV with the 10 domain scores, excluding health 
transition, extracted two primary latent construct with Eigenvalues over one.  Thus, a two factor 
model fit the data and explaining approximately 70% of the variance in persons with HIV.  Role 
function, physical function, social function, and pain loaded on the physical health component 
 171 
factor or latent construct.  The mental health, quality of life, health distress, cognitive function, 
energy/fatigue, and overall health subscales loaded on the mental health component (See Table 
3). 
The two factor model explained approximately 61% of the variance in persons with HIV 
and LD.  Role function, physical function, and pain loaded on the physical health component 
factor.  The mental health, quality of life, health distress, and cognitive function subscales loaded 
on the mental health component.  Energy/fatigue, overall health, and social function cross loaded 
on both factors (See Table 4). 
Discussion 
The MOS-HIV predicted a two factor model (mental and physical) in both the HIV and 
HIV and LD groups.  This finding supports the construct validity of the MOS SF-36 (Wu et al. 
1997).   
Convergent validity of the MOS-HIV was supported in both groups by the loadings on 
the primary component of physical and mental health corresponding with the findings of other 
studies in HIV only samples.  In the sample of persons with HIV only, the factor loading of the 
subscales that should have cross loaded did not do so.  Conversely, the group with both HIV and 
LD loaded as expected based on the literature with three subscales cross loading.  This study 
showed a potential invariance in factor loadings that were hypothesized to cross load in the HIV 
only group, but the HIV and LD group loadings performed well.  The loading of each subscale 
on the components or factors that make up the HRQoL is important to assess prior to applying 
summary scores as opposed to individual subscale scores of the MOS-HIV. 
Discriminative validity was supported by the finding of a significant difference (p=.01) in 
cognitive function as measured by the MOS-HIV when comparing the two groups.  Persons with 
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HIV and LD demonstrated significantly lower self-perceived cognitive function than persons 
with HIV without LD. This could be due to an interaction effect of unemployment and education 
in this sample. Further findings of discriminative validity between the two groups showed a 
difference in mean scores of pain and energy/fatigue with persons with HIV and LD having more 
pain and fatigue with less perceived energy than persons with HIV alone.  These findings are 
expected given the alteration in synthetic functioning of the liver when it is diseased or has a 
toxic insult. 
Predictive validity was supported by a moderately strong correlation between low role 
function score and unemployment.  Furthermore, those that reported that their health affected 
their ability to work in the MOS-HIV role function subscale also reported being unemployed on 
the CRCD Sociodemographic Questionnaire. 
Limitations of this study include the relatively small sample size and the secondary 
nature of the analysis in that the investigators had no control over the data collected.  
Additionally, the type and cause of liver disease were not always available for analysis. 
Specifically, this analysis did not isolate LD related to HCV, a growing subgroup. Furthermore, 
individuals were all screened for AIDS dementia and excluded if there was evidence of 
dementia.  Bias may have been introduced as there was no screening for altered cognitive 
function related to liver disease. 
Conclusion 
This study demonstrates that the MOS-HIV is a valid tool for assessing HRQoL in 
persons with HIV and persons with HIV and LD.  This tool encompasses the issues pertinent to 
the patient with HIV and LD and has been shown to be valid in this sample. 
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The addition of HRQoL measures has been adopted in a multitude of settings and disease 
processes.  The interest of being able to predict outcomes based on HRQoL is of great interest to 
many and varied researchers (Wilson & Cleary 1995, Vidrine et al. 2005).  Understanding the 
multiple dimensions of HRQoL may assist in developing nursing interventions for patients with 
HIV and co-morbid liver disorders (Henderson et al., 2006).  Future research is needed with a 
larger sample size and equally distributed groups.  The goal of the measurement of HRQoL and 
its domains within the population of those persons with HIV and LD would be to empirically 
identify those areas of HRQoL that are most affected and tailor clinical interventions specific to 
the individual with the goal of an improved overall quality of life.  Reasons for measuring 
HRQoL in this HIV subset with LD include: (1) assessing differing rehabilitation needs, (2) 
having a clinically meaningful endpoint in evaluation treatment outcomes, and (3) having a 
predictor for future treatment (Cella 1992). 
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Table 1.  Sample demographics of persons with HIV (N=215) 
  Total HIV HIV and LD  
Characteristics N=215 n=119 n=96 p value  
(2-tailed) 
Age (years) 
Gender(% male) 
Race (% non-white) 
Education (years) 
Not employed (%) 
Comorbidities (M) 
40.6 
67.4 
38.9 
13.3 
64.2 
2.27 
40.1 
65.6 
36.4 
13.6 
58.8 
2.25 
41.3 
69.8 
39.6 
12.9 
70.8 
2.30 
.236 
.511 
.639 
.051 
.081 
.825 
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 Table 2.  Comparison of MOS-HIV transformed subscales scores by independent sample 
t-test  
  HIV HIV and LD  
MOS-HIV 
Subscale 
n=119
(M ± SD)
n=96
(M ± SD)
p value 
(2-tailed)
Mental Health 
Quality of Life 
Health Distress 
Cognitive Function 
Energy/Fatigue 
Overall Health 
Role Function 
Physical Function 
Pain 
Social Function 
Health Transition 
64.61±22.38
65.04±23.37
69.34±28.82
76.99±20.69
52.52±23.13
53.99±24.35
55.51±46.59
68.49±33.88
62.02±28.21
73.95±30.32 
60.38±24.31 
60.98±20.33 
63.02±22.35 
66.54±27.02 
70.16±21.12 
47.07±22.99 
48.18±24.13 
43.75±46.03 
60.76±34.11 
55.63±23.97 
69.57±28.39 
60.68±22.87
.223 
.522 
.470 
.018*
.089 
.082 
.066 
.099 
.079 
.283 
.928 
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Table 3.  Convergent validity of the MOS-HIV with exploratory factor analysis in person 
with HIV (n=119) 
 
Component/Summary 
Score 
Domains Mental Physical 
Mental Health .998 -.174 
Quality of Life .869 -.065 
Health Distress .848 .016 
Cognitive Function .765 .131 
Energy/Fatigue  .705 .196 
Overall Health .624 .248 
Role Function -.123 .958 
Physical Function .097 .778 
Pain .244 .610 
Social Function .439 .450 
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Table 4.  Convergent validity of the MOS-HIV with exploratory factor analysis in 
persons with HIV and LD (n=96) 
Component/Summary Score 
Domains Mental Physical 
Mental Health  .932 -.134 
Health Distress .836 -.025 
Cognitive Function .759 .012 
Quality of Life .644 .179 
Energy/Fatigue  .480 .434 
Overall Health .450 .433 
Physical Function -.079 .861 
Role Function -.114 .847 
Pain .110 .634 
Social Function .248 .590 
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Page 1 of 16
Instrument Number:
(For internal use only)
3 1 1
           0 7 1
CRCD - 311COM, V1.4
February 6, 2004
ID Number:
(month) (day) (year)
/ /Administration Date:
:
CO-MORBIDITY QUESTIONNAIRE
Center for Research in Chronic Disorders
For optimum accuracy, it is recommended that characters be written block style without touching
the sides of the blocks, such as in the following examples.  Place only one letter or one number
in each box as shown....
Please keep these rules in mind when responding to the questions....
Some people have more than one health condition.  We are interested in your health history.
The following is a list of conditions and symptoms you may have experienced.  Please
complete the following questions for each condition.
 1. Have you ever had a heart attack?  (myocardial infarction or MI)
2   No ----> Go to question 2.
1  Yes ----> Please complete the following questions. This condition:
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
1  Yes
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
( FOR STAFF USE ONLY )
If you mark the wrong answer, put an X over it and mark the desired response.
Time:
                      Copyright  1999
by the Center for Research in Chronic Disorders
 The University of Pittsburgh School of Nursing
Study ID:
    1               2              3               4              5               6
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Page 2 of 16
(for internal use only)
/ /Date:ID Number:
(for internal use only)
 2. Have you ever been hospitalized or treated for heart failure?  (You may have felt more short
of breath and the doctor may have told you that you had fluid in your lungs or that your
heart was not working efficiently.)
2   No ----> Go to question 3.
1  Yes ----> Please complete the following questions. This condition:
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1  Yes1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
f. Did you ever have any of the following with your hospitalization for heart failure?
1. Heart attack
2. Rapid irregular heart beat
3. Total body infection (Sepsis)
4. Inflammation of the heart muscle wall (Endocarditis)
5. Pregnancy
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
For the questions that look like this:
Medical
Condition
a. Do you
have this
condition?
b. was
diagnosed
by a
healthcare
provider:
c. was present
in the last 5
years:
d. is currently treated with
the following:
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
e. required
hospital
admission:
f. has decreased your
quality of life:
 Yes        No  Yes        No  Yes         No Yes       No
 0     1     2     3     4 1        2    1     2     3    4     5   1         2   1       2   1       2
0 = Not at all
1 = Slightly
2 = Moderately
3 = Greatly
4 = Extremely
Example:
^ >
>^
Directions for questions beginning on the next page:
1.
2.
Headaches
Example:
Tuberculosis
If your response is "No," DO NOT ANSWER b through f
 and go to the next question.
If your response is "Yes," PLEASE ANSWER b through f
 and then go to the next question.
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
b. was
diagnosed
by a
healthcare
provider:
c. was present
in the last 5
years:
d. is currently treated with
the following:
e. required
hospital
admission:
f. has decreased
your quality of life:
Please answer the following questions regarding the medical conditions listed below as they
pertain to you.
Medical
Condition
 Yes        No
   1        2     1     2     3    4     5  1        2  0    1    2     3     4
Coronary Artery
Disease
Irregular Heart
Rate
Heart Valve
Disorders
Other Heart
Disorders
Yes       No
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
 Yes        No
  1        2
a. Do you
have this
condition?
 Yes        No
   1        2
Specify condition(s):
High Blood
Pressure
Anemia
Other Blood
Disorders
 0 = Not at all
 1 = Slightly
 2 = Moderately
 3 = Greatly
 4 = Extremely
3.
4.
5.
6.
7.
8.
9.
Specify condition(s):
 
 208 
(for internal use only)
/ /Date:ID Number:
(for internal use only)
10.  Do you cough first thing in the morning in the winter?  (Exclude clearing the throat.)
Page 4 of 16
2   No ----> Go to question 11.
1  Yes ----> Please complete the following questions:
1  Yes 2  Noa.   Do you cough during the day in the winter?
1  Yes 2  Nob.   Do you cough during the night in the winter?
1  Yes 2  Noc.   Do you cough like this for most days for 3 months every year?
1  Yes 2  Nod.   Do you cough up mucus on most of these days?
1  Yes 2  Noe.   Has this gone on for at least 2 years?
b. was
diagnosed
by a
healthcare
provider:
c. was present
in the last 5
years:
d. is currently treated with
the following:
e. required
hospital
admission:
f. has decreased
your quality of life:
Please answer the following questions regarding the medical conditions listed below as they 
pertain to you.
Medical
Condition
 Yes        No
   1        2     1     2     3    4     5  1        2  0    1    2     3     4
Asthma or  
Wheezing
Emphysema
Pneumonia
Yes       No
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
 Yes        No
  1        2
a. Do you
have this
condition?
 Yes        No
   1        2
Tuberculosis
Pulmonary
Fibrosis
("stiff lungs")
 0 = Not at all
 1 = Slightly
 2 = Moderately
 3 = Greatly
 4 = Extremely
11.
12.
13.
14.
15.
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
16.  Have you had pain in either leg when walking other than pain in your joints?
Page 5 of 16
1  Calf included
2  Does not include calf
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider as
Peripheral
Vascular
Disease (PVD)
or
Claudication:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1  Yes1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
g. Where in your leg does the pain begin?
l. Have you had a peripheral bypass operation for this problem?
k. How soon until your leg pain goes away?
1  More than 10 minutes
2  Less than 10 minutes
j. What do you do when you get leg pain while walking?
1  Stop or slow down
2  Keep walking at the same pace
i. Does standing still relieve your leg pain?
1  Yes
2  No
h. Do you get leg pain if you walk uphill or hurry?
1  Yes
2  No
3  Do not walk up hill
2   No ----> Go to question 17.
1  Yes ----> Please complete the following questions. This condition:
1  Yes
2  No
f. Does the leg pain begin when you are standing still?
1  Yes
2  No
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CRCD - 312COM, V1.4
February 6, 2004
3 1 2 / / 0 7 1
Please answer the following questions regarding the medical conditions listed below as they
pertain to you.
20.  In the last year, have you had any sudden weakness in your arms or legs?
1  Yes
2  No
1  Yes
2  No
b. Did the weakness occur with pain?
a. Did this weakness come on suddenly and then clear up completely each time?
b. was
diagnosed
by a
healthcare
provider:
c. was present
in the last 5
years:
d. is currently treated with
the following:
e. required
hospital
admission:
f. has decreased
your quality of life:MedicalCondition
Yes       No
  1        2     1     2     3    4     5  1        2  0    1    2     3     4
Yes       No
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
Yes       No
  1        2
a. Do you
have this
condition?
 Yes        No
   1        2
2   No ----> Go to question 21.
1  Yes ----> Please complete the following questions:
 Neuromuscular 
Disorders
 (examples:  
  Parkinson Disease; 
  Multiple Sclerosis)
 Seizures or 
Epilepsy
 Headaches
c. Did this weakness last more than a second or two, but less than a day?
1  Yes
2  No
d.  How has this weakness decreased your quality of life?
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
 0 = Not at all
 1 = Slightly
 2 = Moderately
 3 = Greatly
 4 = Extremely
17.
18.
19.
 
Specify condition(s):
     1        2        3        4        5         6
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21.  In the last year, have you had numbness or tingling or loss of feeling in your arms, legs,
  or face -- that didn't happen because your arm just fell asleep?
22.  In the last year, have you had loss of speech, slurring of speech, or changes in speech?
1  Yes
2  No
1  Yes
2  No
1  Yes
2  No
d.  How has this numbness decreased your quality of life?
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
c. Did this numbness or loss of feeling last more than a second or two, but less than a day?
b. Did this numbness or loss of feeling occur with pain in the same place?
a. Each time, did this numbness or loss of feeling come on suddenly and then clear up completely?
2   No ----> Go to question 22.
1  Yes ----> Please complete the following questions:
1  Yes
2  No
1  Yes
2  No
c.  How has this speech change decreased your quality of life?
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
b. Each time, did this change in speech last more than a second or two, but less than a day?
a. Did this speech change come on suddenly and then clear up completely?
2   No ----> Go to question 23.
1  Yes ----> Please complete the following questions:
(for internal use only)
/ /Date:ID Number:
(for internal use only)
Page 7 of 16  
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
Page 8 of 16
23.  Have you ever had a stroke, "mini strokes," or "TIA's?"
1  No difficulty
2  Yes, with slight one-sided weakness or paralysis
3  Yes, with considerable one-sided weakness or paralysis
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1  Yes1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
f. Do you have difficulty moving an arm or leg as a result of your stroke?
2   No ----> Go to question 24.
1  Yes ----> Please complete the following questions. This condition:
Please answer the following questions regarding the medical conditions listed below as they
pertain to you.
Medical
Condition
 Thyroid or
Endocrine  
 Disorders
 Diabetes or High
Blood Sugar
(do not include high
blood sugar during
pregnancy)
(examples:
 Low Thyroid;
 Goiter)
a. Do you
have this
condition?
b. was
diagnosed
by a
healthcare
provider:
c. was present
in the last 5
years:
d. is currently treated with
the following:
e. required
hospital
admission:
f. has decreased
your quality of life:
 Yes        No
   1        2
 Yes        No
   1        2
 Yes        No
  1        2     1     2     3    4     5
Yes       No
 1        2  0    1    2     3     4
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
Kidney problems
Eye problems requiring treatment with an eye doctor
Changes in the feeling of your feet or legs
Diarrhea at night
1.
3.
2.
4.
Other bowel problems
Impotence (difficulty with erections)
5.
6.
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
 If "No," go to question 26 on the following page.>
^
 0 = Not at all
 1 = Slightly
 2 = Moderately
 3 = Greatly
 4 = Extremely
24.
25.
g. Have you had any of the following problems with your diabetes?
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/ /Date:ID Number:
(for internal use only)
Page 9 of 16
Please answer the following questions regarding the medical conditions listed below as they
pertain to you.
Medical
Condition
a. Do you
have this
condition?
b. was
diagnosed
by a
healthcare
provider:
c. was present
in the last 5
years:
d. is currently treated with
the following:
e. required
hospital
admission:
f. has decreased
your quality of life:
 Yes        No
   1        2
 Yes        No
   1        2
 Yes        No
  1        2     1     2     3    4     5
Yes       No
 1        2  0    1    2     3     4
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
 Bladder  
Problems
 Prostate  
Problems
 Kidney 
Problems
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1.
2.
3.
4. Kidney transplant
Kidney dialysis
Kidney removal
Decreased kidney function
 (example: passing water less frequently)
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
c. is currently treated with the
following:
d. required
hospital
admission:
e. has decreased your
quality of life:
Yes      No
  1         2
Yes      No
 1         2 1       2       3      4      5
Yes      No
 1         2  0      1     2     3     4
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
4  No ----> Go to question 30 on the following page.
3  Yes, temporary hepatitis only
2  Yes, chronic or permanent hepatitis
1  Yes, other
29.  Have you had liver trouble?
>
>
>
This condition:>
 0 = Not at all
 1 = Slightly
 2 = Moderately
 3 = Greatly
 4 = Extremely
 0 = Not at all
 1 = Slightly
 2 = Moderately
 3 = Greatly
 4 = Extremely
^
>   If "No," go to question 29 below.
26.
27.
28.
g.  Have you had any of the following problems with your kidneys?
Specify condition(s):
Specify condition(s):
Specify condition(s):
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Please answer the following questions regarding the medical conditions listed below as they
pertain to you.
Medical
Condition
 Digestive  
Disorders
(examples:  
 Crohn's Disease; 
 Colitis)
30.  Do you have cirrhosis (or hardening) of the liver?
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
1  Yes
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
Have you had any of the following problems with your cirrhosis?f.
Fluid in the abdomen
Enlarged spleen
Bleeding
1.
2.
3.
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
1  Yes 2  No 3  Don't know
a. Do you
have this
condition?
b. was
diagnosed
by a
healthcare
provider:
c. was present
in the last 5
years:
d. is currently treated with
the following:
e. required
hospital
admission:
f. has decreased
your quality of life:
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
 Yes        No  Yes        No  Yes        No
    1     2     3    4     5
Yes       No
   1        2   1        2   1        2  0    1    2     3     4 1        2
2   No ----> Go to question 31.
1  Yes ----> Please complete the following questions. This condition:
 0 = Not at all
 1 = Slightly
 2 = Moderately
 3 = Greatly
 4 = Extremely
31.
32.  Ulcers of Stomach
or Intestines
Specify condition(s):
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
Page 11 of 16
33.  Have you had cancer?  (Ignore skin cancer except for melanoma.)
Please mark the following cancer(s) that you have now or had in the past:  (Choose all that apply)
1.
2.
3.
4.
5.
6.
MelanomaBladder
Lung
Prostate
Colon
Breast
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
Rectal
Thyroid
Sarcoma/Bone
Leukemia
Lymphoma
2   No ----> Go to question 34.
1  Yes ----> Please answer the following questions:
1  Yes
2  No
a. was/were
diagnosed
by a
healthcare
provider:
b. was/were
present in the
last 5 years:
1  Yes
2  No
c. is/are currently treated with
the following:
1  Yes
d. required
hospital
admission:
1  Yes
2  No
e. has/have decreased
your quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
1  Yes
2  No
1  Yes
2  No
g. Has/have your cancer(s) spread from its original site to other parts of the body?
f. Is/are your cancer(s) completely controlled?
My cancer(s):
Cervical
Uterine
Gastric (stomach/esophageal)
Ovarian
Pancreatic
Liver
Neck (throat)
Brain Mouth
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  YesOther21.
Specify condition(s):
h.
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34.  Have you had any arthritis or rheumatic disease?
f.  Please mark the following types(s) of rheumatic disease that you have now or had in the past:
(Choose all that apply)
1.
2.
3.
4.
5.
6.
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
2   No ----> Go to question 35.
1  Yes ----> Please answer the following questions:
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
1  Yes
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
My arthritis or rheumatic disease(s):
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
1  YesOther
Specify condition(s):
Polymyositis
Psoriatic arthritis
Reiter's disease
Fibromyalgia
Raynaud's disease
Scleroderma
Polymyalgia
 rheumatic/temporal
 arthritis
Mixed connective tissue
 disease
Lyme disease
Osteoarthritis
Rheumatoid arthritis
Colitic arthritis
Lupus
Sjogren's
Ankylosing Spondylitis
35.  Do you have Osteoporosis?
2   No ----> Go to question 36.
1  Yes ----> Please complete the following questions. This condition:
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
1  Yes
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
CRCD - 313COM, V1.4
February 6, 2004
 
     1        2        3        4        5         6
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36.  Have you ever had a bone fracture?
2   No ----> Go to question 37.
1  Yes ----> Please specify the nature of the fracture for each. Specify the most recent one first.
A. What was the fracture?
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
1  Yes ----> What was the fracture?
2  No
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
This fracture:
B. Was there another fracture?
1  Yes
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
d. required hospital admission:
1  Yes
2  No
e. has decreased your quality of life:
This fracture:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
1  Yes ----> What was the fracture?
2  No
C. Was there another fracture?
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
d. required hospital admission:
1  Yes
2  No
e. has decreased your quality of life:
This fracture:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
(for internal use only)
/ /Date:ID Number:
(for internal use only)
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/ /Date:ID Number:
(for internal use only)
Page 14 of 16
Please answer the following questions regarding the medical conditions listed below as they
pertain to you.
Medical
Condition
 Skin Disorders
(examples:  
 Acne; Eczema)
37.  Are you HIV positive?
2   No ----> Go to question 38.
1  Yes ----> This condition:
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
1  Yes
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
Do you have Acquired Immune Deficiency Syndrome (AIDS)?f.
1  Yes
2  No
3  Don't know
a. Do you
have this
condition?
b. was
diagnosed
by a
healthcare
provider:
c. was present
in the last 5
years:
d. is currently treated with
the following:
1 = Drugs
2 = Diet
3 = Exercise
4 = Other
5 = None
e. required
hospital
admission:
f. has decreased
your quality of life:
Specify condition(s):
 Depression
 Anxiety
 Other Mental
Problems
Specify condition(s):
42. Other health conditions?
1  Yes ----> Please specify condition(s):
2  No
 0 = Not at all
 1 = Slightly
 2 = Moderately
 3 = Greatly
 4 = Extremely
 Yes        No
   1        2
 Yes        No
   1        2
 Yes        No
  1        2     1     2     3    4     5
Yes       No
 1        2  0    1    2     3     4
38.
39.
40.
41.
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Symptom Checklist
Please indicate which of the following symptoms currently apply to you:
  Skin rashes43.
(for internal use only)
/ /Date:ID Number:
(for internal use only)
Page 15 of 16
Not at all Slightly Moderately Greatly Extremely
           0                         1                        2                         3                        4
44.   Itching
45.   Night sweats
46.   Fever
47.   Fatigue
  Weight loss48.
49.   Weight gain
50.   Nausea
51.   Vomiting
52.   Diarrhea
Symptom b. Has this symptom decreased your quality of life?
 Yes        No
   1        2
a. Do you
have this
symptom?
54.   Loss of appetite
55.   Over-eating
56.   Vision problems
57.   Hearing problems
53.   Constipation
58.    Dizziness or light-
 headedness
59.    Dizziness or light-
 headedness
(sitting or lying)
(with standing)
 
 220 
(for internal use only)
/ /Date:ID Number:
(for internal use only)
Page 16 of 16
Not at all Slightly Moderately Greatly Extremely
           0                         1                        2                         3                        4
Symptom b. Has this symptom decreased your quality of life?
 Yes        No
   1        2
a. Do you
have this
symptom?
Symptom Checklist  (continued)
62.
60.   Fainting or blackouts
61.   Leg or arm weakness
  Leg or arm paralysis
  Shortness of breath63.
64.   Chest palpitations
65.   Pain (generalized)
66.   Chest pain
67.   Abdominal pain
  Back pain68.
69.   Joint pain
70.   Leaking urine
71.   Frequent urination
72.   Sleep problems
74.  Balance problems
73.   Mobility (walking)
problems
(pounds)
(feet) (inches)
75.  What is your weight in pounds?
76.  What is your height?
THANK YOU for completing this questionnaire
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 Instrument Number:
(For internal use only)
3 0 2
(1)   Male
(2)   Female
 1.  What is your sex?
 2.  What is your date of birth?
(month) (day) (year)
 3.  What is your age?  (Please list your age at your last birthday.)
(years)
CRCD - 302SDM, V1.10
February 6, 2004
           0 7 1
/ /    
(staple  here)
Sociodemographic Questionnaire
Center for Research in Chronic Disorders
University of Pittsburgh
Directions: The information requested is important to understand more about you and your health.
A person's characteristics have been shown to influence health, either through heredity or current
and past lifestyle practices.  The information that you provide will be used for research purposes only
and will be held in confidence.  For each question, please select the response that best describes
you.  If you do not know the information requested, mark "Do Not Know" or "Unknown" as indicated.  If
you feel that a question does not apply to you, mark "Not Applicable."
(month) (day) (year)
/ /ID Number: Administration Date:
 
 
                      Copyright  1999
by the Center for Research in Chronic Disorders
 The University of Pittsburgh School of Nursing
( FOR STAFF USE ONLY )
Page 1 of 10
Study ID:
Time:               1             2             3             4              5            6
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ID Number:
(for internal use only) (for internal use only)
/ /
 4.  Which one of the following best describes your current marital status?
(1)   Never married
(2)   Currently married
(3)   Living with partner/significant other
(4)   Widowed
(5)   Separated
(6)   Divorced
(7)   Other (specify) ---->
 5.  How many years have you been at your current marital status?
(years)
(If less than one year, please
 write "00")
Given the ever-increasing ethnic diversity of the population in the United States of America, the following
questions are being asked to gather information on your racial/ethnic background....
 6.  Do you consider yourself to be
 Hispanic or Latino, that is, of Mexican,
 Puerto Rican, Cuban, Caribbean, or of
 Latin American descent?
(1) Yes
(2) No
(3) Do Not
(1) Mexican
(2) Cuban
(3) Puerto Rican
(4) Unknown
(5) Other:
(1) Yes
 7.  What is your race? (Please choose ALL
 categories that apply)
(a.) White
(b.) Black or African American (1) Yes
(c.) American Indian (1) Yes
Please specify the tribe:
Know
(e.) Native Hawaiian or other
(d.) Alaska Native
(1) Yes
(1) Yes
Please specify:
(f.)  Asian
(g.) Unknown
(h.) Other (1) Yes
(1) Yes
(1) Yes
 8.  Is English your primary language (the one you speak most often)?
(1)   Yes
(2)   No -----> Please specify language:
(for office use only)
Page 2 of 10
Pacific Islander
Date:
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ID Number:
(for internal use only)
Date:
(for internal use only)
/ /            
10.  In what type of area did you live most of your childhood?
(1)   Urban, large city
(2)   Urban, small city
(3)   Suburb of large city
(4)   Suburb of small city
(5)   Rural, farm
(6)   Rural, non-farm
(7)   Other (please specify) --->
(For example, if you completed high school in the USA, you would have had 12 years of education.)
   11.  How many years of formal education have you completed?
(years)
(for office use only)
Page 3 of 10
 9.  Where do you live?
(where you live most of the time)
a.  Please enter the 5-digit ZIPCODE of your PRIMARY RESIDENCE:
b.  Please enter the 5-digit ZIPCODE of your SECONDARY RESIDENCE:
(where you live second most of the time)
N/A
(No Secondary Residence)
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ID Number:
(for internal use only)
/ /            
(for internal use only)
    12.  What is your educational background? (Please complete to the highest level of education attained.)
High school (1) Yes (Not Applicable)(Grades  9 - 12)
1)
2)
2)b.)
c.)
Earned G.E.D.     (NotApplicable) (Not Applicable)(1) Yes
(1) Yes
2)1)
(Associate's level)
2 year college
e.)
(1) Yes
2)1)
Vocational /
 Technical school
d.)
(1) Yes
2)1)
(Master's level)
Graduate school
g.)
(1) Yes
2)1)
(Bachelor's level)
4 year college
f.)
(1) Yes
2)1)
(ex: MD, D.V.M., JD)
Professional school
h.)
(1) Yes
2)1)
j.)
Other; please specify:
1) 2)
(1) Yes
i.) Graduate school
(Doctoral level)
(ex: Ph.D., Ed.D.)
a.)
Grade school
(Grades  1- 8)
1) 2)
(1) Yes (Not Applicable)
School:
   Number of
       years
    attended: Did you finish this school?
  If earned a degree, specify the major area
                          of emphasis:
 13.  What is your current employment status?
(1)   Full time (working at least 35 hours a week)
(2)   Part time (working less than 35 hours a week)
(3)   Laid off or unemployed, but looking for work
(4)   Laid off or unemployed, but not looking for work
(5)   Retired, not working at all
(6)   Retired, but working part or full time
(7)   Disabled/unable to work
(8)   Full time homemaker
(9)   Student
(10) Other (specify) ---->
(Graduate Equivalent Diploma)
Page 4 of 10
Date:
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ID Number:
(for internal use only)
/ /
(for internal use only)
(1)   Yes                   > a.) What is your primary occupation?
(2)   No
(3)   I have
 14.  Are you currently employed?
b.) Has this been your primary occupation for most of your working life?
(1)   Yes
(2)   No ----> c.) What was your primary occupation?
NEVER
been
employed
Write in job title:
Write in job title:
(for office use only)
(for office use only)
>
d.) Did you change occupations since your illness?
1   Yes ------------------> e.) Select all that apply:
2   No; my change in
occupation was
not because of
my illness.
1. Because of the physical
demands of my job.
(1) Yes
2. Because of the mental
demands of my job.
(1) Yes
3. Other (specify) (1) Yes
V
f.) When you were employed, what was your primary occupation?
(for office use only)Write in job title:
g.) When was the last year that you were employed?
h.) Did you stop working because of your illness?
1   Yes ------------------->  i.) Select all that apply:
2   No; my stopping
work was not
because of my
illness.
1. Because of the physical
demands of my job.
2. Because of the mental
demands of my job.
3. Other (specify)
(1) Yes
(1) Yes
(1) Yes
V
Page 5 of 10
(the one where you work the most hours per week):
Date:
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ID Number:
(for internal use only)
/ /
(for internal use only)
 16.  How many people presently live in your household including yourself?
(adults)
(children under age 18)
a.
b.
If NONE, enter 00.
17.  Do you have a religious background or preference?
(1)   Yes ---->  a.) Please specify:  (Choose one response only)
(2)   No (1)  Catholic  (ex: Roman Catholic)
(2)  Jewish
(3)  Protestant  (ex: Lutheran; Presbyterian; Methodist; Unitarian)
(4)  Other (specify) ---->
18.  How important is religion or spirituality in your life?
(1)   Not at all important
(2)   Somewhat important
(3)   Extremely important
 15.  Do you have any children?
(1)   Yes ----> a.) Please specify the number of children:
(2)   No
b.) To what extent do you follow the customs and practices of your religion?
(1)  Never
(2)  Sometimes
(3)  Frequently
(4)  Always
(for office use only)
Page 6 of 10
Date:
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19.  Do you have health care insurance?
(1)   Yes --->  a.) What type(s) of insurance do you have?  (Choose all that apply.)
(2)   No
(1) Yes
(1) Yes
(1) Yes
(1) Yes
(1) Yes
1.) Medicare
2.) Medicaid
3.) SSI
4.) Veterans Administration
5.) Workers Compensation
6.) Private health insurance
ID Number:
(for internal use only)
/ /
(for internal use only)
(1) Yes7.) Other (specify)
b.) Does your insurance cover the cost of medication?
(1)   Yes, all
(2)   Yes, some of the cost ---> Please specify in what way:
(3)   No
(4)   Unknown
c.) Does your insurance cover the cost of health care?
(1)   Yes, all
(2)   Yes, some of the cost ---> Please specify in what way:
(3)   No
(4)   Unknown
V
(1) Yes
Page 7 of 10
Date:
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(for internal use only) (for internal use only)
/ /
The following questions concern family and individual income.  We recognize the sensitive nature
of these questions.  This information is important in order to understand the economic impact of
the chronic illness on the family and individual.  Your answers will be held in strict confidence.
20.  What are all the sources of your own total gross annual income (before taxes and deductions):
Wages, salaries, commisions, bonuses, or tips from all jobs
Interest, dividend, net rental income, royalty income, or income
   from estates or trusts
Social security or railroad retirement
Supplemental security income or other public assistance income
Retirement, survivor, or disability pensions
Other (specify):
Self-employment income from farm or non-farm business (1) Yes
(1) Yes
(1) Yes
(1) Yes
(1) Yes
(1) Yes
(1) Yes(a.)
(b.)
(c.)
(d.)
(e.)
(f.)
(g.)
21.  If you are currently employed, please select your own gross annual income from wages only
  (before taxes and deductions):
(Not Employed)
N/A
(1)   Under $10,000
(2)   $10,000 to $14,999
(3)   $15,000 to $19,999
(4)   $20,000 to $29,999
(5)   $30,000 to $39,999
(6)   $40,000 to $49,999
(7)   $50,000 to $59,999
(8)   $60,000 to $69,999
(9)   $70,000 to $79,999
(10)  $80,000 to $99,999
(11)  $100,000 to $150,000
(12)  Over $150,000
(13)  Unknown
(14)  Refused
Page 8 of 10
Date:
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(for internal use only) (for internal use only)
/ /
24.  Does your current household income meet your basic needs (such as food, housing, utilities,
  and health care):
(1) Yes
(2) No
(1)   Not at all difficult
(2)   Somewhat difficult
(3)   Extremely difficult
(1)   Under $10,000
(2)   $10,000 to $13,000
(3)   $13,000 to $20,000
(4)   $20,000 to $30,000
(5)   $30,000 to $50,000
(6)   Over $50,000
23.  What is the total gross annual income for your household from all sources (before taxes and
  deductions):
22.  If you are not currently employed, but were employed in the past, please select your own gross 
  annual income from wages (before taxes and deductions) for the last year you worked:
N/A
(Never Employed)(1)   Under $10,000
(2)   $10,000 to $14,999
(3)   $15,000 to $19,999
(4)   $20,000 to $29,999
(5)   $30,000 to $39,999
(6)   $40,000 to $49,999
(7)   $50,000 to $59,999
(8)   $60,000 to $69,999
(9)   $70,000 to $79,999
(10)  $80,000 to $99,999
(11)  $100,000 to $150,000
(12)  Over $150,000
(13)  Unknown
(14)  Refused
 
Page 9 of 10
Date:
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Instrument Number:
(For internal use only)
3 0 3
CRCD - 303SDM, V1.10
February 6, 2004
           0 7 1
(staple  here)
Sociodemographic Questionnaire  (continued)
Center for Research in Chronic Disorders
University of Pittsburgh
(month) (day) (year)
/ /ID Number: Administration Date:
 
( FOR STAFF USE ONLY )
Page 10 of 10
25.  How difficult is it to pay for your basic needs?
(1)   Not at all difficult
(2)   Somewhat difficult
(3)   Extremely difficult
Study ID:
               1             2             3             4              5            6Time:
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Instrument Number:
(For internal use only)
8 2 2
Page 1 of 5
0 7 1
CRCD - 822HEA, V1.0
December 9, 2003
Study ID:
HEALTH SURVEY
Center for Research in Chronic Disorders
/ /ID Number: Administration Date:
( FOR STAFF USE ONLY )
                                                     1                2               3                4                5               6
(month)  (day) (year)
Time:
Most recent CD4 T-Cell Count:
Is your viral load detectable?
1   Yes ------>
2   No
  1.
  2.
a. Most recent viral load:
Please complete the following questions to the best of your ability.
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ID Number: Date: / /
(for internal use only) (for internal use only)
  3. Current medications and dosages:
Doses/day # of Pills/doseMedication
 (1.)
(b) (c)
(for office use only)
(a)
 (2.)
(for office use only)
 (3.)
(for office use only)
 (4.)
(for office use only)
 (5.)
(for office use only)
 (6.)
(for office use only)
 (7.)
(for office use only)
 (8.)
(for office use only)
 (9.)
(for office use only)
(10.)
(for office use only)
(continued on next page)
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ID Number: Date: / /
(for internal use only) (for internal use only)
Page 3 of 5
Doses/day # of Pills/doseMedication
(b) (c)(a)
(for office use only)
(for office use only)
(for office use only)
(11.)
(for office use only)
(12.)
(13.)
(14.)
(for office use only)
(15.)
Hospitalizations?
1   Yes ------>
2   No
(1.)
  4.
a.  Reason(s): (for office use only)
(2.)
(4.)
(3.)
Emergency room visits?
1   Yes ------>
2   No
(1.)
  5.
a.  Reason(s): (for office use only)
(2.)
(4.)
(3.)
  3. Current medications and dosages:   (continued)
Please complete the following questions.  We are interested in obtaining information since ____________ .
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How many? a.
Missed medical appointments?
1   Yes ------>
2   No
  6.
(for office use only)
ID Number: Date: / /
(for internal use only) (for internal use only)
Page 4 of 5
(1.)
(2.)
(3.)
b.  Reason(s):
Please list: a.
Do you have any current infections related to HIV?
1   Yes ------>
2   No
  7.
(for office use only)
Please list: a.
Are you currently involved in a clinical trial or research study, other than this one?
1   Yes ------>
2   No
  8.
(for office use only)
(1.)
(2.)
(1.)
(2.)
(3.)
Do you currently use any alternative therapies or treatments for HIV infection?
1   Yes ------>
2   No
  9.
a.  Are you currently using any of these:
1
Yes
1
Yes
4.  Exercise
3.  Herbal therapy
2.  Meditation
1.  Yoga 5.  Vitamins
6.  Acupuncture
7.  Aromatherapy
8.  Other
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ID Number: Date: / /
(for internal use only) (for internal use only)
Page 5 of 5
Are you currently involved in one-on-one counseling?
1   Yes
2   No
10.
Please list: a.1   Yes ------>
2   No
Are you currently involved in group counseling or support groups?11.
(1.)
(2.)
(for office use only)
Please list: a.1   Yes ------>
2   No
Do you currently receive assistance from a community-based organization?12.
(1.)
(2.)
(for office use only)
How satisfied are you with your relationship with your health care provider?
      1             2            3             4            5            6              7             8            9            10
13.
    Not
Satisfied
   Very
Satisfied
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Instrument Number:
(For internal use only)
8 2 4
Page 1 of 4
0 7 1
CRCD - 824MRR, V1.0
December 9, 2003
Study ID:
MEDICAL RECORD REVIEW
Center for Research in Chronic Disorders
/ /ID Number: Administration Date:
( FOR STAFF USE ONLY )
                                                     1                2               3                4                5               6
(month)  (day) (year)
Time:
Please keep these rules in mind when responding to the questions....
CD4 T-Cell Count:
/ /
Date:
Viral load detectable?
1   Yes ------>
2   No (a.)
/ /
(c.)  Sensitivity:
<
(d.)  Date:
(b.)  Date:
  1.  2.
 (month) (day) (year)
  3.
Viral load/HIV RNA:
/ /
 (month) (day) (year)
 (month) (day) (year)
>
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ID Number: Date: / /
(for internal use only) (for internal use only)
Number of hospitalizations: Reason(s):
Number of emergency room visits: Reason(s):
Number of outpatient surgical visits: Reason(s):
Current illicit drug use?
Current alcohol abuse?
1   Yes
2   No
1   Yes
2   No
1   Yes ----->
2   No
Any missed appointments?
Resolution to these missed appointments:
 4.
How many? a.
 b.
 5.
 6.
 7.
 8.
 9.
10. Current opportunistic infections:
 a.
 b.
 c.
 d.
 e.
(for office use only)
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ID Number: Date: / /
(for internal use only) (for internal use only)
Page 3 of 4
Doses/day # of Pills/doseMedication
 (1.)
(b) (c)
(for office use only)
(a)
 (2.)
(for office use only)
 (3.)
(for office use only)
 (4.)
(for office use only)
 (5.)
(for office use only)
 (6.)
(for office use only)
 (7.)
(for office use only)
 (8.)
(for office use only)
 (9.)
(for office use only)
(10.)
(for office use only)
(continued on next page)
11. Current medications and dosages:
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ID Number: Date: / /
(for internal use only) (for internal use only)
Page 4 of 4
Doses/day # of Pills/doseMedication
(b) (c)(a)
(for office use only)
(for office use only)
(for office use only)
(11.)
(for office use only)
(12.)
(13.)
(14.)
(for office use only)
(15.)
11. Current medications and dosages:   (continued)
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Instrument Number:
(For internal use only)
8 2 6
Page 1 of 2
0 7 1
CRCD - 826MRRA, V1.0
February 7, 2005
Study ID:
MEDICAL RECORD REVIEW
Center for Research in Chronic Disorders
/ /ID Number: Administration Date:
( FOR STAFF USE ONLY )
                                                     1                2               3                4                5
(month)  (day) (year)
Time:
New medical record information available since last data collection? 1.
1   Yes
2   No
Addendum  A
Evidence of assessment of adherence since last data collection? 2.
1   Yes ---->
2   No
1   Yes ----> Answer the following:
2   No Yes
Yes
Yes
  (1)
 a. Evidence of referral to in-house adherence program?
 b.
 c. Evidence of tools/devices recommended for adherence
(pill box, beeper, diary)?
Evidence of referral to outside adherence program?
 Evidence of adherence intervention?
Please use the following example to answer all questions:
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
Diagnosed with Hepatitis C+? 3.
1   Yes ---->
2   No
 b. HCV Genotype available?
 a. Quantitative HCV Viral Load available?
1   Yes ---->
2   No / /
(month)  (day) (year)
Quantitative HCV Viral Load date:
Copies/ML:
Log IU/ML:
.
a.
c.
b. IU/ML:
2. Viral Load detectable?
1.
1   Yes ---->
2   No
1   Yes ---->
2   No / /
(month)  (day) (year)
HCV Genotype date:
HCV Genotype:
1.
2.
 a.
  (#) (letter)
 b.
 c.
 d.
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Center for Research in Chronic Disorders
CO-MORBIDITY CONDITIONS
Instrument Number:
(For internal use only)
7 2 9
Study ID:  0 3 1
/ /
(month) (day) (year)
 
CRCD - 729COO, V1.0
June 13, 2000
ID Number:
     1            2            3             4            5            6
  
Administration Date:
Source:
Problem List:
1.
2.
3.
4.
5.
6.
7.
8.
9.
Visit  Number:
10.
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Instrument Number:
(For internal use only)
8 1 4
           0 7 1
CRCD - 814CMA, V1.0
May 4, 2004
ID Number:
(month) (day) (year)
/ /Administration Date:
:
CO-MORBIDITY QUESTIONNAIRE
Center for Research in Chronic Disorders
Do you have pain in your arms or legs?
2  No ----> Go to question 78.
1  Yes ---> Please complete the following questions:
1  Yes ---> Please identify the
2  No
a. Was this diagnosed by a healthcare
provider as neuropathy?
b. was
present in
the last
5 years:
1  Yes
2  No
c. is currently treated
with the following:
1 Yes
d. required
hospital
admission:
1  Yes
2  No
e. has decreased
your quality of
life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
( FOR STAFF USE ONLY )
Time:
Study ID:
    1               2              3               4              5               6
ADDENDUM
77.
  location of the pain:
(for office use only)
1 Yes
1 Yes
1 Yes
1 Yes
Does the pain worsen with movement or exercise? 1  Yes 2  No
Is the pain constant?
Does pain restrict your mobility?
Does pain affect your sleep?
1  Yes 2  No
1  Yes 2  No
1  Yes 2  No
 f.
 g.
 i.
 h.
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
2  No ----> Go to question 79.
1  Yes ---> Please choose all that apply:
78. Have you ever had hepatitis?
1  Yes
2  No
a. was
 diagnosed
 by a
 healthcare
 provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
1  Yes
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
a.  Hepatitis  A
b.  Hepatitis  B
c.  Hepatitis  C
d.  Hepatitis Unknown or Other
Please complete the following questions:
 Yes
1
2  No ----> Go to question 80.
1  Yes ---> Please complete the following questions:
79. Do you have fat redistribution syndrome (lipodystrophy)?
1  Yes
2  No
a. was
diagnosed
by a
healthcare
provider:
b. was
present in the
last 5 years:
1  Yes
2  No
c. is currently treated with the
following:
1  Yes
d. required
hospital
admission:
1  Yes
2  No
e. has decreased your
quality of life:
1. Drugs
2. Diet
3. Exercise
4. Other
5. None
1  Yes
1  Yes
1  Yes
1  Yes
0  Not at all
1  Slightly
2  Moderately
3  Greatly
4  Extremely
Do you have fat redistribution on the
back of your neck?
Do you have central weight gain
 (weight gain in abdomen, breast
   enlargement)?
Do you have peripheral fat wasting
 (fat loss in face, arms, legs, or buttocks)?
1  Yes 2  No
1  Yes 2  No
1  Yes 2  No
 f.
 g.
 h.
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
           0                         1                        2                         3                        4
Symptom  b. Has this symptom decreased your quality of life?
   1        2
  1.
  2.
  3.
Genital Warts
Gonorrhea
Chlamydia
Genital Herpes
Oral Herpes
PID  (Pelvic Inflammatory
Disease)
Trichomoniasis
Not at all Slightly Moderately Greatly Extremely  Yes       No
 a. Do you
 have this
 symptom?
  4.
  5.
  6.
  8.
  7.
80. Do you currently have any of the following:
HPV  (Human 
Papillomavirus)
CMV  (Cytomegalovirus)
10. Bacterial Vaginosa
  9.
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MOS-HIV HEALTH SURVEY
Center for Research in Chronic Disorders
1   Excellent
2   Very good
3   Good
4   Fair
5   Poor
0 7 1
(For internal use only)
Instrument Number:
1 0 4
CRCD - 104HHS, V1.0
February 5, 2004
/ /
ID Number:
Study ID:
( FOR STAFF USE ONLY )
Page 1 of 6
(year)(day)(month)
In general, would you say your health is:   (Choose ONE response only.)
How much bodily pain have you generally had during the past 4 weeks?
(Choose ONE response only.)
    1.
    2.
Administration Date:
Please use the following example to answer all questions:
                1             2            3            4            5            6Time:
INSTRUCTIONS TO PATIENT: Please answer the following questions by filling in ONE circle for each
question that corresponds best to your response.
1   None
2   Very mild
3   Mild
4   Moderate
5   Severe
6   Very severe
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
Page 2 of 6
1   Not at all
2   A little bit
3   Moderately
4   Quite a bit
5   Extremely
During the past 4 weeks, how much did pain interfere with your normal work (or your normal activities,
including work outside the home and housework)?   (Choose ONE response only.)
    3.
The kinds or amounts of vigorous activities
you can do, like lifting heavy objects, running,
or participating in strenuous sports
 1                                            2                                           3
   a.
    4. The following questions are about activities you might do during a typical day.  Does your health now
limit you in these activities?  If so, how much?  (Choose ONE response on each line.)
The kinds or amounts of moderate activities
you can do, like moving a table, carrying
groceries, or bowling
   b.
Walking uphill or climbing (a few flights of stairs)   c.
Bending, lifting, or stooping   d.
Walking one block   e.
Eating, dressing, bathing, or using the toilet   f.
1   Yes
2   No
Does your health keep you from working at a job, doing work around the house, or going to school?
(Choose ONE response only.)
    5.
1   Yes
2   No
Have you been unable to do certain kinds or amounts of work, housework, or schoolwork because of
your health?   (Choose ONE response only.)
    6.
     NO,
not limited
      YES,
limited a little
     YES,
limited a lot
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(for internal use only)
/ /Date:ID Number:
(for internal use only)
Page 3 of 6
    7. How much of the time during the past 4 weeks has your health limited your social activities (like visiting
with friends or close relatives)?
How much of the time during the past 4 weeks:    8.
For each of the following questions, choose the ONE answer that comes closest to the way you have
been feeling during the past 4 weeks.
have you been a very nervous person?
have you felt calm and peaceful?
   a.
   b.
     1                       2                      3                     4                      5                       6
have you felt downhearted and blue?
have you been a happy person?
   c.
   d.
have you felt so down in the dumps
that nothing could cheer you up?
   e.
None
of the
time
 A little
 of the
  time
A good
 bit of
the time
Most
of the
time
 All
of the
time
Some
of the
time
      1                                 2                                 3                                 4                                 5                                 6
None
of the
 time
A little
of the
 time
A good
 bit of
the time
 Most
of the
 time
  All
of the
 time
Some
of the
time
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(for internal use only)
/ /Date:
(for internal use only)
ID Number:
Page 4 of 6
For each of the following questions, choose the ONE answer that comes closest to the way you have
been feeling during the past 4 weeks.
How often during the past 4 weeks:    9.
   a. did you feel full of pep?
   b. did you feel worn out?
   c. did you feel tired?
did you have enough energy to do the
things you wanted to do?
   d.
did you feel weighed down by your
health problems?
   e.
were you discouraged by your health
problems?
   f.
did you feel despair over your health
problems?
   g.
were you afraid because of your
health?
   h.
      1                      2                      3                     4                      5                        6
None
of the
time
 A little
 of the
  time
A good
 bit of
the time
Most
of the
time
 All
of the
time
Some
of the
time
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(for internal use only)
/ /Date:
(for internal use only)
ID Number:
Page 5 of 6
How much of the time during the past 4 weeks:  10.
   a. did you have difficulty reasoning and
solving problems (for example, making
plans, making decisions, learning new
things)?
        1                       2                      3                      4                      5                      6
None
of the
time
 A little
 of the
  time
A good
 bit of
the time
Most
of the
time
 All
of the
time
Some
of the
time
   b. did you forget things that happened
recently (for example, where you put
things and when you had
appointments)?
   c. did you have trouble keeping your
attention on any activity for long?
   d. did you have difficulty doing activities
involving concentration and thinking?
  11. Please respond to the following statements by choosing how "True" or "False" each statement is for
you.   (Choose ONE response only per statement.)
Definitely
   True
          1                           2                         3                          4                          5
   a. I am somewhat ill.
Mostly
True Not Sure
Mostly
 False
Definitely
   False
   b. I am as healthy as anybody I know.
   c. My health is excellent.
   d. I have been feeling bad lately.
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(for internal use only)
/ /Date:
(for internal use only)
ID Number:
Page 6 of 6
1   Very well; could hardly be better
2   Pretty good
3   Good and bad parts about equal
4   Pretty bad
5   Very bad; could hardly be worse
How has the quality of your life been during the past 4 weeks?  That is, how have things been going
for you?   (Choose ONE response only.)
How would you rate your physical health and emotional condition now compared to 4 weeks ago?
(Choose ONE response only.)
  13.
1   Much better
2   A little better
3   About the same
4   A little worse
5   Much worse
  12.
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Center for Research in Chronic Disorders
Scoring Sheet
Instrument Number:
(For internal use only)
8 2 8
           0 7 1
CRCD - 828POI, V1.0
December 9, 2003
Perception of Illness
Living with HIV has had __________ on my life. 1.
Visual Analog Scale
Living with HIV has become __________. 2.
There is __________ I can do to control my HIV. 3.
My state of mind plays a __________ part in managing my illness. 4.
There is __________ that can be done to control my illness. 5.
.
Study ID:
/ /ID Number: Administration Date:
( FOR STAFF USE ONLY )
                                                     1                2               3                4                5               6
(month)  (day) (year)
Time:
DIRECTIONS: Place a vertical line on the lines below that best describe your perception of the statements.
no effect a major effect
.
easier more difficult
.
little  much
.
minor major
.
nothing  a lot
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Center for Research in Chronic Disorders
THE SATISFACTION WITH LIFE SCALE
Instrument Number:
(For internal use only)
2 4 5
           0 7 1
For optimum accuracy, it is recommended that characters be written block style without touching
the sides of the blocks, such as in the following examples.  Place only one letter or one number
in each box as shown....
Please keep these rules in mind when responding to the questions....
Instructions:    Please fill in the circle that corresponds to how much you agree or disagree with each
statement below.  Please fill in only one circle for each statement.  Use the following scale as a basis for
your answers:
 1. In most ways, my life is close to my ideal.
STRONGLY
DISAGREE
            1                    2                  3                   4                   5                   6                   7
SLIGHTLY
DISAGREE
NEITHER
AGREE
NOR
DISAGREE
SLIGHTLY
AGREE
 
AGREE
STRONGLY
AGREEDISAGREE
 5. If I could live my life over, I would change almost nothing.
 4. So far I have gotten the important things I want in life.
 3. I am satisfied with my life.
 2. The conditions of my life are excellent.
[1]  =  Strongly Disagree
[2]  =  Disagree
[3]  =  Slightly Disagree
[4]  =  Neither Agree nor Disagree
[5]  =  Slightly Agree
[6]  =  Agree
[7]  =  Strongly Agree
                                / /
(month) (day)
                      :
CRCD - 245SLS, V3.1
November 6, 2003
(year)
(hr) (min)
ID Number:
Time:
Administration Date:
Administration Time:
( FOR STAFF USE ONLY )
Study ID:
                1             2             3             4              5          6
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 Page 2 of 4
 7. I often meet or talk with family or friends.
DEFINITELY
   FALSE
PROBABLY
  FALSE
         0                          1                           2                          3
PROBABLY
  TRUE
DEFINITELY
   TRUE
 8. Most people I know think highly of me.
 9. If I needed a ride to the airport very early in the morning, I would
have a hard time finding someone to take me.
10. I feel like I'm not always included by my circle of friends.
11. There really is no one who can give me an objective view of how
 I'm handling my problems.
12. There are several different people I enjoy spending time with.
13. I think that my friends feel that I'm not very good at helping them
solve their problems.
14. If I were sick and needed someone (friend, family member, or
acquaintance) to take me to the doctor, I would have trouble
finding someone.
15. If I wanted to go on a trip for a day (example: to the mountains,
beach, or country), I would have a hard time finding someone to
go with me.
16. If I needed a place to stay for a week because of an emergency
(for example: water or electricity out in my apartment or house), I
could easily find someone who would put me up.
17. I feel that there is no one I can share my most private worries
and fears with.
18. If I were sick, I could easily find someone to help me with my
 daily chores.
19. There is someone I can turn to for advice about handling problems
with my family.
20. I am as good at doing things as most other people are.
(continued on next page)
(for internal use only)
/ /Date:ID Number:
(for internal use only)
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DEFINITELY
   FALSE
PROBABLY
  FALSE
         0                          1                           2                          3
PROBABLY
  TRUE
DEFINITELY
   TRUE
21. If I decide one afternoon that I would like to go to a movie that
evening, I could easily find someone to go with me.
23. If I needed an emergency loan of $100, there is someone (friend,
relative, or acquaintance) I could get it from.
22. When I need suggestions on how to deal with a personal problem, 
I know someone I can turn to.
24. In general, people do not have much confidence in me.
25. Most people I know do not enjoy the same things that I do.
26. There is someone I could turn to for advice about making career
plans or about changing my job.
27. I often don't get invited to do things with others.
28. Most of my friends are more successful at making changes in their
lives than I am.
29. If I had to go out of town for a few weeks, it would be difficult to find
someone who would look after my house or apartment (the plants,
pets, garden, etc.).
30. There is really no one I can trust to give me good financial advice.
31. If I wanted to have lunch with someone, I could easily find someone
to join me.
32. I am more satisfied with my life than most people are with theirs.
33. If I was stranded 10 miles from home, there is someone I could call
who would come and get me.
34. No one I know would throw a birthday party for me.
35. It would be difficult to find someone who would lend me their car for
a few hours.
(continued on next page)
(for internal use only)
/ /Date:ID Number:
(for internal use only)
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DEFINITELY
   FALSE
PROBABLY
  FALSE
         0                          1                           2                          3
PROBABLY
  TRUE
DEFINITELY
   TRUE
36. If a family crisis arose, it would be difficult to find someone who
could give me good advice about how to handle it.
37. I am closer to my friends than most other people are to theirs.
38. There is at least one person I know whose advice I really trust.
39. If I needed some help in moving to a new house or apartment, I
would have a hard time finding someone to help me.
40. I have a hard time keeping pace with my friends.
(for internal use only)
/ /Date:ID Number:
(for internal use only)
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